ID   CFTR_HUMAN              Reviewed;        1480 AA.
AC   P13569; Q20BG8; Q20BH2; Q2I0A1; Q2I102;
DT   01-JAN-1990, integrated into UniProtKB/Swiss-Prot.
DT   15-MAY-2007, sequence version 3.
DT   18-JUN-2025, entry version 283.
DE   RecName: Full=Cystic fibrosis transmembrane conductance regulator {ECO:0000305};
DE            Short=CFTR;
DE   AltName: Full=ATP-binding cassette sub-family C member 7;
DE   AltName: Full=Channel conductance-controlling ATPase;
DE            EC=5.6.1.6 {ECO:0000269|PubMed:11524016, ECO:0000269|PubMed:15284228, ECO:0000269|PubMed:26627831, ECO:0000269|PubMed:8910473};
DE   AltName: Full=cAMP-dependent chloride channel;
GN   Name=CFTR {ECO:0000312|HGNC:HGNC:1884}; Synonyms=ABCC7;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT MET-470.
RX   PubMed=2475911; DOI=10.1126/science.2475911;
RA   Riordan J.R., Rommens J.M., Kerem B., Alon N., Rozmahel R., Grzelczak Z.,
RA   Zielenski J., Lok S., Plavsic N., Chou J.-L., Drumm M.L., Iannuzzi M.C.,
RA   Collins F.S., Tsui L.-C.;
RT   "Identification of the cystic fibrosis gene: cloning and characterization
RT   of complementary DNA.";
RL   Science 245:1066-1073(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT MET-470.
RX   PubMed=1710598; DOI=10.1016/0888-7543(91)90503-7;
RA   Zielenski J., Rozmahel R., Bozon D., Kerem B., Grzelczak Z., Riordan J.R.,
RA   Rommens J., Tsui L.-C.;
RT   "Genomic DNA sequence of the cystic fibrosis transmembrane conductance
RT   regulator (CFTR) gene.";
RL   Genomics 10:214-228(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS MET-470 AND TRP-1453.
RA   Stacy R., Subramanian S., Deodato C., Burkhardt P., Song Y., Paddock M.,
RA   Chang J., Zhou Y., Haugen E., Waring D., Chapman P., Hayden H., Levy R.,
RA   Wu Z., Rouse G., James R., Phelps K., Olson M.V., Kaul R.;
RL   Submitted (JAN-2006) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K.,
RA   Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A.,
RA   Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H.,
RA   Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A.,
RA   Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P.,
RA   Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M.,
RA   Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S.,
RA   Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R.,
RA   Strowmatt C., Latreille P., Miller N., Johnson D., Murray J.,
RA   Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W.,
RA   Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A.,
RA   Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E.,
RA   Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A.,
RA   Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A.,
RA   Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R.,
RA   McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H.,
RA   Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12690205; DOI=10.1126/science.1083423;
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D.,
RA   Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S.,
RA   Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R.,
RA   Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N.,
RA   Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E.,
RA   Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R.,
RA   Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T.,
RA   Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W.,
RA   Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A.,
RA   Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X.,
RA   Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E.,
RA   Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H.,
RA   Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J.,
RA   Adams M.D., Tsui L.-C.;
RT   "Human chromosome 7: DNA sequence and biology.";
RL   Science 300:767-772(2003).
RN   [6]
RP   PHOSPHORYLATION AT SER-660; SER-686; SER-700; SER-737; SER-768; SER-790;
RP   SER-795 AND SER-813.
RX   PubMed=1377674; DOI=10.1016/s0021-9258(18)42339-3;
RA   Picciotto M.R., Cohn J.A., Bertuzzi G., Greenguard P., Nairn A.C.;
RT   "Phosphorylation of the cystic fibrosis transmembrane conductance
RT   regulator.";
RL   J. Biol. Chem. 267:12742-12752(1992).
RN   [7]
RP   GLYCOSYLATION AT ASN-894 AND ASN-900, AND TOPOLOGY.
RX   PubMed=7518437; DOI=10.1016/s0021-9258(17)32347-5;
RA   Chang X.-B., Hou Y.-X., Jensen T.J., Riordan J.R.;
RT   "Mapping of cystic fibrosis transmembrane conductance regulator membrane
RT   topology by glycosylation site insertion.";
RL   J. Biol. Chem. 269:18572-18575(1994).
RN   [8]
RP   PHOSPHORYLATION AT SER-660; SER-700; SER-712; SER-737; SER-753; SER-768;
RP   SER-795 AND SER-813.
RX   PubMed=9385646; DOI=10.1002/pro.5560061117;
RA   Neville D.C.A., Rozanas C.R., Rice E.M., Gruis D.B., Verkman A.S.,
RA   Townsend R.R.;
RT   "Evidence for phosphorylation of serine 753 in CFTR using a novel metal-ion
RT   affinity resin and matrix-assisted laser desorption mass spectrometry.";
RL   Protein Sci. 6:2436-2445(1997).
RN   [9]
RP   ALTERNATIVE SPLICING (ISOFORM 2).
RX   PubMed=10766763; DOI=10.1074/jbc.m910165199;
RA   Pagani F., Buratti E., Stuani C., Romano M., Zuccato E., Niksic M.,
RA   Giglio L., Faraguna D., Baralle F.E.;
RT   "Splicing factors induce cystic fibrosis transmembrane regulator exon 9
RT   skipping through a nonevolutionary conserved intronic element.";
RL   J. Biol. Chem. 275:21041-21047(2000).
RN   [10]
RP   DOMAIN, FUNCTION, TRANSPORTER ACTIVITY, SUBCELLULAR LOCATION, AND
RP   PHOSPHORYLATION.
RX   PubMed=10792060; DOI=10.1073/pnas.100588797;
RA   Ostedgaard L.S., Baldursson O., Vermeer D.W., Welsh M.J., Robertson A.D.;
RT   "A functional R domain from cystic fibrosis transmembrane conductance
RT   regulator is predominantly unstructured in solution.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:5657-5662(2000).
RN   [11]
RP   FUNCTION, TRANSPORTER ACTIVITY, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION,
RP   AND SUBUNIT.
RX   PubMed=11524016; DOI=10.1021/bi0108195;
RA   Ramjeesingh M., Li C., Kogan I., Wang Y., Huan L.J., Bear C.E.;
RT   "A monomer is the minimum functional unit required for channel and ATPase
RT   activity of the cystic fibrosis transmembrane conductance regulator.";
RL   Biochemistry 40:10700-10706(2001).
RN   [12]
RP   INTERACTION WITH GOPC, FUNCTION, TRANSPORTER ACTIVITY, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=11707463; DOI=10.1074/jbc.m110177200;
RA   Cheng J., Moyer B.D., Milewski M., Loffing J., Ikeda M., Mickle J.E.,
RA   Cutting G.R., Li M., Stanton B.A., Guggino W.B.;
RT   "A Golgi-associated PDZ domain protein modulates cystic fibrosis
RT   transmembrane regulator plasma membrane expression.";
RL   J. Biol. Chem. 277:3520-3529(2002).
RN   [13]
RP   INTERACTION WITH SLC4A7 AND NHERF1, AND FUNCTION.
RX   PubMed=12403779; DOI=10.1074/jbc.m201862200;
RA   Park M., Ko S.B.H., Choi J.Y., Muallem G., Thomas P.J., Pushkin A.,
RA   Lee M.-S., Kim J.Y., Lee M.G., Muallem S., Kurtz I.;
RT   "The cystic fibrosis transmembrane conductance regulator interacts with and
RT   regulates the activity of the HCO3- salvage transporter human Na+-HCO3-
RT   cotransport isoform 3.";
RL   J. Biol. Chem. 277:50503-50509(2002).
RN   [14]
RP   FUNCTION, TRANSPORTER ACTIVITY, SUBCELLULAR LOCATION, AND PHOSPHORYLATION
RP   BY AMPK.
RX   PubMed=12519745; DOI=10.1152/ajpcell.00227.2002;
RA   Hallows K.R., Kobinger G.P., Wilson J.M., Witters L.A., Foskett J.K.;
RT   "Physiological modulation of CFTR activity by AMP-activated protein kinase
RT   in polarized T84 cells.";
RL   Am. J. Physiol. 284:C1297-C1308(2003).
RN   [15]
RP   FUNCTION, TRANSPORTER ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND
RP   MUTAGENESIS OF ARG-347; LYS-464 AND LYS-1250.
RX   PubMed=12727866; DOI=10.1093/emboj/cdg194;
RA   Kogan I., Ramjeesingh M., Li C., Kidd J.F., Wang Y., Leslie E.M.,
RA   Cole S.P., Bear C.E.;
RT   "CFTR directly mediates nucleotide-regulated glutathione flux.";
RL   EMBO J. 22:1981-1989(2003).
RN   [16]
RP   FUNCTION, TRANSPORTER ACTIVITY, AND SUBCELLULAR LOCATION.
RX   PubMed=15010471; DOI=10.1074/jbc.m313323200;
RA   Shcheynikov N., Kim K.H., Kim K.M., Dorwart M.R., Ko S.B., Goto H.,
RA   Naruse S., Thomas P.J., Muallem S.;
RT   "Dynamic control of cystic fibrosis transmembrane conductance regulator
RT   Cl(-)/HCO3(-) selectivity by external Cl(-).";
RL   J. Biol. Chem. 279:21857-21865(2004).
RN   [17]
RP   INTERACTION WITH MYO6, AND SUBCELLULAR LOCATION.
RX   PubMed=15247260; DOI=10.1074/jbc.m403141200;
RA   Swiatecka-Urban A., Boyd C., Coutermarsh B., Karlson K.H., Barnaby R.,
RA   Aschenbrenner L., Langford G.M., Hasson T., Stanton B.A.;
RT   "Myosin VI regulates endocytosis of the cystic fibrosis transmembrane
RT   conductance regulator.";
RL   J. Biol. Chem. 279:38025-38031(2004).
RN   [18]
RP   REVIEW.
RX   PubMed=1378801; DOI=10.1096/fasebj.6.10.1378801;
RA   McIntosh I., Cutting G.R.;
RT   "Cystic fibrosis transmembrane conductance regulator and the etiology and
RT   pathogenesis of cystic fibrosis.";
RL   FASEB J. 6:2775-2782(1992).
RN   [19]
RP   ALTERNATIVE SPLICING (ISOFORM 3).
RX   PubMed=12913074; DOI=10.1093/hmg/ddg215;
RA   Aznarez I., Chan E.M., Zielenski J., Blencowe B.J., Tsui L.-C.;
RT   "Characterization of disease-associated mutations affecting an exonic
RT   splicing enhancer and two cryptic splice sites in exon 13 of the cystic
RT   fibrosis transmembrane conductance regulator gene.";
RL   Hum. Mol. Genet. 12:2031-2040(2003).
RN   [20]
RP   FUNCTION, TRANSPORTER ACTIVITY, CHANNEL GATING REGULATION, PHOSPHORYLATION,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=12588899; DOI=10.1113/jphysiol.2002.035790;
RA   Chappe V., Hinkson D.A., Zhu T., Chang X.B., Riordan J.R., Hanrahan J.W.;
RT   "Phosphorylation of protein kinase C sites in NBD1 and the R domain control
RT   CFTR channel activation by PKA.";
RL   J. Physiol. (Lond.) 548:39-52(2003).
RN   [21]
RP   FUNCTION.
RX   PubMed=14668433; DOI=10.1073/pnas.2634339100;
RA   Coakley R.D., Grubb B.R., Paradiso A.M., Gatzy J.T., Johnson L.G.,
RA   Kreda S.M., O'Neal W.K., Boucher R.C.;
RT   "Abnormal surface liquid pH regulation by cultured cystic fibrosis
RT   bronchial epithelium.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:16083-16088(2003).
RN   [22]
RP   FUNCTION, CATALYTIC ACTIVITY, AND DOMAIN.
RX   PubMed=15284228; DOI=10.1074/jbc.m407666200;
RA   Kidd J.F., Ramjeesingh M., Stratford F., Huan L.J., Bear C.E.;
RT   "A heteromeric complex of the two nucleotide binding domains of cystic
RT   fibrosis transmembrane conductance regulator (CFTR) mediates ATPase
RT   activity.";
RL   J. Biol. Chem. 279:41664-41669(2004).
RN   [23]
RP   FUNCTION.
RX   PubMed=16645176; DOI=10.1164/rccm.200506-987oc;
RA   Blouquit S., Regnier A., Dannhoffer L., Fermanian C., Naline E.,
RA   Boucher R., Chinet T.;
RT   "Ion and fluid transport properties of small airways in cystic fibrosis.";
RL   Am. J. Respir. Crit. Care Med. 174:299-305(2006).
RN   [24]
RP   DOMAIN, PHOSPHORYLATION, SUBCELLULAR LOCATION, FUNCTION, AND TRANSPORTER
RP   ACTIVITY.
RX   PubMed=17036051; DOI=10.1038/sj.emboj.7601373;
RA   Mense M., Vergani P., White D.M., Altberg G., Nairn A.C., Gadsby D.C.;
RT   "In vivo phosphorylation of CFTR promotes formation of a nucleotide-binding
RT   domain heterodimer.";
RL   EMBO J. 25:4728-4739(2006).
RN   [25]
RP   IDENTIFICATION IN A COMPLEX WITH RAB11A AND MYO5B, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=17462998; DOI=10.1074/jbc.m608531200;
RA   Swiatecka-Urban A., Talebian L., Kanno E., Moreau-Marquis S.,
RA   Coutermarsh B., Hansen K., Karlson K.H., Barnaby R., Cheney R.E.,
RA   Langford G.M., Fukuda M., Stanton B.A.;
RT   "Myosin Vb is required for trafficking of the cystic fibrosis transmembrane
RT   conductance regulator in Rab11a-specific apical recycling endosomes in
RT   polarized human airway epithelial cells.";
RL   J. Biol. Chem. 282:23725-23736(2007).
RN   [26]
RP   FUNCTION.
RX   PubMed=17434346; DOI=10.1016/j.jcf.2007.03.001;
RA   Lu C., Jiang C., Pribanic S., Rotin D.;
RT   "CFTR stabilizes ENaC at the plasma membrane.";
RL   J. Cyst. Fibros. 6:419-422(2007).
RN   [27]
RP   DOMAIN.
RX   PubMed=17660831; DOI=10.1038/nsmb1278;
RA   Baker J.M., Hudson R.P., Kanelis V., Choy W.Y., Thibodeau P.H.,
RA   Thomas P.J., Forman-Kay J.D.;
RT   "CFTR regulatory region interacts with NBD1 predominantly via multiple
RT   transient helices.";
RL   Nat. Struct. Mol. Biol. 14:738-745(2007).
RN   [28]
RP   FUNCTION, TRANSPORTER ACTIVITY, UBIQUITINATION, AND SUBCELLULAR LOCATION.
RX   PubMed=19398555; DOI=10.1074/jbc.m109.001685;
RA   Bomberger J.M., Barnaby R.L., Stanton B.A.;
RT   "The deubiquitinating enzyme USP10 regulates the post-endocytic sorting of
RT   cystic fibrosis transmembrane conductance regulator in airway epithelial
RT   cells.";
RL   J. Biol. Chem. 284:18778-18789(2009).
RN   [29]
RP   FUNCTION, TRANSPORTER ACTIVITY, AND SUBCELLULAR LOCATION.
RX   PubMed=19019741; DOI=10.1016/j.jcf.2008.10.004;
RA   Tang L., Fatehi M., Linsdell P.;
RT   "Mechanism of direct bicarbonate transport by the CFTR anion channel.";
RL   J. Cyst. Fibros. 8:115-121(2009).
RN   [30]
RP   FUNCTION, TRANSPORTER ACTIVITY, AND SUBCELLULAR LOCATION.
RX   PubMed=19621064; DOI=10.1371/journal.pbio.1000155;
RA   Zhang L., Button B., Gabriel S.E., Burkett S., Yan Y., Skiadopoulos M.H.,
RA   Dang Y.L., Vogel L.N., McKay T., Mengos A., Boucher R.C., Collins P.L.,
RA   Pickles R.J.;
RT   "CFTR delivery to 25% of surface epithelial cells restores normal rates of
RT   mucus transport to human cystic fibrosis airway epithelium.";
RL   PLoS Biol. 7:E1000155-E1000155(2009).
RN   [31]
RP   INTERACTION WITH CSE1L.
RX   PubMed=20933420; DOI=10.1016/j.cub.2010.09.012;
RA   Bagnat M., Navis A., Herbstreith S., Brand-Arzamendi K., Curado S.,
RA   Gabriel S., Mostov K., Huisken J., Stainier D.Y.;
RT   "Cse1l is a negative regulator of CFTR-dependent fluid secretion.";
RL   Curr. Biol. 20:1840-1845(2010).
RN   [32]
RP   SUBCELLULAR LOCATION, CHARACTERIZATION OF VARIANT CF PHE-508 DEL,
RP   MUTAGENESIS OF ASN-894 AND ASN-900, AND GLYCOSYLATION AT ASN-894 AND
RP   ASN-900.
RX   PubMed=20008117; DOI=10.1152/ajplung.00016.2009;
RA   Cholon D.M., O'Neal W.K., Randell S.H., Riordan J.R., Gentzsch M.;
RT   "Modulation of endocytic trafficking and apical stability of CFTR in
RT   primary human airway epithelial cultures.";
RL   Am. J. Physiol. 298:L304-L314(2010).
RN   [33]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=19923167; DOI=10.1093/humrep/dep406;
RA   Li C.Y., Jiang L.Y., Chen W.Y., Li K., Sheng H.Q., Ni Y., Lu J.X., Xu W.X.,
RA   Zhang S.Y., Shi Q.X.;
RT   "CFTR is essential for sperm fertilizing capacity and is correlated with
RT   sperm quality in humans.";
RL   Hum. Reprod. 25:317-327(2010).
RN   [34]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-549, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [35]
RP   FUNCTION, TRANSPORTER ACTIVITY, SUBCELLULAR LOCATION, AND INTERACTION WITH
RP   ANO1.
RX   PubMed=22178883; DOI=10.1159/000335765;
RA   Ousingsawat J., Kongsuphol P., Schreiber R., Kunzelmann K.;
RT   "CFTR and TMEM16A are separate but functionally related Cl-channels.";
RL   Cell. Physiol. Biochem. 28:715-724(2011).
RN   [36]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=22207244; DOI=10.1007/s00418-011-0904-1;
RA   Enuka Y., Hanukoglu I., Edelheit O., Vaknine H., Hanukoglu A.;
RT   "Epithelial sodium channels (ENaC) are uniformly distributed on motile
RT   cilia in the oviduct and the respiratory airways.";
RL   Histochem. Cell Biol. 137:339-353(2012).
RN   [37]
RP   INTERACTION WITH SLC26A8.
RX   PubMed=22121115; DOI=10.1093/hmg/ddr558;
RA   Rode B., Dirami T., Bakouh N., Rizk-Rabin M., Norez C., Lhuillier P.,
RA   Lores P., Jollivet M., Melin P., Zvetkova I., Bienvenu T., Becq F.,
RA   Planelles G., Edelman A., Gacon G., Toure A.;
RT   "The testis anion transporter TAT1 (SLC26A8) physically and functionally
RT   interacts with the cystic fibrosis transmembrane conductance regulator
RT   channel: a potential role during sperm capacitation.";
RL   Hum. Mol. Genet. 21:1287-1298(2012).
RN   [38]
RP   PHOSPHORYLATION AT SER-660; SER-686; SER-700; SER-712; THR-717; SER-737;
RP   SER-795; SER-1444 AND SER-1456, UBIQUITINATION AT LYS-688, PALMITOYLATION
RP   AT CYS-524 AND CYS-1395, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=22119790; DOI=10.1093/protein/gzr054;
RA   McClure M., Delucas L.J., Wilson L., Ray M., Rowe S.M., Wu X., Dai Q.,
RA   Hong J.S., Sorscher E.J., Kappes J.C., Barnes S.;
RT   "Purification of CFTR for mass spectrometry analysis: identification of
RT   palmitoylation and other post-translational modifications.";
RL   Protein Eng. Des. Sel. 25:7-14(2012).
RN   [39]
RP   UBIQUITINATION BY RNF185.
RX   PubMed=24019521; DOI=10.1074/jbc.m113.470500;
RA   El Khouri E., Le Pavec G., Toledano M.B., Delaunay-Moisan A.;
RT   "RNF185 is a novel E3 ligase of endoplasmic reticulum-associated
RT   degradation (ERAD) that targets cystic fibrosis transmembrane conductance
RT   regulator (CFTR).";
RL   J. Biol. Chem. 288:31177-31191(2013).
RN   [40]
RP   INTERACTION WITH MARCHF2, UBIQUITINATION, CHARACTERIZATION OF VARIANT CF
RP   PHE-508 DEL, AND MUTAGENESIS OF 1478-TYR--LEU-1480.
RX   PubMed=23818989; DOI=10.1371/journal.pone.0068001;
RA   Cheng J., Guggino W.;
RT   "Ubiquitination and degradation of CFTR by the E3 ubiquitin ligase MARCH2
RT   through its association with adaptor proteins CAL and STX6.";
RL   PLoS ONE 8:e68001-e68001(2013).
RN   [41]
RP   FUNCTION, TRANSPORTER ACTIVITY, CHARACTERIZATION OF CF VARIANT PHE-508 DEL,
RP   SUBCELLULAR LOCATION, PHOSPHORYLATION AT SER-660; SER-670; SER-700;
RP   SER-712; SER-737; SER-753; SER-768; SER-795 AND SER-813, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY.
RX   PubMed=25330774; DOI=10.1002/pmic.201400218;
RA   Pasyk S., Molinski S., Ahmadi S., Ramjeesingh M., Huan L.J., Chin S.,
RA   Du K., Yeger H., Taylor P., Moran M.F., Bear C.E.;
RT   "The major cystic fibrosis causing mutation exhibits defective propensity
RT   for phosphorylation.";
RL   Proteomics 15:447-461(2015).
RN   [42]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=26627831; DOI=10.1074/jbc.m115.704809;
RA   Ehrhardt A., Chung W.J., Pyle L.C., Wang W., Nowotarski K., Mulvihill C.M.,
RA   Ramjeesingh M., Hong J., Velu S.E., Lewis H.A., Atwell S., Aller S.,
RA   Bear C.E., Lukacs G.L., Kirk K.L., Sorscher E.J.;
RT   "Channel gating regulation by the cystic fibrosis transmembrane conductance
RT   regulator (CFTR) first cytosolic loop.";
RL   J. Biol. Chem. 291:1854-1865(2016).
RN   [43]
RP   FUNCTION.
RX   PubMed=26823428; DOI=10.1126/science.aad5589;
RA   Shah V.S., Meyerholz D.K., Tang X.X., Reznikov L., Abou Alaiwa M.,
RA   Ernst S.E., Karp P.H., Wohlford-Lenane C.L., Heilmann K.P., Leidinger M.R.,
RA   Allen P.D., Zabner J., McCray P.B. Jr., Ostedgaard L.S., Stoltz D.A.,
RA   Randak C.O., Welsh M.J.;
RT   "Airway acidification initiates host defense abnormalities in cystic
RT   fibrosis mice.";
RL   Science 351:503-507(2016).
RN   [44]
RP   FUNCTION.
RX   PubMed=27941075; DOI=10.1152/ajplung.00375.2016;
RA   Rauh R., Hoerner C., Korbmacher C.;
RT   "deltabetagamma-ENaC is inhibited by CFTR but stimulated by cAMP in Xenopus
RT   laevis oocytes.";
RL   Am. J. Physiol. 312:L277-L287(2017).
RN   [45]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=28130590; DOI=10.1007/s00418-016-1535-3;
RA   Hanukoglu I., Boggula V.R., Vaknine H., Sharma S., Kleyman T.,
RA   Hanukoglu A.;
RT   "Expression of epithelial sodium channel (ENaC) and CFTR in the human
RT   epidermis and epidermal appendages.";
RL   Histochem. Cell Biol. 147:733-748(2017).
RN   [46]
RP   FUNCTION.
RX   PubMed=27714810; DOI=10.1002/jcp.25634;
RA   Puga Molina L.C., Pinto N.A., Torres Rodriguez P., Romarowski A.,
RA   Vicens Sanchez A., Visconti P.E., Darszon A., Trevino C.L., Buffone M.G.;
RT   "Essential role of CFTR in PKA-dependent phosphorylation, alkalinization,
RT   and hyperpolarization during human sperm capacitation.";
RL   J. Cell. Physiol. 232:1404-1414(2017).
RN   [47]
RP   INTERACTION WITH ADGRG2.
RX   PubMed=29393851; DOI=10.7554/elife.33432;
RA   Zhang D.L., Sun Y.J., Ma M.L., Wang Y.J., Lin H., Li R.R., Liang Z.L.,
RA   Gao Y., Yang Z., He D.F., Lin A., Mo H., Lu Y.J., Li M.J., Kong W.,
RA   Chung K.Y., Yi F., Li J.Y., Qin Y.Y., Li J., Thomsen A.R.B., Kahsai A.W.,
RA   Chen Z.J., Xu Z.G., Liu M., Li D., Yu X., Sun J.P.;
RT   "Gq activity- and beta-arrestin-1 scaffolding-mediated ADGRG2/CFTR coupling
RT   are required for male fertility.";
RL   Elife 7:0-0(2018).
RN   [48]
RP   3D-STRUCTURE MODELING OF 425-638.
RX   PubMed=9517543;
RX   DOI=10.1002/(sici)1097-0134(19980215)30:3<275::aid-prot7>3.3.co;2-l;
RA   Hoedemaeker F.J., Davidson A.R., Rose D.R.;
RT   "A model for the nucleotide-binding domains of ABC transporters based on
RT   the large domain of aspartate aminotransferase.";
RL   Proteins 30:275-286(1998).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 1476-1480 IN COMPLEX WITH NHERF1.
RX   PubMed=11304524; DOI=10.1074/jbc.c100154200;
RA   Karthikeyan S., Leung T., Ladias J.A.A.;
RT   "Structural basis of the Na+/H+ exchanger regulatory factor PDZ1
RT   interaction with the carboxyl-terminal region of the cystic fibrosis
RT   transmembrane conductance regulator.";
RL   J. Biol. Chem. 276:19683-19686(2001).
RN   [50] {ECO:0007744|PDB:2LOB}
RP   STRUCTURE BY NMR OF 1473-1480 IN COMPLEX WITH GOPC.
RX   PubMed=16331976; DOI=10.1021/bi0516475;
RA   Piserchio A., Fellows A., Madden D.R., Mierke D.F.;
RT   "Association of the cystic fibrosis transmembrane regulator with CAL:
RT   structural features and molecular dynamics.";
RL   Biochemistry 44:16158-16166(2005).
RN   [51] {ECO:0007744|PDB:1XMI, ECO:0007744|PDB:1XMJ}
RP   X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) OF 389-678 OF WILD-TYPE AND VARIANT
RP   CF PHE-508 DEL IN COMPLEX WITH ATP, AND CHARACTERIZATION OF VARIANT CF
RP   PHE-508 DEL.
RX   PubMed=15528182; DOI=10.1074/jbc.m410968200;
RA   Lewis H.A., Zhao X., Wang C., Sauder J.M., Rooney I., Noland B.W.,
RA   Lorimer D., Kearins M.C., Conners K., Condon B., Maloney P.C.,
RA   Guggino W.B., Hunt J.F., Emtage S.;
RT   "Impact of the deltaF508 mutation in first nucleotide-binding domain of
RT   human cystic fibrosis transmembrane conductance regulator on domain folding
RT   and structure.";
RL   J. Biol. Chem. 280:1346-1353(2005).
RN   [52] {ECO:0007744|PDB:3GD7}
RP   X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 1193-1435 AND 1458-1470 IN
RP   COMPLEX WITH ATP ANALOG.
RA   Atwell S., Antonysamy S., Guggino W.B., Conners K., Emtage S., Gheyi T.,
RA   Hunt J.F., Lewis H.A., Lu F., Sauder J.M., Weber P.C., Wetmore D., Zhao X.;
RT   "Crystal structure of human NBD2 complexed with N6-phenylethyl-ATP (P-
RT   ATP).";
RL   Submitted (FEB-2009) to the PDB data bank.
RN   [53] {ECO:0007744|PDB:2BBO, ECO:0007744|PDB:2BBS, ECO:0007744|PDB:2BBT}
RP   X-RAY CRYSTALLOGRAPHY (2.05 ANGSTROMS) OF 389-677 IN COMPLEX WITH ATP.
RX   PubMed=19944699; DOI=10.1016/j.jmb.2009.11.051;
RA   Lewis H.A., Wang C., Zhao X., Hamuro Y., Conners K., Kearins M.C., Lu F.,
RA   Sauder J.M., Molnar K.S., Coales S.J., Maloney P.C., Guggino W.B.,
RA   Wetmore D.R., Weber P.C., Hunt J.F.;
RT   "Structure and dynamics of NBD1 from CFTR characterized using
RT   crystallography and hydrogen/deuterium exchange mass spectrometry.";
RL   J. Mol. Biol. 396:406-430(2010).
RN   [54] {ECO:0007744|PDB:2PZE, ECO:0007744|PDB:2PZF, ECO:0007744|PDB:2PZG}
RP   X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 387-646 IN COMPLEX WITH ATP, AND
RP   CHARACTERIZATION OF VARIANT CF PHE-508 DEL.
RX   PubMed=20150177; DOI=10.1093/protein/gzq004;
RA   Atwell S., Brouillette C.G., Conners K., Emtage S., Gheyi T., Guggino W.B.,
RA   Hendle J., Hunt J.F., Lewis H.A., Lu F., Protasevich I.I., Rodgers L.A.,
RA   Romero R., Wasserman S.R., Weber P.C., Wetmore D., Zhang F.F., Zhao X.;
RT   "Structures of a minimal human CFTR first nucleotide-binding domain as a
RT   monomer, head-to-tail homodimer, and pathogenic mutant.";
RL   Protein Eng. Des. Sel. 23:375-384(2010).
RN   [55]
RP   STRUCTURE BY ELECTRON MICROSCOPY (9 ANGSTROMS).
RX   PubMed=21931164; DOI=10.1074/jbc.m111.292268;
RA   Rosenberg M.F., O'Ryan L.P., Hughes G., Zhao Z., Aleksandrov L.A.,
RA   Riordan J.R., Ford R.C.;
RT   "The cystic fibrosis transmembrane conductance regulator (CFTR): three-
RT   dimensional structure and localization of a channel gate.";
RL   J. Biol. Chem. 286:42647-42654(2011).
RN   [56] {ECO:0007744|PDB:4WZ6}
RP   X-RAY CRYSTALLOGRAPHY (2.05 ANGSTROMS) OF 389-678.
RX   PubMed=26444971; DOI=10.1002/pro.2821;
RA   Hall J.D., Wang H., Byrnes L.J., Shanker S., Wang K., Efremov I.V.,
RA   Chong P.A., Forman-Kay J.D., Aulabaugh A.E.;
RT   "Binding screen for cystic fibrosis transmembrane conductance regulator
RT   correctors finds new chemical matter and yields insights into cystic
RT   fibrosis therapeutic strategy.";
RL   Protein Sci. 25:360-373(2016).
RN   [57] {ECO:0007744|PDB:5UAK}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.87 ANGSTROMS), AND TOPOLOGY.
RA   Liu F., Zhang Z., Chen J.;
RT   "Structure of human cystic fibrosis transmembrane conductance regulator
RT   (CFTR).";
RL   Submitted (DEC-2016) to the PDB data bank.
RN   [58]
RP   REVIEW ON VARIANTS.
RX   PubMed=1284534; DOI=10.1002/humu.1380010304;
RA   Tsui L.-C.;
RT   "Mutations and sequence variations detected in the cystic fibrosis
RT   transmembrane conductance regulator (CFTR) gene: a report from the Cystic
RT   Fibrosis Genetic Analysis Consortium.";
RL   Hum. Mutat. 1:197-203(1992).
RN   [59]
RP   CHARACTERIZATION OF VARIANT CF TRP-334; ILE-507 DEL; PHE-508 DEL; ASP-551
RP   AND ILE-549, MUTAGENESIS OF LYS-464; PHE-508 AND LYS-1250, AND
RP   GLYCOSYLATION.
RX   PubMed=1699669; DOI=10.1016/0092-8674(90)90148-8;
RA   Cheng S.H., Gregory R.J., Marshall J., Paul S., Souza D.W., White G.A.,
RA   O'Riordan C.R., Smith A.E.;
RT   "Defective intracellular transport and processing of CFTR is the molecular
RT   basis of most cystic fibrosis.";
RL   Cell 63:827-834(1990).
RN   [60]
RP   VARIANTS CF ASN-549; ASP-551 AND THR-559.
RX   PubMed=1695717; DOI=10.1038/346366a0;
RA   Cutting G.R., Kasch L.M., Rosenstein B.J., Zielenski J., Tsui L.-C.,
RA   Antonarakis S.E., Kazazian H.H. Jr.;
RT   "A cluster of cystic fibrosis mutations in the first nucleotide-binding
RT   fold of the cystic fibrosis conductance regulator protein.";
RL   Nature 346:366-369(1990).
RN   [61]
RP   VARIANTS CF GLU-455; ARG-549; ILE-549; ASP-551; THR-560; ASN-563 AND
RP   HIS-574.
RX   PubMed=2236053; DOI=10.1073/pnas.87.21.8447;
RA   Kerem B.-S., Zielenski J., Markiewicz D., Bozon D., Gazit E., Yahav J.,
RA   Kennedy D., Riordan J.R., Collins F.S., Rommens J.M., Tsui L.-C.;
RT   "Identification of mutations in regions corresponding to the two putative
RT   nucleotide (ATP)-binding folds of the cystic fibrosis gene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:8447-8451(1990).
RN   [62]
RP   VARIANTS CF.
RX   PubMed=1710600; DOI=10.1016/0888-7543(91)90510-l;
RA   White M.B., Krueger L.J., Holsclaw D.S. Jr., Gerrard B.C., Stewart C.,
RA   Quittell L., Dolganov G., Baranov V., Ivaschenko T., Kapronov N.I.,
RA   Sebastio G., Castiglione O., Dean M.;
RT   "Detection of three rare frameshift mutations in the cystic fibrosis gene
RT   in an African-American (CF444delA), an Italian (CF2522insC), and a Soviet
RT   (CF3821delT).";
RL   Genomics 10:266-269(1991).
RN   [63]
RP   CHARACTERIZATION OF CF VARIANTS ILE-507 DEL; PHE-508 DEL; ILE-549; ARG-549;
RP   ASP-551; THR-559; ASN-572; LYS-1303 AND ASP-1349, FUNCTION, TRANSPORTER
RP   ACTIVITY, SUBCELLULAR LOCATION, AND MUTAGENESIS OF PHE-508.
RX   PubMed=1712898; DOI=10.1128/mcb.11.8.3886-3893.1991;
RA   Gregory R.J., Rich D.P., Cheng S.H., Souza D.W., Paul S., Manavalan P.,
RA   Anderson M.P., Welsh M.J., Smith A.E.;
RT   "Maturation and function of cystic fibrosis transmembrane conductance
RT   regulator variants bearing mutations in putative nucleotide-binding domains
RT   1 and 2.";
RL   Mol. Cell. Biol. 11:3886-3893(1991).
RN   [64]
RP   VARIANTS VAL-44; MET-470; VAL-506; CYS-508; ALA-576; CYS-668; PHE-997;
RP   THR-1027 AND LEU-1162, AND VARIANTS CF GLY-44; ARG-178; ARG-225; TRP-334;
RP   PHE-508 DEL; 542-GLY--LEU-1480 DEL; ASP-551; ILE-562; ARG-628;
RP   710-LYS--LEU-1480 DEL; 846-TRP--LEU-1480 DEL; CYS-913; 1063-TRP--LEU-1480
RP   DEL; CYS-1066; 1092-TYR--LEU-1480 DEL; 1162-ARG--LEU-1480 DEL; GLU-1200;
RP   1282-TRP--LEU-1480 DEL AND LYS-1303.
RX   PubMed=1379210; DOI=10.1016/0888-7543(92)90152-i;
RA   Fanen P., Ghanem N., Vidaud M., Besmond C., Martin J., Costes B.,
RA   Plassa F., Goossens M.;
RT   "Molecular characterization of cystic fibrosis: 16 novel mutations
RT   identified by analysis of the whole cystic fibrosis conductance
RT   transmembrane regulator (CFTR) coding regions and splice site junctions.";
RL   Genomics 13:770-776(1992).
RN   [65]
RP   VARIANTS CF PHE-520 AND HIS-1291.
RX   PubMed=1284466; DOI=10.1093/hmg/1.1.11;
RA   Jones C.T., McIntosh I., Keston M., Ferguson A., Brock D.J.H.;
RT   "Three novel mutations in the cystic fibrosis gene detected by chemical
RT   cleavage: analysis of variant splicing and a nonsense mutation.";
RL   Hum. Mol. Genet. 1:11-17(1992).
RN   [66]
RP   VARIANT CF MET-1283.
RX   PubMed=1284468; DOI=10.1093/hmg/1.2.123;
RA   Cheadle J.P., Meredith A.L., Al-Jader L.N.;
RT   "A new missense mutation (R1283M) in exon 20 of the cystic fibrosis
RT   transmembrane conductance regulator gene.";
RL   Hum. Mol. Genet. 1:123-125(1992).
RN   [67]
RP   VARIANT CF PRO-1255.
RX   PubMed=1284530; DOI=10.1093/hmg/1.6.441;
RA   Lissens W., Bonduelle M., Malfroot A., Dab I., Liebaers I.;
RT   "A serine to proline substitution (S1255P) in the second nucleotide binding
RT   fold of the cystic fibrosis gene.";
RL   Hum. Mol. Genet. 1:441-442(1992).
RN   [68]
RP   VARIANTS CF LYS-92 AND CYS-117.
RX   PubMed=1284529; DOI=10.1093/hmg/1.6.439;
RA   Shackleton S., Beards F., Harris A.;
RT   "Detection of novel and rare mutations in exon 4 of the cystic fibrosis
RT   gene by SSCP.";
RL   Hum. Mol. Genet. 1:439-440(1992).
RN   [69]
RP   CHARACTERIZATION OF VARIANT CF PHE-508 DEL AND ASP-551, SUBCELLULAR
RP   LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=1284548; DOI=10.1038/ng0892-321;
RA   Kartner N., Augustinas O., Jensen T.J., Naismith A.L., Riordan J.R.;
RT   "Mislocalization of delta F508 CFTR in cystic fibrosis sweat gland.";
RL   Nat. Genet. 1:321-327(1992).
RN   [70]
RP   VARIANT CF LYS-1101.
RX   PubMed=7680525;
RA   Zielenski J., Fugiwara T.M., Markiewicz D., Paradis A.J., Anacleto A.I.,
RA   Richards B., Schwartz R.H., Klinger K.W., Tsui L.-C., Morgan K.;
RT   "Identification of the M1101K mutation in the cystic fibrosis transmembrane
RT   conductance regulator (CFTR) gene and complete detection of cystic fibrosis
RT   mutations in the Hutterite population.";
RL   Am. J. Hum. Genet. 52:609-615(1993).
RN   [71]
RP   VARIANTS CF VAL-1052; ARG-1061; LEU-1066; GLN-1070; ARG-1085 AND ARG-1101.
RX   PubMed=7683628; DOI=10.1006/geno.1993.1183;
RA   Mercier B., Lissens W., Novelli G., Kalaydjieva L., De Arce M.,
RA   Kapranov N., Klain N.C., Lenoir G., Chauveau P., Lenaerts C., Rault G.,
RA   Cashman S., Sangiuolo F., Audrezet M.-P., Dallapiccola B., Guillermit H.,
RA   Bonduelle M., Liebaers I., Quere I., Verlingue C., Ferec C.;
RT   "Identification of eight novel mutations in a collaborative analysis of a
RT   part of the second transmembrane domain of the CFTR gene.";
RL   Genomics 16:296-297(1993).
RN   [72]
RP   VARIANTS CF HIS-117; LYS-336; GLU-455; VAL-458; ARG-628; ARG-1235; ASN-1251
RP   AND LYS-1303.
RX   PubMed=7508414; DOI=10.1016/s0888-7543(05)80376-3;
RA   Cuppens H., Marynen P., De Boeck C., Cassiman J.J.;
RT   "Detection of 98.5% of the mutations in 200 Belgian cystic fibrosis alleles
RT   by reverse dot-blot and sequencing of the complete coding region and
RT   exon/intron junctions of the CFTR gene.";
RL   Genomics 18:693-697(1993).
RN   [73]
RP   VARIANT CF LEU-693.
RX   PubMed=8406518; DOI=10.1159/000154147;
RA   Audrezet M.P., Novelli G., Mercier B., Sangiuolo F., Maceratesi P.,
RA   Ferec C., Dallapiccola B.;
RT   "Identification of three novel cystic fibrosis mutations in a sample of
RT   Italian cystic fibrosis patients.";
RL   Hum. Hered. 43:295-300(1993).
RN   [74]
RP   VARIANT CF LYS-92.
RX   PubMed=7683954; DOI=10.1093/hmg/2.1.79;
RA   Nunes V., Chillon M., Doerk T., Tuemmler B., Casals T., Estivill X.;
RT   "A new missense mutation (E92K) in the first transmembrane domain of the
RT   CFTR gene causes a benign cystic fibrosis phenotype.";
RL   Hum. Mol. Genet. 2:79-80(1993).
RN   [75]
RP   VARIANT CF SER-205.
RX   PubMed=7505694; DOI=10.1093/hmg/2.10.1741;
RA   Chillon M., Casals T., Nunes V., Gimenez J., Ruiz E.P., Estivill X.;
RT   "Identification of a new missense mutation (P205S) in the first
RT   transmembrane domain of the CFTR gene associated with a mild cystic
RT   fibrosis phenotype.";
RL   Hum. Mol. Genet. 2:1741-1742(1993).
RN   [76]
RP   VARIANTS CF HIS-347; LEU-347; GLN-352 AND LYS-359.
RX   PubMed=7504969; DOI=10.1002/humu.1380020511;
RA   Gasparini P., Marigo C., Bisceglia G., Nicolis E., Zelante L., Bombieri C.,
RA   Borgo G., Pignatti P.F., Cabrini G.;
RT   "Screening of 62 mutations in a cohort of cystic fibrosis patients from
RT   north eastern Italy: their incidence and clinical features of defined
RT   genotypes.";
RL   Hum. Mutat. 2:389-394(1993).
RN   [77]
RP   VARIANTS CYS-31 AND ILE-1220, AND VARIANTS CF 890-GLN--LEU-1480 DEL;
RP   LEU-912; TYR-949; PRO-1065; PRO-1071 AND 1204-TRP--LEU-1480 DEL.
RX   PubMed=7522211; DOI=10.1006/geno.1994.1290;
RA   Ghanem N., Costes B., Girodon E., Martin J., Fanen P., Goossens M.;
RT   "Identification of eight mutations and three sequence variations in the
RT   cystic fibrosis transmembrane conductance regulator (CFTR) gene.";
RL   Genomics 21:434-436(1994).
RN   [78]
RP   VARIANT CF PHE-456.
RX   PubMed=7505767; DOI=10.1007/bf00218916;
RA   Doerk T., Fislage R., Neumann T., Wulf B., Tuemmler B.;
RT   "Exon 9 of the CFTR gene: splice site haplotypes and cystic fibrosis
RT   mutations.";
RL   Hum. Genet. 93:67-73(1994).
RN   [79]
RP   VARIANT CF PRO-346.
RX   PubMed=7513296; DOI=10.1007/bf00202817;
RA   Boteva K., Papageorgiou E., Georgiou C., Angastiniotis M., Middleton L.T.,
RA   Constantinou-Deltas C.D.;
RT   "Novel cystic fibrosis mutation associated with mild disease in Cypriot
RT   patients.";
RL   Hum. Genet. 93:529-532(1994).
RN   [80]
RP   VARIANTS CF TYR-199; SER-619; ARG-1005 AND ARG-1291.
RX   PubMed=7525450; DOI=10.1007/bf00211022;
RA   Doerk T., Mekus F., Schmidt K., Bosshammer J., Fislage R., Heuer T.,
RA   Dziadek V., Neumann T., Kaelin N., Wulbrand U., Wulf B., von der Hardt H.,
RA   Maass G., Tuemmler B.;
RT   "Detection of more than 50 different CFTR mutations in a large group of
RT   German cystic fibrosis patients.";
RL   Hum. Genet. 94:533-542(1994).
RN   [81]
RP   VARIANT CF GLU-1249.
RX   PubMed=7520022; DOI=10.1159/000154223;
RA   Greil I., Wagner K., Rosenkranz W.;
RT   "A new missense mutation G1249E in exon 20 of the cystic fibrosis
RT   transmembrane conductance regulator (CFTR) gene.";
RL   Hum. Hered. 44:238-240(1994).
RN   [82]
RP   VARIANT CF GLU-1397.
RX   PubMed=7524913; DOI=10.1093/hmg/3.6.999;
RA   Petreska L., Koceva S., Gordova-Muratovska A., Nestorov R., Efremov G.D.;
RT   "Identification of two new mutations (711 +3A-->G and V1397E) in CF
RT   chromosomes of Albanian and Macedonian origin.";
RL   Hum. Mol. Genet. 3:999-1000(1994).
RN   [83]
RP   VARIANT CF CYS-109.
RX   PubMed=7524909; DOI=10.1093/hmg/3.6.1001;
RA   Schaedel C., Kristoffersson A.-C., Kornfaelt R., Holmberg L.;
RT   "A novel cystic fibrosis mutation, Y109C, in the first transmembrane domain
RT   of CFTR.";
RL   Hum. Mol. Genet. 3:1001-1002(1994).
RN   [84]
RP   VARIANT CF THR-120.
RX   PubMed=7517264; DOI=10.1002/humu.1380030308;
RA   Chillon M., Casals T., Gimenez J., Nunes V., Estivill X.;
RT   "Analysis of the CFTR gene in the Spanish population: SSCP-screening for 60
RT   known mutations and identification of four new mutations (Q30X, A120T,
RT   1812-1 G-->A, and 3667del4).";
RL   Hum. Mutat. 3:223-230(1994).
RN   [85]
RP   VARIANT CF LEU-87.
RX   PubMed=8081395; DOI=10.1002/humu.1380030412;
RA   Bienvenu T., Petitpretz P., Beldjord C., Kaplan J.C.;
RT   "A missense mutation (F87L) in exon 3 of the cystic fibrosis transmembrane
RT   conductance regulator gene.";
RL   Hum. Mutat. 3:395-396(1994).
RN   [86]
RP   VARIANTS CBAVD ARG-149; LYS-193; GLY-258 AND GLY-800.
RX   PubMed=7529962;
RA   Mercier B., Verlingue C., Lissens W., Silber S.J., Novelli G.,
RA   Bonduelle M., Audrezet M.-P., Ferec C.;
RT   "Is congenital bilateral absence of vas deferens a primary form of cystic
RT   fibrosis? Analyses of the CFTR gene in 67 patients.";
RL   Am. J. Hum. Genet. 56:272-277(1995).
RN   [87]
RP   VARIANTS CBAVD HIS-117 AND TRP-1070, AND VARIANT VAL-1067.
RX   PubMed=7539342;
RA   Jezequel P., Dorval I., Fergelot P., Chauvel B., Le Treut A.,
RA   Le Gall J.-Y., Le Lannou D., Blayau M.;
RT   "Structural analysis of CFTR gene in congenital bilateral absence of vas
RT   deferens.";
RL   Clin. Chem. 41:833-835(1995).
RN   [88]
RP   VARIANT CF SER-551.
RX   PubMed=7606851; DOI=10.1111/j.1399-0004.1995.tb03931.x;
RA   Orozco L., Lezana J.L., Villarreal M.T., Chavez M., Carnevale A.;
RT   "Mild cystic fibrosis disease in three Mexican delta-F508/G551S compound
RT   heterozygous siblings.";
RL   Clin. Genet. 47:96-98(1995).
RN   [89]
RP   VARIANTS CF GLY-57; LYS-193 AND GLY-579.
RX   PubMed=7544319; DOI=10.1007/bf00210414;
RA   Brancolini V., Cremonesi L., Belloni E., Pappalardo E., Bordoni R.,
RA   Seia M., Russo S., Padoan R., Giunta A., Ferrari M.;
RT   "Search for mutations in pancreatic sufficient cystic fibrosis Italian
RT   patients: detection of 90% of molecular defects and identification of three
RT   novel mutations.";
RL   Hum. Genet. 96:312-318(1995).
RN   [90]
RP   VARIANT CF TRP-206.
RX   PubMed=8522333; DOI=10.1007/bf00210305;
RA   Desgeorges M., Rodier M., Piot M., Demaille J., Claustres M.;
RT   "Four adult patients with the missense mutation L206W and a mild cystic
RT   fibrosis phenotype.";
RL   Hum. Genet. 96:717-720(1995).
RN   [91]
RP   VARIANTS CF LEU-31 AND ARG-1098.
RX   PubMed=7537150; DOI=10.1002/humu.1380050106;
RA   Zielenski J., Markiewicz D., Chen H.S., Schappert K.T., Seller A.,
RA   Durie P., Corey M., Tsui L.-C.;
RT   "Identification of six mutations (R31L, 441delA, 681delC, 1461ins4, W1089R,
RT   E1104X) in the cystic fibrosis transmembrane conductance regulator (CFTR)
RT   gene.";
RL   Hum. Mutat. 5:43-47(1995).
RN   [92]
RP   VARIANT CF ASN-572.
RX   PubMed=7541273; DOI=10.1002/humu.1380050304;
RA   Verlingue C., Kapranov N.I., Mercier B., Ginter E.K., Petrova N.V.,
RA   Audrezet M.P., Ferec C.;
RT   "Complete screening of mutations in the coding sequence of the CFTR gene in
RT   a sample of CF patients from Russia: identification of three novel
RT   alleles.";
RL   Hum. Mutat. 5:205-209(1995).
RN   [93]
RP   VARIANT CF ARG-98.
RX   PubMed=7581407; DOI=10.1002/humu.1380060216;
RA   Romey M.-C., Desgeorges M., Ray P., Godard P., Demaille J., Claustres M.;
RT   "Novel missense mutation in the first transmembrane segment of the CFTR
RT   gene (Q98R) identified in a male adult.";
RL   Hum. Mutat. 6:190-191(1995).
RN   [94]
RP   VARIANT CF ILE-338.
RX   PubMed=7543567; DOI=10.1016/s0022-3476(95)70310-1;
RA   Leoni G.B., Pitzalis S., Podda R., Zanda M., Silvetti M., Caocci L.,
RA   Cao A., Rosatelli M.C.;
RT   "A specific cystic fibrosis mutation (T338I) associated with the phenotype
RT   of isolated hypotonic dehydration.";
RL   J. Pediatr. 127:281-283(1995).
RN   [95]
RP   VARIANTS CF PHE-42; LEU-117; ARG-139 AND GLU-1006.
RX   PubMed=7541510; DOI=10.1016/s0890-8508(95)80038-7;
RA   Ferec C., Novelli G., Verlingue C., Quere I., Dallapiccola B.,
RA   Audrezet M.P., Mercier B.;
RT   "Identification of six novel CFTR mutations in a sample of Italian cystic
RT   fibrosis patients.";
RL   Mol. Cell. Probes 9:135-137(1995).
RN   [96]
RP   VARIANT CF SER-665.
RX   PubMed=8800923; DOI=10.1159/000472165;
RA   Messaoud T., Verlingue C., Denamur E., Pascaud O., Quere I., Fattoum S.,
RA   Elion J., Ferec C.;
RT   "Distribution of CFTR mutations in cystic fibrosis patients of Tunisian
RT   origin: identification of two novel mutations.";
RL   Eur. J. Hum. Genet. 4:20-24(1996).
RN   [97]
RP   VARIANT CF ARG-314.
RX   PubMed=8829633;
RX   DOI=10.1002/(sici)1098-1004(1996)7:2<151::aid-humu10>3.0.co;2-1;
RA   Nasr S.Z., Strong T.V., Mansoura M.K., Dawson D.C., Collins F.S.;
RT   "Novel missense mutation (G314R) in a cystic fibrosis patient with hepatic
RT   failure.";
RL   Hum. Mutat. 7:151-154(1996).
RN   [98]
RP   VARIANT CF CYS-569.
RX   PubMed=8723693; DOI=10.1002/humu.1380070402;
RA   Petreska L., Plaseska D., Koseva S., Stavljenic-Rukavina A., Efremov G.D.;
RT   "A novel mutation in exon 12 (Y569C) of the CFTR gene identified in a
RT   patient of Croatian origin.";
RL   Hum. Mutat. 7:374-375(1996).
RN   [99]
RP   VARIANT CF ARG-1061.
RX   PubMed=8723695;
RX   DOI=10.1002/(sici)1098-1004(1996)7:4<376::aid-humu18>3.0.co;2-#;
RA   Bienvenu T., Chertkoff L., Beldjord C., Segal E., Carniglia L.,
RA   Barreiro C., Kaplan J.-C.;
RT   "Identification of three novel mutations in the cystic fibrosis
RT   transmembrane conductance regulator gene in Argentinian CF patients.";
RL   Hum. Mutat. 7:376-377(1996).
RN   [100]
RP   VARIANT CF LEU-562.
RX   PubMed=8956039;
RX   DOI=10.1002/(sici)1098-1004(1996)8:4<340::aid-humu7>3.0.co;2-b;
RA   Hughes D.J., Hill A.J.M., Macek M. Jr., Redmond A.O., Nevin N.C.,
RA   Graham C.A.;
RT   "Mutation characterization of CFTR gene in 206 Northern Irish CF families:
RT   thirty mutations, including two novel, account for approximately 94% of CF
RT   chromosomes.";
RL   Hum. Mutat. 8:340-347(1996).
RN   [101]
RP   CHARACTERIZATION OF VARIANT CF ASP-551, FUNCTION, TRANSPORTER ACTIVITY,
RP   CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, AND PHOSPHORYLATION.
RX   PubMed=8910473; DOI=10.1074/jbc.271.45.28463;
RA   Li C., Ramjeesingh M., Wang W., Garami E., Hewryk M., Lee D., Rommens J.M.,
RA   Galley K., Bear C.E.;
RT   "ATPase activity of the cystic fibrosis transmembrane conductance
RT   regulator.";
RL   J. Biol. Chem. 271:28463-28468(1996).
RN   [102]
RP   VARIANT CBAVD TYR-50.
RX   PubMed=9067761;
RX   DOI=10.1002/(sici)1098-1004(1997)9:2<183::aid-humu13>3.0.co;2-z;
RA   Zielenski J., Patrizio P., Markiewicz D., Asch R.H., Tsui L.-C.;
RT   "Identification of two mutations (S50Y and 4173delC) in the CFTR gene from
RT   patients with congenital bilateral absence of vas deferens (CBAVD).";
RL   Hum. Mutat. 9:183-184(1997).
RN   [103]
RP   VARIANT CF MET-1140 DEL.
RX   PubMed=9101301;
RX   DOI=10.1002/(sici)1098-1004(1997)9:4<368::aid-humu13>3.0.co;2-0;
RA   Clavel C., Pennaforte F., Pigeon F., Verlingue C., Birembaut P., Ferec C.;
RT   "Identification of four novel mutations in the cystic fibrosis
RT   transmembrane conductance regulator gene: E664X, 2113delA, 306delTAGA, and
RT   delta M1140.";
RL   Hum. Mutat. 9:368-369(1997).
RN   [104]
RP   VARIANT CF ASP-141.
RX   PubMed=9222768;
RX   DOI=10.1002/(sici)1098-1004(1997)10:1<86::aid-humu15>3.0.co;2-w;
RA   Gouya L., Pascaud O., Munck A., Elion J., Denamur E.;
RT   "Novel mutation (A141D) in exon 4 of the CFTR gene identified in an
RT   Algerian patient.";
RL   Hum. Mutat. 10:86-87(1997).
RN   [105]
RP   VARIANT CF CYS-1066.
RX   PubMed=9375855;
RX   DOI=10.1002/(sici)1098-1004(1997)10:5<387::aid-humu9>3.0.co;2-c;
RA   Casals T., Pacheco P., Barreto C., Gimenez J., Ramos M.D., Pereira S.,
RA   Pinheiro J.A., Cobos N., Curvelo A., Vazquez C., Rocha H., Seculi J.L.,
RA   Perez E., Dapena J., Carrilho E., Duarte A., Palacio A.M., Nunes V.,
RA   Lavinha J., Estivill X.;
RT   "Missense mutation R1066C in the second transmembrane domain of CFTR causes
RT   a severe cystic fibrosis phenotype: study of 19 heterozygous and 2
RT   homozygous patients.";
RL   Hum. Mutat. 10:387-392(1997).
RN   [106]
RP   VARIANTS CF GLU-85; HIS-117; TYR-287; GLU-455; ASP-551; PRO-1070 AND
RP   LYS-1303.
RX   PubMed=9401006;
RX   DOI=10.1002/(sici)1098-1004(1997)10:6<436::aid-humu4>3.0.co;2-b;
RA   Shrimpton A.E., Borowitz D., Swender P.;
RT   "Cystic fibrosis mutation frequencies in upstate New York.";
RL   Hum. Mutat. 10:436-442(1997).
RN   [107]
RP   VARIANT CF PHE-311 DEL.
RX   PubMed=9443874; DOI=10.1086/301681;
RA   Friedman K.J., Leigh M.W., Czarnecki P., Feldman G.L.;
RT   "Cystic fibrosis transmembrane-conductance regulator mutations among
RT   African Americans.";
RL   Am. J. Hum. Genet. 62:195-196(1998).
RN   [108]
RP   CHARACTERIZATION OF VARIANTS CF VAL-1137; MET-1140 DEL AND HIS-1152,
RP   MUTAGENESIS OF MET-1137; ILE-1139 AND ASP-1154, SUBCELLULAR LOCATION,
RP   FUNCTION, AND TRANSPORTER ACTIVITY.
RX   PubMed=9804160; DOI=10.1016/s0014-5793(98)01042-4;
RA   Vankeerberghen A., Wei L., Teng H., Jaspers M., Cassiman J.J., Nilius B.,
RA   Cuppens H.;
RT   "Characterization of mutations located in exon 18 of the CFTR gene.";
RL   FEBS Lett. 437:1-4(1998).
RN   [109]
RP   VARIANTS CF GLN-75; HIS-110; SER-571; ILE-952; LEU-1013; ILE-1028 AND
RP   LYS-1303.
RX   PubMed=9521595; DOI=10.1007/s004390050683;
RA   Onay T., Topaloglu O., Zielenski J., Gokgoz N., Kayserili H., Camcioglu Y.,
RA   Cokugras H., Akcakaya N., Apak M., Tsui L.-C., Kirdar B.;
RT   "Analysis of the CFTR gene in Turkish cystic fibrosis patients:
RT   identification of three novel mutations (3172delAC, P1013L and M1028I).";
RL   Hum. Genet. 102:224-230(1998).
RN   [110]
RP   VARIANTS CYS-31; GLN-75; VAL-506 AND CYS-668, AND VARIANTS CF CYS-301;
RP   ASN-651; MET-754 AND LEU-1072.
RX   PubMed=9921909; DOI=10.1007/s004390050897;
RA   Bombieri C., Benetazzo M., Saccomani A., Belpinati F., Gile L.S.,
RA   Luisetti M., Pignatti P.F.;
RT   "Complete mutational screening of the CFTR gene in 120 patients with
RT   pulmonary disease.";
RL   Hum. Genet. 103:718-722(1998).
RN   [111]
RP   CHARACTERIZATION OF VARIANTS CF PHE-601; SER-610; THR-613; GLY-614;
RP   THR-618; SER-619; GLN-620; PRO-620; ARG-628; PRO-633; SER-665; LEU-693 AND
RP   LYS-822, CHARACTERIZATION OF VARIANTS CBAVD ASP-622; MET-766; GLY-792;
RP   GLY-800 AND MET-807, AND CHARACTERIZATION OF VARIANT THORACIC SARCOIDOSIS
RP   LYS-826.
RX   PubMed=9736778; DOI=10.1093/hmg/7.11.1761;
RA   Vankeerberghen A., Wei L., Jaspers M., Cassiman J.-J., Nilius B.,
RA   Cuppens H.;
RT   "Characterization of 19 disease-associated missense mutations in the
RT   regulatory domain of the cystic fibrosis transmembrane conductance
RT   regulator.";
RL   Hum. Mol. Genet. 7:1761-1769(1998).
RN   [112]
RP   VARIANTS CF SER-560 AND ASP-569.
RX   PubMed=9482579;
RX   DOI=10.1002/(sici)1098-1004(1998)11:2<152::aid-humu8>3.0.co;2-l;
RA   Malone G., Haworth A., Schwarz M.J., Cuppens H., Super M.;
RT   "Detection of five novel mutations of the cystic fibrosis transmembrane
RT   regulator (CFTR) gene in Pakistani patients with cystic fibrosis: Y569D,
RT   Q98X, 296+12(T>C), 1161delC and 621+2(T>C).";
RL   Hum. Mutat. 11:152-157(1998).
RN   [113]
RP   VARIANTS CF PHE-13 AND ILE-338.
RX   PubMed=9554753;
RA   Leoni G.B., Pitzalis S., Tonelli R., Cao A.;
RT   "Identification of a novel mutation (S13F) in the CFTR gene in a CF patient
RT   of Sardinian origin.";
RL   Hum. Mutat. 11:337-337(1998).
RN   [114]
RP   VARIANTS CF PRO-117 AND ASP-192 DEL.
RX   PubMed=9452048; DOI=10.1002/humu.1380110127;
RA   Feldmann D., Sardet A., Cougoureux E., Plouvier E., Fontaine J.-L.,
RA   Tournier G., Aymard P.;
RT   "Identification of three novel mutations in the CFTR gene, R117P,
RT   deltaD192, and 3121+1G-->A in four French patients.";
RL   Hum. Mutat. Suppl. 1:S78-S80(1998).
RN   [115]
RP   VARIANT CF ARG-1065.
RX   PubMed=9452054; DOI=10.1002/humu.1380110133;
RA   Casals T., Ramos M.D., Gimenez J., Nadal M., Nunes V., Estivill X.;
RT   "Paternal origin of a de novo novel CFTR mutation (L1065R) causing cystic
RT   fibrosis.";
RL   Hum. Mutat. Suppl. 1:S99-S102(1998).
RN   [116]
RP   VARIANT CF ASN-LYS-370 INS.
RX   PubMed=9452073; DOI=10.1002/humu.1380110152;
RA   Shackleton S., Harris A.;
RT   "A 2-amino acid insertion mutation (1243insACAAAA) in exon 7 of the CFTR
RT   gene.";
RL   Hum. Mutat. Suppl. 1:S156-S157(1998).
RN   [117]
RP   VARIANT CBAVD GLY-513, AND VARIANT MET-470.
RX   PubMed=10651488;
RA   Bienvenu T., Bousquet S., Vidaud D., Hubert D., Francoual C., Beldjord C.,
RA   Kaplan J.-C.;
RT   "A novel missense mutation D513G in exon 10 of the cystic fibrosis
RT   transmembrane conductance regulator (CFTR) gene identified in a French
RT   CBAVD patient.";
RL   Hum. Mutat. 12:213-214(1998).
RN   [118]
RP   VARIANTS CBAVD LEU-111; LYS-244; VAL-544 AND VAL-1364.
RA   de Meeus A., Guittard C., Desgeorges M., Carles S., Demaille J.,
RA   Claustres M.;
RT   "Genetic findings in congenital bilateral aplasia of vas deferens patients
RT   and identification of six novel mutations.";
RL   Hum. Mutat. 12:480-480(1998).
RN   [119]
RP   VARIANT CF LEU-67.
RX   PubMed=9507391; DOI=10.1136/jmg.35.2.122;
RA   Gilfillan A., Warner J.P., Kirk J.M., Marshall T., Greening A., Ho L.P.,
RA   Hargreave T., Stack B., McIntyre D., Davidson R., Dean J.C., Middleton W.,
RA   Brock D.J.;
RT   "P67L: a cystic fibrosis allele with mild effects found at high frequency
RT   in the Scottish population.";
RL   J. Med. Genet. 35:122-125(1998).
RN   [120]
RP   VARIANT CBAVD ASN-307.
RX   PubMed=10066035; DOI=10.1034/j.1399-0004.1999.550112.x;
RA   Onay T., Kayserili H., Apak M.Y., Kirdar B.;
RT   "Analysis of infertile brothers with congenital bilateral absence of vas
RT   deferens for mutations in the CFTR gene.";
RL   Clin. Genet. 55:63-64(1999).
RN   [121]
RP   VARIANT CF GLY-579.
RX   PubMed=10094564;
RX   DOI=10.1002/(sici)1098-1004(1999)13:2<173::aid-humu20>3.0.co;2-3;
RA   Picci L., Cameran M., Olante P., Zacchello F., Scarpa M.;
RT   "Identification of a D579G homozygote cystic fibrosis patient with
RT   pancreatic sufficiency and minor lung involvement.";
RL   Hum. Mutat. 13:173-173(1999).
RN   [122]
RP   VARIANT CF HIS-569.
RX   PubMed=10869121;
RX   DOI=10.1002/1096-8628(20000717)93:2<161::aid-ajmg15>3.0.co;2-l;
RA   Kabra M., Kabra S.K., Ghosh M., Khanna A., Arora S., Menon P.S.,
RA   Verma I.C., Wallace A.;
RT   "Is the spectrum of mutations in Indian patients with cystic fibrosis
RT   different?";
RL   Am. J. Med. Genet. 93:161-163(2000).
RN   [123]
RP   VARIANT CF HIS-569, AND REVIEW.
RX   PubMed=10923036;
RX   DOI=10.1002/1098-1004(200008)16:2<143::aid-humu7>3.0.co;2-j;
RA   Claustres M., Guittard C., Bozon D., Chevalier F., Verlingue C., Ferec C.,
RA   Girodon E., Cazeneuve C., Bienvenu T., Lalau G., Dumur V., Feldmann D.,
RA   Bieth E., Blayau M., Clavel C., Creveaux I., Malinge M.C., Monnier N.,
RA   Malzac P., Mittre H., Chomel J.C., Bonnefont J.P., Iron A., Chery M.,
RA   Georges M.D.;
RT   "Spectrum of CFTR mutations in cystic fibrosis and in congenital absence of
RT   the vas deferens in France.";
RL   Hum. Mutat. 16:143-156(2000).
RN   [124]
RP   CHARACTERIZATION OF VARIANTS CF HIS-117; THR-148; ARG-178; LYS-193;
RP   ASP-551; SER-551; GLN-620; VAL-648; GLY-800; TYR-949; THR-1067; GLN-1070;
RP   GLU-1244; PRO-1255 AND ASP-1349.
RX   PubMed=11242048; DOI=10.1038/35065099;
RA   Choi J.Y., Muallem D., Kiselyov K., Lee M.G., Thomas P.J., Muallem S.;
RT   "Aberrant CFTR-dependent HCO3- transport in mutations associated with
RT   cystic fibrosis.";
RL   Nature 410:94-97(2001).
RN   [125]
RP   VARIANTS CF THR-148; PHE-508 DEL; 890-GLN--LEU-1480 DEL; 1023-ILE-VAL-1024
RP   DEL AND LYS-1303.
RX   PubMed=12394343; DOI=10.1097/00125817-200209000-00001;
RA   Rohlfs E.M., Zhou Z., Sugarman E.A., Heim R.A., Pace R.G., Knowles M.R.,
RA   Silverman L.M., Allitto B.A.;
RT   "The I148T CFTR allele occurs on multiple haplotypes: a complex allele is
RT   associated with cystic fibrosis.";
RL   Genet. Med. 4:319-323(2002).
RN   [126]
RP   VARIANT CF LEU-693.
RX   PubMed=12167682; DOI=10.1056/nejmoa011899;
RA   Groman J.D., Meyer M.E., Wilmott R.W., Zeitlin P.L., Cutting G.R.;
RT   "Variant cystic fibrosis phenotypes in the absence of CFTR mutations.";
RL   N. Engl. J. Med. 347:401-407(2002).
RN   [127]
RP   CHARACTERIZATION OF VARIANT CF TYR-287 AND PHE-508 DEL, SUBCELLULAR
RP   LOCATION, FUNCTION, TRANSPORTER ACTIVITY, AND GLYCOSYLATION.
RX   PubMed=12529365; DOI=10.1074/jbc.m212843200;
RA   Silvis M.R., Picciano J.A., Bertrand C., Weixel K., Bridges R.J.,
RA   Bradbury N.A.;
RT   "A mutation in the cystic fibrosis transmembrane conductance regulator
RT   generates a novel internalization sequence and enhances endocytic rates.";
RL   J. Biol. Chem. 278:11554-11560(2003).
RN   [128]
RP   CHARACTERIZATION OF VARIANT CF PHE-508 DEL, SUBCELLULAR LOCATION, FUNCTION,
RP   AND TISSUE SPECIFICITY.
RX   PubMed=15716351; DOI=10.1091/mbc.e04-11-1010;
RA   Kreda S.M., Mall M., Mengos A., Rochelle L., Yankaskas J., Riordan J.R.,
RA   Boucher R.C.;
RT   "Characterization of wild-type and deltaF508 cystic fibrosis transmembrane
RT   regulator in human respiratory epithelia.";
RL   Mol. Biol. Cell 16:2154-2167(2005).
RN   [129]
RP   CHARACTERIZATION OF VARIANTS CF PHE-508 DEL; THR-560; GLU-561 AND ILE-562.
RX   PubMed=17098864; DOI=10.1073/pnas.0608312103;
RA   Roxo-Rosa M., Xu Z., Schmidt A., Neto M., Cai Z., Soares C.M.,
RA   Sheppard D.N., Amaral M.D.;
RT   "Revertant mutants G550E and 4RK rescue cystic fibrosis mutants in the
RT   first nucleotide-binding domain of CFTR by different mechanisms.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:17891-17896(2006).
RN   [130]
RP   CHARACTERIZATION OF VARIANT CF THR-148.
RX   PubMed=16822950; DOI=10.1152/ajpcell.00088.2006;
RA   Suaud L., Yan W., Rubenstein R.C.;
RT   "Abnormal regulatory interactions of I148T-CFTR and the epithelial Na+
RT   channel in Xenopus oocytes.";
RL   Am. J. Physiol. 292:C603-C611(2007).
RN   [131]
RP   CHARACTERIZATION OF VARIANT CF LYS-1303, FUNCTION, TRANSPORTER ACTIVITY,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=17182731; DOI=10.1152/ajpcell.00064.2006;
RA   Suaud L., Yan W., Carattino M.D., Robay A., Kleyman T.R., Rubenstein R.C.;
RT   "Regulatory interactions of N1303K-CFTR and ENaC in Xenopus oocytes:
RT   evidence that chloride transport is not necessary for inhibition of ENaC.";
RL   Am. J. Physiol. 292:C1553-C1561(2007).
RN   [132]
RP   VARIANTS GLN-75 AND MET-470, AND VARIANTS CBAVD TRP-74; HIS-110; HIS-117;
RP   HIS-170; TRP-206; ASP-232; TRP-334; TYR-443; PHE-508 DEL; VAL-556; ILE-562;
RP   ALA-576; ASP-622; CYS-668; GLY-938; ILE-952; VAL-959; PHE-977; PHE-997;
RP   CYS-1032; ARG-1069; HIS-1152; GLU-1153; ASN-1270; 1282-TRP--LEU-1480 DEL;
RP   HIS-1352 AND 1473-GLU--LEU-1480 DEL.
RX   PubMed=17329263; DOI=10.1093/humrep/dem024;
RA   Ratbi I., Legendre M., Niel F., Martin J., Soufir J.C., Izard V.,
RA   Costes B., Costa C., Goossens M., Girodon E.;
RT   "Detection of cystic fibrosis transmembrane conductance regulator (CFTR)
RT   gene rearrangements enriches the mutation spectrum in congenital bilateral
RT   absence of the vas deferens and impacts on genetic counselling.";
RL   Hum. Reprod. 22:1285-1291(2007).
RN   [133]
RP   VARIANT [LARGE SCALE ANALYSIS] MET-470.
RX   PubMed=18987736; DOI=10.1038/nature07485;
RA   Ley T.J., Mardis E.R., Ding L., Fulton B., McLellan M.D., Chen K.,
RA   Dooling D., Dunford-Shore B.H., McGrath S., Hickenbotham M., Cook L.,
RA   Abbott R., Larson D.E., Koboldt D.C., Pohl C., Smith S., Hawkins A.,
RA   Abbott S., Locke D., Hillier L.W., Miner T., Fulton L., Magrini V.,
RA   Wylie T., Glasscock J., Conyers J., Sander N., Shi X., Osborne J.R.,
RA   Minx P., Gordon D., Chinwalla A., Zhao Y., Ries R.E., Payton J.E.,
RA   Westervelt P., Tomasson M.H., Watson M., Baty J., Ivanovich J., Heath S.,
RA   Shannon W.D., Nagarajan R., Walter M.J., Link D.C., Graubert T.A.,
RA   DiPersio J.F., Wilson R.K.;
RT   "DNA sequencing of a cytogenetically normal acute myeloid leukaemia
RT   genome.";
RL   Nature 456:66-72(2008).
RN   [134]
RP   VARIANTS CF 220-GLN--LEU-1480 DEL; MET-470; PHE-508 DEL; ILE-562 AND
RP   GLU-1006.
RX   PubMed=20691141; DOI=10.25011/cim.v33i4.14226;
RA   Tomaiuolo A.C., Alghisi F., Petrocchi S., Surace C., Roberti M.C.,
RA   Bella S., Lucidi V., Angioni A.;
RT   "Clinical hallmarks and genetic polymorphisms in the CFTR gene contribute
RT   to the disclosure of the A1006E mutation.";
RL   Clin. Invest. Med. 33:E234-E239(2010).
RN   [135]
RP   CHARACTERIZATION OF VARIANT CF PHE-508 DEL, INTERACTION WITH GORASP2,
RP   SUBCELLULAR LOCATION, AND GLYCOSYLATION.
RX   PubMed=21884936; DOI=10.1016/j.cell.2011.07.021;
RA   Gee H.Y., Noh S.H., Tang B.L., Kim K.H., Lee M.G.;
RT   "Rescue of DeltaF508-CFTR trafficking via a GRASP-dependent unconventional
RT   secretion pathway.";
RL   Cell 146:746-760(2011).
RN   [136]
RP   CHARACTERIZATION OF VARIANT CF PHE-508 DEL.
RX   PubMed=27241308; DOI=10.1016/j.jmb.2016.05.016;
RA   Faure G., Bakouh N., Lourdel S., Odolczyk N., Premchandar A., Servel N.,
RA   Hatton A., Ostrowski M.K., Xu H., Saul F.A., Moquereau C., Bitam S.,
RA   Pranke I., Planelles G., Teulon J., Herrmann H., Roldan A.,
RA   Zielenkiewicz P., Dadlez M., Lukacs G.L., Sermet-Gaudelus I., Ollero M.,
RA   Corringer P.J., Edelman A.;
RT   "Rattlesnake phospholipase A2 increases CFTR-chloride channel current and
RT   corrects DelF508CFTR dysfunction: impact in cystic fibrosis.";
RL   J. Mol. Biol. 428:2898-2915(2016).
RN   [137]
RP   CHARACTERIZATION OF VARIANT CF HIS-117, FUNCTION, TRANSPORTER ACTIVITY, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=26846474; DOI=10.1113/jp271723;
RA   Yu Y.C., Sohma Y., Hwang T.C.;
RT   "On the mechanism of gating defects caused by the R117H mutation in cystic
RT   fibrosis transmembrane conductance regulator.";
RL   J. Physiol. (Lond.) 594:3227-3244(2016).
RN   [138]
RP   CHARACTERIZATION OF VARIANT CF PHE-508 DEL, SUBCELLULAR LOCATION, AND
RP   MUTAGENESIS OF ILE-539.
RX   PubMed=28001373; DOI=10.1021/acs.biochem.6b00853;
RA   Zhang Z., Baksh M.M., Finn M.G., Heidary D.K., Richards C.I.;
RT   "Direct measurement of trafficking of the cystic fibrosis transmembrane
RT   conductance regulator to the cell surface and binding to a chemical
RT   chaperone.";
RL   Biochemistry 56:240-249(2017).
RN   [139]
RP   CHARACTERIZATION OF VARIANTS CF PHE-508 DEL AND ASP-551, SUBCELLULAR
RP   LOCATION, FUNCTION, AND TRANSPORTER ACTIVITY.
RX   PubMed=28087700; DOI=10.1074/jbc.m116.751537;
RA   Meng X., Wang Y., Wang X., Wrennall J.A., Rimington T.L., Li H., Cai Z.,
RA   Ford R.C., Sheppard D.N.;
RT   "Two small molecules restore stability to a sub-population of the cystic
RT   fibrosis transmembrane conductance regulator with the predominant disease-
RT   causing mutation.";
RL   J. Biol. Chem. 292:3706-3719(2017).
RN   [140]
RP   CHARACTERIZATION OF VARIANT CF PHE-508 DEL, AND SUBCELLULAR LOCATION.
RX   PubMed=28067262; DOI=10.1038/srep39887;
RA   Piao H., Kim J., Noh S.H., Kweon H.S., Kim J.Y., Lee M.G.;
RT   "Sec16A is critical for both conventional and unconventional secretion of
RT   CFTR.";
RL   Sci. Rep. 7:39887-39887(2017).
RN   [141]
RP   VARIANT CF ASN-307, AND REVIEW.
RX   PubMed=32026723; DOI=10.5144/0256-4947.2020.15;
RA   Banjar H.H., Tuleimat L., El Seoudi A.A.A., Mogarri I., Alhaider S.,
RA   Nizami I.Y., AlMaghamsi T., Alkaf S.A., Moghrabi N.;
RT   "Genotype patterns for mutations of the cystic fibrosis transmembrane
RT   conductance regulator gene: a retrospective descriptive study from Saudi
RT   Arabia.";
RL   Ann. Saudi Med. 40:15-24(2020).
RN   [142]
RP   VARIANT CF ASN-307, AND REVIEW.
RX   PubMed=33572515; DOI=10.3390/genes12020206;
RA   Bozdogan S.T., Mujde C., Boga I., Sonmezler O., Hanta A.,
RA   Rencuzogullari C., Ozcan D., Altintas D.U., Bisgin A.;
RT   "Current Status of Genetic Diagnosis Laboratories and Frequency of Genetic
RT   Variants Associated with Cystic Fibrosis through a Newborn-Screening
RT   Program in Turkey.";
RL   Genes (Basel) 12:0-0(2021).
CC   -!- FUNCTION: Epithelial ion channel that plays an important role in the
CC       regulation of epithelial ion and water transport and fluid homeostasis
CC       (PubMed:26823428). Mediates the transport of chloride ions across the
CC       cell membrane (PubMed:10792060, PubMed:11524016, PubMed:11707463,
CC       PubMed:12519745, PubMed:12529365, PubMed:12588899, PubMed:12727866,
CC       PubMed:15010471, PubMed:17036051, PubMed:1712898, PubMed:17182731,
CC       PubMed:19398555, PubMed:19621064, PubMed:22178883, PubMed:25330774,
CC       PubMed:26846474, PubMed:28087700, PubMed:8910473, PubMed:9804160).
CC       Possesses an intrinsic ATPase activity and utilizes ATP to gate its
CC       channel; the passive flow of anions through the channel is gated by
CC       cycles of ATP binding and hydrolysis by the ATP-binding domains
CC       (PubMed:11524016, PubMed:15284228, PubMed:26627831, PubMed:8910473).
CC       The ion channel is also permeable to HCO(3)(-); selectivity depends on
CC       the extracellular chloride concentration (PubMed:15010471,
CC       PubMed:19019741). In vitro, mediates ATP-dependent glutathione flux
CC       (PubMed:12727866). Exerts its function also by modulating the activity
CC       of other ion channels and transporters (PubMed:12403779,
CC       PubMed:22121115, PubMed:22178883, PubMed:27941075). Plays an important
CC       role in airway fluid homeostasis (PubMed:16645176, PubMed:19621064,
CC       PubMed:26823428). Contributes to the regulation of the pH and the ion
CC       content of the airway surface fluid layer and thereby plays an
CC       important role in defense against pathogens (PubMed:14668433,
CC       PubMed:16645176, PubMed:26823428). Modulates the activity of the
CC       epithelial sodium channel (ENaC) complex, in part by regulating the
CC       cell surface expression of the ENaC complex (PubMed:17182731,
CC       PubMed:17434346, PubMed:27941075). Inhibits the activity of the ENaC
CC       channel containing subunits SCNN1A, SCNN1B and SCNN1G
CC       (PubMed:17182731). Inhibits the activity of the ENaC channel containing
CC       subunits SCNN1D, SCNN1B and SCNN1G, but not of the ENaC channel
CC       containing subunits SCNN1A, SCNN1B and SCNN1G (PubMed:17182731,
CC       PubMed:27941075). May regulate bicarbonate secretion and salvage in
CC       epithelial cells by regulating the transporter SLC4A7
CC       (PubMed:12403779). Can inhibit the chloride channel activity of ANO1
CC       (PubMed:22178883). Plays a role in the chloride and bicarbonate
CC       homeostasis during sperm epididymal maturation and capacitation
CC       (PubMed:19923167, PubMed:27714810, PubMed:29393851).
CC       {ECO:0000269|PubMed:10792060, ECO:0000269|PubMed:11524016,
CC       ECO:0000269|PubMed:11707463, ECO:0000269|PubMed:12403779,
CC       ECO:0000269|PubMed:12519745, ECO:0000269|PubMed:12529365,
CC       ECO:0000269|PubMed:12588899, ECO:0000269|PubMed:12727866,
CC       ECO:0000269|PubMed:14668433, ECO:0000269|PubMed:15010471,
CC       ECO:0000269|PubMed:15284228, ECO:0000269|PubMed:16645176,
CC       ECO:0000269|PubMed:17036051, ECO:0000269|PubMed:1712898,
CC       ECO:0000269|PubMed:17182731, ECO:0000269|PubMed:19019741,
CC       ECO:0000269|PubMed:19398555, ECO:0000269|PubMed:19621064,
CC       ECO:0000269|PubMed:22178883, ECO:0000269|PubMed:25330774,
CC       ECO:0000269|PubMed:26627831, ECO:0000269|PubMed:26823428,
CC       ECO:0000269|PubMed:26846474, ECO:0000269|PubMed:27714810,
CC       ECO:0000269|PubMed:27941075, ECO:0000269|PubMed:28087700,
CC       ECO:0000269|PubMed:29393851, ECO:0000269|PubMed:8910473,
CC       ECO:0000269|PubMed:9804160, ECO:0000305|PubMed:19923167}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + H2O + closed Cl(-) channel = ADP + phosphate + open
CC         Cl(-) channel.; EC=5.6.1.6; Evidence={ECO:0000269|PubMed:11524016,
CC         ECO:0000269|PubMed:15284228, ECO:0000269|PubMed:26627831,
CC         ECO:0000269|PubMed:8910473};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=chloride(in) = chloride(out); Xref=Rhea:RHEA:29823,
CC         ChEBI:CHEBI:17996; Evidence={ECO:0000269|PubMed:10792060,
CC         ECO:0000269|PubMed:11524016, ECO:0000269|PubMed:11707463,
CC         ECO:0000269|PubMed:12519745, ECO:0000269|PubMed:12529365,
CC         ECO:0000269|PubMed:12588899, ECO:0000269|PubMed:12727866,
CC         ECO:0000269|PubMed:15010471, ECO:0000269|PubMed:17036051,
CC         ECO:0000269|PubMed:1712898, ECO:0000269|PubMed:17182731,
CC         ECO:0000269|PubMed:19398555, ECO:0000269|PubMed:19621064,
CC         ECO:0000269|PubMed:22178883, ECO:0000269|PubMed:25330774,
CC         ECO:0000269|PubMed:26846474, ECO:0000269|PubMed:28087700,
CC         ECO:0000269|PubMed:8910473, ECO:0000269|PubMed:9804160};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=hydrogencarbonate(in) = hydrogencarbonate(out);
CC         Xref=Rhea:RHEA:28695, ChEBI:CHEBI:17544;
CC         Evidence={ECO:0000269|PubMed:15010471, ECO:0000269|PubMed:19019741};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + H2O = ADP + phosphate + H(+); Xref=Rhea:RHEA:13065,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:456216;
CC         Evidence={ECO:0000269|PubMed:11524016, ECO:0000269|PubMed:15284228,
CC         ECO:0000269|PubMed:26627831, ECO:0000269|PubMed:8910473};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:13066;
CC         Evidence={ECO:0000269|PubMed:8910473};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.47 mM for glutathione (in the presence of MgAMP-PNP)
CC         {ECO:0000269|PubMed:12727866};
CC         Vmax=612 pmol/h/ug enzyme (in the presence of MgAMP-PNP)
CC         {ECO:0000269|PubMed:12727866};
CC   -!- SUBUNIT: Monomer; does not require oligomerization for channel activity
CC       (PubMed:11524016). May form oligomers in the membrane
CC       (PubMed:11524016). Interacts with SLC26A3, SLC26A6 and SHANK2 (By
CC       similarity). Interacts with NHERF1 and MYO6 (PubMed:11304524,
CC       PubMed:12403779, PubMed:15247260). Interacts (via C-terminus) with GOPC
CC       (via PDZ domain); this promotes CFTR internalization and thereby
CC       decreases channel activity (PubMed:11707463, PubMed:16331976).
CC       Interacts with SLC4A7 through NHERF1 (PubMed:12403779). Found in a
CC       complex with MYO5B and RAB11A (PubMed:17462998). Interacts with ANO1
CC       (PubMed:22178883). Interacts with SLC26A8 (PubMed:22121115). Interacts
CC       with AHCYL1; the interaction increases CFTR activity (By similarity).
CC       Interacts with CSE1L (PubMed:20933420). The core-glycosylated form
CC       interacts with GORASP2 (via PDZ GRASP-type 1 domain) in respone to ER
CC       stress (PubMed:21884936). Interacts with MARCHF2; the interaction leads
CC       to CFTR ubiqtuitination and degradation (PubMed:23818989). Interacts
CC       with ADGRG2 (PubMed:29393851). {ECO:0000250|UniProtKB:P26361,
CC       ECO:0000250|UniProtKB:P34158, ECO:0000269|PubMed:11304524,
CC       ECO:0000269|PubMed:11524016, ECO:0000269|PubMed:11707463,
CC       ECO:0000269|PubMed:12403779, ECO:0000269|PubMed:15247260,
CC       ECO:0000269|PubMed:16331976, ECO:0000269|PubMed:17462998,
CC       ECO:0000269|PubMed:20933420, ECO:0000269|PubMed:21884936,
CC       ECO:0000269|PubMed:22121115, ECO:0000269|PubMed:22178883,
CC       ECO:0000269|PubMed:23818989, ECO:0000269|PubMed:29393851}.
CC   -!- INTERACTION:
CC       P13569; Q6UWZ7: ABRAXAS1; NbExp=3; IntAct=EBI-349854, EBI-1263451;
CC       P13569; Q96QU6: ACCS; NbExp=3; IntAct=EBI-349854, EBI-743387;
CC       P13569; O14734: ACOT8; NbExp=3; IntAct=EBI-349854, EBI-1237371;
CC       P13569; P60709: ACTB; NbExp=6; IntAct=EBI-349854, EBI-353944;
CC       P13569; O43865: AHCYL1; NbExp=7; IntAct=EBI-349854, EBI-2371423;
CC       P13569; O95154: AKR7A3; NbExp=4; IntAct=EBI-349854, EBI-748869;
CC       P13569; P09972: ALDOC; NbExp=8; IntAct=EBI-349854, EBI-2952751;
CC       P13569; Q9BT30: ALKBH7; NbExp=4; IntAct=EBI-349854, EBI-2878075;
CC       P13569; Q9NP61: ARFGAP3; NbExp=8; IntAct=EBI-349854, EBI-2875816;
CC       P13569; P16615-1: ATP2A2; NbExp=6; IntAct=EBI-349854, EBI-11613988;
CC       P13569; P51572: BCAP31; NbExp=9; IntAct=EBI-349854, EBI-77683;
CC       P13569; A1A5D9: BICDL2; NbExp=3; IntAct=EBI-349854, EBI-10171799;
CC       P13569; Q9H7E9: C8orf33; NbExp=5; IntAct=EBI-349854, EBI-715389;
CC       P13569; P62158: CALM3; NbExp=18; IntAct=EBI-349854, EBI-397435;
CC       P13569; O43852-1: CALU; NbExp=2; IntAct=EBI-349854, EBI-5280679;
CC       P13569; P27824: CANX; NbExp=26; IntAct=EBI-349854, EBI-355947;
CC       P13569; Q01518: CAP1; NbExp=14; IntAct=EBI-349854, EBI-2808398;
CC       P13569; P07384: CAPN1; NbExp=7; IntAct=EBI-349854, EBI-1542113;
CC       P13569; P47756: CAPZB; NbExp=23; IntAct=EBI-349854, EBI-353595;
CC       P13569; O14936: CASK; NbExp=4; IntAct=EBI-349854, EBI-1215506;
CC       P13569; Q9Y3X0: CCDC9; NbExp=4; IntAct=EBI-349854, EBI-2557532;
CC       P13569; Q53EZ4: CEP55; NbExp=5; IntAct=EBI-349854, EBI-747776;
CC       P13569; Q8NCH0: CHST14; NbExp=3; IntAct=EBI-349854, EBI-21717278;
CC       P13569; P51790-2: CLCN3; NbExp=2; IntAct=EBI-349854, EBI-25495635;
CC       P13569; O00299: CLIC1; NbExp=15; IntAct=EBI-349854, EBI-347404;
CC       P13569; Q13057: COASY; NbExp=7; IntAct=EBI-349854, EBI-745967;
CC       P13569; Q9Y678: COPG1; NbExp=21; IntAct=EBI-349854, EBI-1049127;
CC       P13569; P29762: CRABP1; NbExp=4; IntAct=EBI-349854, EBI-725950;
CC       P13569; Q96BA8: CREB3L1; NbExp=3; IntAct=EBI-349854, EBI-6942903;
CC       P13569; Q14406: CSHL1; NbExp=3; IntAct=EBI-349854, EBI-21022791;
CC       P13569; Q13616: CUL1; NbExp=7; IntAct=EBI-349854, EBI-359390;
CC       P13569; Q8N8Q1: CYB561D1; NbExp=3; IntAct=EBI-349854, EBI-12873482;
CC       P13569; Q6PI48: DARS2; NbExp=5; IntAct=EBI-349854, EBI-3917045;
CC       P13569; Q96HY6: DDRGK1; NbExp=4; IntAct=EBI-349854, EBI-1054024;
CC       P13569; Q9NUU7: DDX19A; NbExp=9; IntAct=EBI-349854, EBI-740301;
CC       P13569; Q9UHI6: DDX20; NbExp=5; IntAct=EBI-349854, EBI-347658;
CC       P13569; Q9BUN8: DERL1; NbExp=8; IntAct=EBI-349854, EBI-398977;
CC       P13569; Q7L2E3: DHX30; NbExp=5; IntAct=EBI-349854, EBI-1211456;
CC       P13569; Q8TBM8: DNAJB14; NbExp=3; IntAct=EBI-349854, EBI-2689808;
CC       P13569; Q96KC8: DNAJC1; NbExp=7; IntAct=EBI-349854, EBI-296550;
CC       P13569; Q9Y295: DRG1; NbExp=9; IntAct=EBI-349854, EBI-719554;
CC       P13569; P60981: DSTN; NbExp=16; IntAct=EBI-349854, EBI-745191;
CC       P13569; O60869: EDF1; NbExp=3; IntAct=EBI-349854, EBI-781301;
CC       P13569; P07099: EPHX1; NbExp=5; IntAct=EBI-349854, EBI-6138796;
CC       P13569; Q6P6B1: ERICH5; NbExp=4; IntAct=EBI-349854, EBI-11343491;
CC       P13569; P13804: ETFA; NbExp=7; IntAct=EBI-349854, EBI-1052886;
CC       P13569; Q0VG06: FAAP100; NbExp=4; IntAct=EBI-349854, EBI-2557990;
CC       P13569; Q9NYY8: FASTKD2; NbExp=5; IntAct=EBI-349854, EBI-1055752;
CC       P13569; Q14314: FGL2; NbExp=6; IntAct=EBI-349854, EBI-21370828;
CC       P13569; Q14192: FHL2; NbExp=10; IntAct=EBI-349854, EBI-701903;
CC       P13569; O75344: FKBP6; NbExp=4; IntAct=EBI-349854, EBI-744771;
CC       P13569; Q9UJY5: GGA1; NbExp=6; IntAct=EBI-349854, EBI-447141;
CC       P13569; P62879: GNB2; NbExp=12; IntAct=EBI-349854, EBI-356942;
CC       P13569; Q9HD26: GOPC; NbExp=10; IntAct=EBI-349854, EBI-349832;
CC       P13569; Q9H8Y8: GORASP2; NbExp=6; IntAct=EBI-349854, EBI-739467;
CC       P13569; P07203: GPX1; NbExp=3; IntAct=EBI-349854, EBI-7209024;
CC       P13569; P0CG30: GSTT2B; NbExp=4; IntAct=EBI-349854, EBI-13572836;
CC       P13569; Q9P035: HACD3; NbExp=15; IntAct=EBI-349854, EBI-359013;
CC       P13569; Q9BX68: HINT2; NbExp=3; IntAct=EBI-349854, EBI-8523143;
CC       P13569; P19367: HK1; NbExp=5; IntAct=EBI-349854, EBI-713162;
CC       P13569; O75330: HMMR; NbExp=7; IntAct=EBI-349854, EBI-2556203;
CC       P13569; P10809: HSPD1; NbExp=24; IntAct=EBI-349854, EBI-352528;
CC       P13569; O15554: KCNN4; NbExp=5; IntAct=EBI-349854, EBI-2924473;
CC       P13569; O94889: KLHL18; NbExp=3; IntAct=EBI-349854, EBI-2510096;
CC       P13569; O15131: KPNA5; NbExp=4; IntAct=EBI-349854, EBI-540602;
CC       P13569; P05787: KRT8; NbExp=11; IntAct=EBI-349854, EBI-297852;
CC       P13569; Q08380: LGALS3BP; NbExp=18; IntAct=EBI-349854, EBI-354956;
CC       P13569; Q9HBW0: LPAR2; NbExp=3; IntAct=EBI-349854, EBI-765995;
CC       P13569; P33241: LSP1; NbExp=4; IntAct=EBI-349854, EBI-9060697;
CC       P13569; Q9HCC0: MCCC2; NbExp=5; IntAct=EBI-349854, EBI-2211296;
CC       P13569; P08582: MELTF; NbExp=7; IntAct=EBI-349854, EBI-7172128;
CC       P13569; Q92552: MRPS27; NbExp=5; IntAct=EBI-349854, EBI-2211879;
CC       P13569; Q96S97: MYADM; NbExp=3; IntAct=EBI-349854, EBI-13301517;
CC       P13569; P41227: NAA10; NbExp=5; IntAct=EBI-349854, EBI-747693;
CC       P13569; O14745: NHERF1; NbExp=26; IntAct=EBI-349854, EBI-349787;
CC       P13569; Q15599: NHERF2; NbExp=28; IntAct=EBI-349854, EBI-1149760;
CC       P13569; Q9NZM5: NOP53; NbExp=4; IntAct=EBI-349854, EBI-720156;
CC       P13569; Q9BVG4: PBDC1; NbExp=3; IntAct=EBI-349854, EBI-722092;
CC       P13569; P08559: PDHA1; NbExp=5; IntAct=EBI-349854, EBI-715747;
CC       P13569; P30101: PDIA3; NbExp=12; IntAct=EBI-349854, EBI-979862;
CC       P13569; Q5T2W1: PDZK1; NbExp=3; IntAct=EBI-349854, EBI-349819;
CC       P13569; O60831: PRAF2; NbExp=4; IntAct=EBI-349854, EBI-2506064;
CC       P13569; P55036: PSMD4; NbExp=13; IntAct=EBI-349854, EBI-359318;
CC       P13569; P26599: PTBP1; NbExp=13; IntAct=EBI-349854, EBI-350540;
CC       P13569; O75127: PTCD1; NbExp=3; IntAct=EBI-349854, EBI-2560233;
CC       P13569; Q96PK6: RBM14; NbExp=13; IntAct=EBI-349854, EBI-954272;
CC       P13569; Q99942: RNF5; NbExp=8; IntAct=EBI-349854, EBI-348482;
CC       P13569; Q7Z5V6: SAXO4; NbExp=3; IntAct=EBI-349854, EBI-4311771;
CC       P13569; O15126: SCAMP1; NbExp=7; IntAct=EBI-349854, EBI-954338;
CC       P13569; P31040: SDHA; NbExp=15; IntAct=EBI-349854, EBI-1057265;
CC       P13569; Q9P0V3: SH3BP4; NbExp=4; IntAct=EBI-349854, EBI-1049513;
CC       P13569; P29353: SHC1; NbExp=6; IntAct=EBI-349854, EBI-78835;
CC       P13569; Q96RN1: SLC26A8; NbExp=2; IntAct=EBI-349854, EBI-1792052;
CC       P13569; O00400: SLC33A1; NbExp=6; IntAct=EBI-349854, EBI-11135403;
CC       P13569; P63162: SNRPN; NbExp=6; IntAct=EBI-349854, EBI-712493;
CC       P13569; Q9UHB9: SRP68; NbExp=7; IntAct=EBI-349854, EBI-1048560;
CC       P13569; Q9NSC7: ST6GALNAC1; NbExp=5; IntAct=EBI-349854, EBI-2854712;
CC       P13569; O95793: STAU1; NbExp=13; IntAct=EBI-349854, EBI-358174;
CC       P13569; Q9P289: STK26; NbExp=6; IntAct=EBI-349854, EBI-618239;
CC       P13569; Q92734: TFG; NbExp=7; IntAct=EBI-349854, EBI-357061;
CC       P13569; Q96Q45: TMEM237; NbExp=4; IntAct=EBI-349854, EBI-2602465;
CC       P13569; Q8WWA1: TMEM40; NbExp=9; IntAct=EBI-349854, EBI-39962964;
CC       P13569; O14545: TRAFD1; NbExp=9; IntAct=EBI-349854, EBI-1396921;
CC       P13569; P19474: TRIM21; NbExp=24; IntAct=EBI-349854, EBI-81290;
CC       P13569; Q13049: TRIM32; NbExp=5; IntAct=EBI-349854, EBI-742790;
CC       P13569; Q9C035: TRIM5; NbExp=3; IntAct=EBI-349854, EBI-924214;
CC       P13569; Q13432: UNC119; NbExp=4; IntAct=EBI-349854, EBI-711260;
CC       P13569; Q14694: USP10; NbExp=7; IntAct=EBI-349854, EBI-2510389;
CC       P13569; O94966: USP19; NbExp=6; IntAct=EBI-349854, EBI-2511895;
CC       P13569; Q9BXU7: USP26; NbExp=4; IntAct=EBI-349854, EBI-1641713;
CC       P13569; Q9P0L0: VAPA; NbExp=13; IntAct=EBI-349854, EBI-1059156;
CC       P13569; O95292: VAPB; NbExp=12; IntAct=EBI-349854, EBI-1188298;
CC       P13569; P45880: VDAC2; NbExp=10; IntAct=EBI-349854, EBI-354022;
CC       P13569; Q9UN37: VPS4A; NbExp=9; IntAct=EBI-349854, EBI-1171942;
CC       P13569; Q9UEU0: VTI1B; NbExp=10; IntAct=EBI-349854, EBI-723716;
CC       P13569; O00308: WWP2; NbExp=3; IntAct=EBI-349854, EBI-743923;
CC       P13569; Q8WTP9: XAGE3; NbExp=4; IntAct=EBI-349854, EBI-6448284;
CC       P13569; Q9BYJ9: YTHDF1; NbExp=5; IntAct=EBI-349854, EBI-1051237;
CC       P13569; P17026: ZNF22; NbExp=2; IntAct=EBI-349854, EBI-20803387;
CC       P13569; P19120: HSPA8; Xeno; NbExp=2; IntAct=EBI-349854, EBI-907802;
CC       P13569; Q9QX74: Shank2; Xeno; NbExp=3; IntAct=EBI-349854, EBI-397902;
CC   -!- SUBCELLULAR LOCATION: Apical cell membrane
CC       {ECO:0000269|PubMed:12519745, ECO:0000269|PubMed:12529365,
CC       ECO:0000269|PubMed:1284548, ECO:0000269|PubMed:15247260,
CC       ECO:0000269|PubMed:15716351, ECO:0000269|PubMed:17462998,
CC       ECO:0000269|PubMed:19398555, ECO:0000269|PubMed:19621064,
CC       ECO:0000269|PubMed:20008117, ECO:0000269|PubMed:22207244,
CC       ECO:0000269|PubMed:28130590}; Multi-pass membrane protein
CC       {ECO:0000269|Ref.57}. Early endosome membrane
CC       {ECO:0000269|PubMed:19398555, ECO:0000269|PubMed:20008117}; Multi-pass
CC       membrane protein {ECO:0000269|Ref.57}. Cell membrane
CC       {ECO:0000269|PubMed:10792060, ECO:0000269|PubMed:11524016,
CC       ECO:0000269|PubMed:11707463, ECO:0000269|PubMed:12588899,
CC       ECO:0000269|PubMed:15010471, ECO:0000269|PubMed:17036051,
CC       ECO:0000269|PubMed:1712898, ECO:0000269|PubMed:17182731,
CC       ECO:0000269|PubMed:19019741, ECO:0000269|PubMed:19398555,
CC       ECO:0000269|PubMed:21884936, ECO:0000269|PubMed:22178883,
CC       ECO:0000269|PubMed:25330774, ECO:0000269|PubMed:26846474,
CC       ECO:0000269|PubMed:28001373, ECO:0000269|PubMed:28067262,
CC       ECO:0000269|PubMed:28087700, ECO:0000269|PubMed:28130590,
CC       ECO:0000269|PubMed:9804160, ECO:0000305|PubMed:8910473}; Multi-pass
CC       membrane protein {ECO:0000269|Ref.57}. Recycling endosome membrane
CC       {ECO:0000305|PubMed:17462998}; Multi-pass membrane protein
CC       {ECO:0000269|Ref.57}. Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:11707463, ECO:0000269|PubMed:25330774}; Multi-pass
CC       membrane protein {ECO:0000269|Ref.57}. Nucleus
CC       {ECO:0000250|UniProtKB:P34158}. Note=The channel is internalized from
CC       the cell surface into an endosomal recycling compartment, from where it
CC       is recycled to the cell membrane (PubMed:17462998, PubMed:19398555,
CC       PubMed:20008117). In the oviduct and bronchus, detected on the apical
CC       side of epithelial cells, but not associated with cilia
CC       (PubMed:22207244). In Sertoli cells, a processed product is detected in
CC       the nucleus (By similarity). ER stress induces GORASP2-mediated
CC       unconventional (ER/Golgi-independent) trafficking of core-glycosylated
CC       CFTR to cell membrane (PubMed:21884936). {ECO:0000250|UniProtKB:P34158,
CC       ECO:0000269|PubMed:19398555, ECO:0000269|PubMed:20008117,
CC       ECO:0000269|PubMed:21884936, ECO:0000269|PubMed:22207244,
CC       ECO:0000305|PubMed:17462998}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P13569-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P13569-2; Sequence=VSP_022123;
CC       Name=3;
CC         IsoId=P13569-3; Sequence=VSP_022124, VSP_022125;
CC   -!- TISSUE SPECIFICITY: Expressed in the respiratory airway, including
CC       bronchial epithelium, and in the female reproductive tract, including
CC       oviduct (at protein level) (PubMed:15716351, PubMed:22207244). Detected
CC       in pancreatic intercalated ducts in the exocrine tissue, on epithelial
CC       cells in intralobular striated ducts in sublingual salivary glands, on
CC       apical membranes of crypt cells throughout the small and large
CC       intestine, and on the reabsorptive duct in eccrine sweat glands
CC       (PubMed:1284548, PubMed:28130590). Detected on the equatorial segment
CC       of the sperm head (at protein level) (PubMed:19923167). Detected in
CC       nasal and bronchial superficial epithelium (PubMed:15716351). Expressed
CC       by the central cells on the sebaceous glands, dermal adipocytes and, at
CC       lower levels, by epithelial cells (PubMed:28130590).
CC       {ECO:0000269|PubMed:1284548, ECO:0000269|PubMed:15716351,
CC       ECO:0000269|PubMed:19923167, ECO:0000269|PubMed:22207244,
CC       ECO:0000269|PubMed:28130590}.
CC   -!- DOMAIN: Binds and hydrolyzes ATP via the two cytoplasmic ABC
CC       transporter nucleotide-binding domains (PubMed:15284228). The two ATP-
CC       binding domains interact with each other, forming a head-to-tail dimer
CC       (PubMed:17036051). Normal ATPase activity requires interaction between
CC       the two domains (PubMed:15284228). The first ABC transporter
CC       nucleotide-binding domain has no ATPase activity by itself (By
CC       similarity). {ECO:0000250|UniProtKB:P26361,
CC       ECO:0000269|PubMed:15284228, ECO:0000269|PubMed:17036051}.
CC   -!- DOMAIN: The PDZ-binding motif mediates interactions with GOPC and with
CC       the SLC4A7, NHERF1/EBP50 complex. {ECO:0000269|PubMed:11304524,
CC       ECO:0000269|PubMed:11707463, ECO:0000269|PubMed:16331976}.
CC   -!- DOMAIN: The R region is intrinsically disordered (PubMed:10792060,
CC       PubMed:17660831). It mediates channel activation when it is
CC       phosphorylated, but not in the absence of phosphorylation
CC       (PubMed:10792060). {ECO:0000269|PubMed:10792060,
CC       ECO:0000269|PubMed:17660831}.
CC   -!- PTM: N-glycosylated. {ECO:0000269|PubMed:12529365,
CC       ECO:0000269|PubMed:1699669, ECO:0000269|PubMed:20008117,
CC       ECO:0000269|PubMed:21884936, ECO:0000269|PubMed:28067262}.
CC   -!- PTM: Phosphorylated; cAMP treatment promotes phosphorylation and
CC       activates the channel (PubMed:12588899, PubMed:17036051,
CC       PubMed:8910473). Dephosphorylation decreases the ATPase activity (in
CC       vitro) (PubMed:8910473). Phosphorylation at PKA sites activates the
CC       channel (PubMed:10792060, PubMed:12519745, PubMed:12588899,
CC       PubMed:25330774). Phosphorylation at PKC sites enhances the response to
CC       phosphorylation by PKA (PubMed:12588899). Phosphorylated by AMPK; this
CC       inhibits channel activity (PubMed:12519745).
CC       {ECO:0000269|PubMed:10792060, ECO:0000269|PubMed:12519745,
CC       ECO:0000269|PubMed:12588899, ECO:0000269|PubMed:1377674,
CC       ECO:0000269|PubMed:17036051, ECO:0000269|PubMed:22119790,
CC       ECO:0000269|PubMed:25330774, ECO:0000269|PubMed:8910473,
CC       ECO:0000269|PubMed:9385646}.
CC   -!- PTM: Ubiquitinated, leading to its degradation in the lysosome
CC       (PubMed:19398555, PubMed:23818989). Deubiquitination by USP10 in early
CC       endosomes enhances its endocytic recycling to the cell membrane
CC       (PubMed:19398555). Ubiquitinated by RNF185 during ER stress
CC       (PubMed:24019521). Ubiquitinated by MARCHF2 (PubMed:23818989).
CC       {ECO:0000269|PubMed:19398555, ECO:0000269|PubMed:22119790,
CC       ECO:0000269|PubMed:23818989, ECO:0000269|PubMed:24019521}.
CC   -!- DISEASE: Cystic fibrosis (CF) [MIM:219700]: A common generalized
CC       disorder of the exocrine glands which impairs clearance of secretions
CC       in a variety of organs. It is characterized by the triad of chronic
CC       bronchopulmonary disease (with recurrent respiratory infections),
CC       pancreatic insufficiency (which leads to malabsorption and growth
CC       retardation) and elevated sweat electrolytes. It is the most common
CC       genetic disease in Caucasians, with a prevalence of about 1 in 2'000
CC       live births. Inheritance is autosomal recessive.
CC       {ECO:0000269|PubMed:10094564, ECO:0000269|PubMed:10869121,
CC       ECO:0000269|PubMed:10923036, ECO:0000269|PubMed:11242048,
CC       ECO:0000269|PubMed:12167682, ECO:0000269|PubMed:12394343,
CC       ECO:0000269|PubMed:12529365, ECO:0000269|PubMed:1284466,
CC       ECO:0000269|PubMed:1284468, ECO:0000269|PubMed:1284529,
CC       ECO:0000269|PubMed:1284530, ECO:0000269|PubMed:1284548,
CC       ECO:0000269|PubMed:1379210, ECO:0000269|PubMed:15528182,
CC       ECO:0000269|PubMed:15716351, ECO:0000269|PubMed:16822950,
CC       ECO:0000269|PubMed:1695717, ECO:0000269|PubMed:1699669,
CC       ECO:0000269|PubMed:17098864, ECO:0000269|PubMed:1710600,
CC       ECO:0000269|PubMed:1712898, ECO:0000269|PubMed:17182731,
CC       ECO:0000269|PubMed:20008117, ECO:0000269|PubMed:20150177,
CC       ECO:0000269|PubMed:20691141, ECO:0000269|PubMed:21884936,
CC       ECO:0000269|PubMed:2236053, ECO:0000269|PubMed:23818989,
CC       ECO:0000269|PubMed:25330774, ECO:0000269|PubMed:26846474,
CC       ECO:0000269|PubMed:27241308, ECO:0000269|PubMed:28001373,
CC       ECO:0000269|PubMed:28067262, ECO:0000269|PubMed:28087700,
CC       ECO:0000269|PubMed:32026723, ECO:0000269|PubMed:33572515,
CC       ECO:0000269|PubMed:7504969, ECO:0000269|PubMed:7505694,
CC       ECO:0000269|PubMed:7505767, ECO:0000269|PubMed:7508414,
CC       ECO:0000269|PubMed:7513296, ECO:0000269|PubMed:7517264,
CC       ECO:0000269|PubMed:7520022, ECO:0000269|PubMed:7522211,
CC       ECO:0000269|PubMed:7524909, ECO:0000269|PubMed:7524913,
CC       ECO:0000269|PubMed:7525450, ECO:0000269|PubMed:7537150,
CC       ECO:0000269|PubMed:7541273, ECO:0000269|PubMed:7541510,
CC       ECO:0000269|PubMed:7543567, ECO:0000269|PubMed:7544319,
CC       ECO:0000269|PubMed:7581407, ECO:0000269|PubMed:7606851,
CC       ECO:0000269|PubMed:7680525, ECO:0000269|PubMed:7683628,
CC       ECO:0000269|PubMed:7683954, ECO:0000269|PubMed:8081395,
CC       ECO:0000269|PubMed:8406518, ECO:0000269|PubMed:8522333,
CC       ECO:0000269|PubMed:8723693, ECO:0000269|PubMed:8723695,
CC       ECO:0000269|PubMed:8800923, ECO:0000269|PubMed:8829633,
CC       ECO:0000269|PubMed:8910473, ECO:0000269|PubMed:8956039,
CC       ECO:0000269|PubMed:9101301, ECO:0000269|PubMed:9222768,
CC       ECO:0000269|PubMed:9375855, ECO:0000269|PubMed:9401006,
CC       ECO:0000269|PubMed:9443874, ECO:0000269|PubMed:9452048,
CC       ECO:0000269|PubMed:9452054, ECO:0000269|PubMed:9452073,
CC       ECO:0000269|PubMed:9482579, ECO:0000269|PubMed:9507391,
CC       ECO:0000269|PubMed:9521595, ECO:0000269|PubMed:9554753,
CC       ECO:0000269|PubMed:9736778, ECO:0000269|PubMed:9804160,
CC       ECO:0000269|PubMed:9921909}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry. There is some evidence
CC       that the functional defect caused by the most common variant Phe-508
CC       DEL can be corrected by the binding to the snake phospholipase A2
CC       crotoxin basic subunit CB. This toxin both disrupts the Phe-508 DEL-
CC       cytokeratin 8 complex, allowing for the escape from degradation, and
CC       increases the chloride channel current (PubMed:27241308).
CC       {ECO:0000269|PubMed:27241308}.
CC   -!- DISEASE: Congenital bilateral absence of the vas deferens (CBAVD)
CC       [MIM:277180]: An autosomal recessive disease characterized by vas
CC       deferens aplasia resulting in azoospermia and male infertility. CBAVD
CC       may occur in isolation or as a manifestation of cystic fibrosis.
CC       {ECO:0000269|PubMed:10066035, ECO:0000269|PubMed:10651488,
CC       ECO:0000269|PubMed:17329263, ECO:0000269|PubMed:7529962,
CC       ECO:0000269|PubMed:7539342, ECO:0000269|PubMed:9067761,
CC       ECO:0000269|PubMed:9736778, ECO:0000269|Ref.118}. Note=The disease is
CC       caused by variants affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: [Isoform 2]: Exon 9 splicing depends upon 2 polymorphic
CC       tracts within intron 8, a T(n) tract and TG(n) tract, where the number
CC       of T and/or TG repeats affect the extent of correct splicing of exon 9.
CC       Low numbers of T residues and high numbers of TG repeats give rise to
CC       less efficient splicing. Transcripts that lack exon 9 sequences fail to
CC       mature. Causes congenital bilateral absence of the vas deferens
CC       (CBAVD). {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 3]: Alternative acceptor site favored by
CC       mutation in an exonic splicing enhancer (ESE). Causes cystic fibrosis
CC       (CF). {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the ABC transporter superfamily. ABCC family.
CC       CFTR transporter (TC 3.A.1.202) subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=CFTR entry;
CC       URL="https://en.wikipedia.org/wiki/Cystic_fibrosis_transmembrane_conductance_regulator";
CC   -!- WEB RESOURCE: Name=ABCMdb; Note=Database for mutations in ABC proteins;
CC       URL="http://abcm2.hegelab.org/search";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M28668; AAA35680.1; -; mRNA.
DR   EMBL; M55131; AAC13657.1; -; Genomic_DNA.
DR   EMBL; M55106; AAC13657.1; JOINED; Genomic_DNA.
DR   EMBL; M55107; AAC13657.1; JOINED; Genomic_DNA.
DR   EMBL; M55108; AAC13657.1; JOINED; Genomic_DNA.
DR   EMBL; M55110; AAC13657.1; JOINED; Genomic_DNA.
DR   EMBL; M55111; AAC13657.1; JOINED; Genomic_DNA.
DR   EMBL; M55112; AAC13657.1; JOINED; Genomic_DNA.
DR   EMBL; M55113; AAC13657.1; JOINED; Genomic_DNA.
DR   EMBL; M55114; AAC13657.1; JOINED; Genomic_DNA.
DR   EMBL; M55115; AAC13657.1; JOINED; Genomic_DNA.
DR   EMBL; M55116; AAC13657.1; JOINED; Genomic_DNA.
DR   EMBL; M55117; AAC13657.1; JOINED; Genomic_DNA.
DR   EMBL; M55118; AAC13657.1; JOINED; Genomic_DNA.
DR   EMBL; M55119; AAC13657.1; JOINED; Genomic_DNA.
DR   EMBL; M55120; AAC13657.1; JOINED; Genomic_DNA.
DR   EMBL; M55121; AAC13657.1; JOINED; Genomic_DNA.
DR   EMBL; M55122; AAC13657.1; JOINED; Genomic_DNA.
DR   EMBL; M55123; AAC13657.1; JOINED; Genomic_DNA.
DR   EMBL; M55124; AAC13657.1; JOINED; Genomic_DNA.
DR   EMBL; M55125; AAC13657.1; JOINED; Genomic_DNA.
DR   EMBL; M55126; AAC13657.1; JOINED; Genomic_DNA.
DR   EMBL; M55127; AAC13657.1; JOINED; Genomic_DNA.
DR   EMBL; M55128; AAC13657.1; JOINED; Genomic_DNA.
DR   EMBL; M55129; AAC13657.1; JOINED; Genomic_DNA.
DR   EMBL; M55130; AAC13657.1; JOINED; Genomic_DNA.
DR   EMBL; DQ354388; ABC79050.1; -; Genomic_DNA.
DR   EMBL; DQ354389; ABC79052.1; -; Genomic_DNA.
DR   EMBL; DQ354390; ABC79054.1; -; Genomic_DNA.
DR   EMBL; DQ354391; ABC79056.1; -; Genomic_DNA.
DR   EMBL; DQ356258; ABC87055.1; -; Genomic_DNA.
DR   EMBL; DQ356259; ABC87057.1; -; Genomic_DNA.
DR   EMBL; DQ356261; ABC87061.1; -; Genomic_DNA.
DR   EMBL; DQ356262; ABC87063.1; -; Genomic_DNA.
DR   EMBL; DQ356263; ABC87065.1; -; Genomic_DNA.
DR   EMBL; DQ356264; ABC87067.1; -; Genomic_DNA.
DR   EMBL; DQ388128; ABD72183.1; -; Genomic_DNA.
DR   EMBL; DQ388129; ABD72185.1; -; Genomic_DNA.
DR   EMBL; DQ388131; ABD72189.1; -; Genomic_DNA.
DR   EMBL; DQ388132; ABD72191.1; -; Genomic_DNA.
DR   EMBL; DQ388133; ABD72193.1; -; Genomic_DNA.
DR   EMBL; DQ388134; ABD72195.1; -; Genomic_DNA.
DR   EMBL; DQ388135; ABD72197.1; -; Genomic_DNA.
DR   EMBL; DQ388138; ABD72203.1; -; Genomic_DNA.
DR   EMBL; DQ388139; ABD72205.1; -; Genomic_DNA.
DR   EMBL; DQ388140; ABD72207.1; -; Genomic_DNA.
DR   EMBL; DQ388141; ABD72209.1; -; Genomic_DNA.
DR   EMBL; DQ388142; ABD72211.1; -; Genomic_DNA.
DR   EMBL; DQ388143; ABD72213.1; -; Genomic_DNA.
DR   EMBL; DQ388145; ABD72217.1; -; Genomic_DNA.
DR   EMBL; AC000061; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC000111; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH236947; EAL24353.1; -; Genomic_DNA.
DR   EMBL; M65196; AAA51979.1; -; Genomic_DNA.
DR   EMBL; M65197; AAA51980.1; -; Genomic_DNA.
DR   CCDS; CCDS5773.1; -. [P13569-1]
DR   PIR; A39069; DVHUCF.
DR   RefSeq; NP_000483.3; NM_000492.3. [P13569-1]
DR   PDB; 1XMI; X-ray; 2.25 A; A/B/C/D/E=389-678.
DR   PDB; 1XMJ; X-ray; 2.30 A; A=389-677.
DR   PDB; 2BBO; X-ray; 2.55 A; A=389-678.
DR   PDB; 2BBS; X-ray; 2.05 A; A/B=389-677.
DR   PDB; 2BBT; X-ray; 2.30 A; A/B=389-678.
DR   PDB; 2LOB; NMR; -; B=1473-1480.
DR   PDB; 2PZE; X-ray; 1.70 A; A/B=387-646.
DR   PDB; 2PZF; X-ray; 2.00 A; A/B=387-646.
DR   PDB; 2PZG; X-ray; 1.80 A; A/B=375-646.
DR   PDB; 3GD7; X-ray; 2.70 A; A/B/C/D=1193-1427.
DR   PDB; 3ISW; X-ray; 2.80 A; C=5-20.
DR   PDB; 4WZ6; X-ray; 2.05 A; A=389-678.
DR   PDB; 5D2D; X-ray; 2.10 A; C=747-774.
DR   PDB; 5D3E; X-ray; 2.75 A; C/G/K=762-801.
DR   PDB; 5D3F; X-ray; 2.74 A; C=747-774.
DR   PDB; 5TF7; X-ray; 1.93 A; A=387-646.
DR   PDB; 5TF8; X-ray; 1.86 A; A=387-646.
DR   PDB; 5TFA; X-ray; 1.87 A; A=387-646.
DR   PDB; 5TFB; X-ray; 1.87 A; A=387-646.
DR   PDB; 5TFC; X-ray; 1.92 A; A=387-646.
DR   PDB; 5TFD; X-ray; 1.89 A; A=387-646.
DR   PDB; 5TFF; X-ray; 1.89 A; A=387-646.
DR   PDB; 5TFG; X-ray; 1.91 A; A=387-646.
DR   PDB; 5TFI; X-ray; 1.89 A; A=387-646.
DR   PDB; 5TFJ; X-ray; 1.85 A; A=387-646.
DR   PDB; 5TGK; X-ray; 1.91 A; A=387-646.
DR   PDB; 5UAK; EM; 3.87 A; A=1-1480.
DR   PDB; 6GJQ; X-ray; 2.49 A; A/C/E/G=387-646.
DR   PDB; 6GJS; X-ray; 1.95 A; A=387-646.
DR   PDB; 6GJU; X-ray; 2.60 A; A=387-646.
DR   PDB; 6GK4; X-ray; 2.91 A; A/D=387-646.
DR   PDB; 6GKD; X-ray; 2.99 A; A/F/I/L/O/R=387-646.
DR   PDB; 6HEP; X-ray; 1.86 A; E/F=747-774.
DR   PDB; 6MSM; EM; 3.20 A; A=1-1480.
DR   PDB; 6O1V; EM; 3.20 A; A=1-1480.
DR   PDB; 6O2P; EM; 3.30 A; A=1-1480.
DR   PDB; 6UK1; X-ray; 2.69 A; A/B/C/D=1202-1430.
DR   PDB; 6WBS; X-ray; 1.86 A; A/B=388-646.
DR   PDB; 6ZE1; X-ray; 2.71 A; A=387-646.
DR   PDB; 7QI1; X-ray; 1.76 A; E/F=747-774.
DR   PDB; 7SV7; EM; 3.80 A; A=1-1480.
DR   PDB; 7SVD; EM; 2.70 A; A=1-1480.
DR   PDB; 7SVR; EM; 3.90 A; A=1-1480.
DR   PDB; 8EIG; EM; 3.60 A; A=1-1480.
DR   PDB; 8EIO; EM; 2.80 A; A=1-1480.
DR   PDB; 8EIQ; EM; 3.00 A; A=1-1480.
DR   PDB; 8EJ1; EM; 6.90 A; A=1-1480.
DR   PDB; 8FZQ; EM; 4.30 A; A=1-1480.
DR   PDB; 8GLS; EM; 3.80 A; A=1-1480.
DR   PDB; 8UBR; EM; 2.70 A; A=1-1480.
DR   PDB; 8V7Z; EM; 3.40 A; A=11-1431.
DR   PDB; 8V81; EM; 3.60 A; A=3-1440.
DR   PDB; 9DW4; EM; 9.00 A; A=1-1480.
DR   PDB; 9DW5; EM; 3.80 A; A=1-1480.
DR   PDB; 9DW7; EM; 6.00 A; A=1-1480.
DR   PDB; 9DW8; EM; 3.50 A; A=1-1480.
DR   PDB; 9DW9; EM; 2.80 A; A=1-1480.
DR   PDBsum; 1XMI; -.
DR   PDBsum; 1XMJ; -.
DR   PDBsum; 2BBO; -.
DR   PDBsum; 2BBS; -.
DR   PDBsum; 2BBT; -.
DR   PDBsum; 2LOB; -.
DR   PDBsum; 2PZE; -.
DR   PDBsum; 2PZF; -.
DR   PDBsum; 2PZG; -.
DR   PDBsum; 3GD7; -.
DR   PDBsum; 3ISW; -.
DR   PDBsum; 4WZ6; -.
DR   PDBsum; 5D2D; -.
DR   PDBsum; 5D3E; -.
DR   PDBsum; 5D3F; -.
DR   PDBsum; 5TF7; -.
DR   PDBsum; 5TF8; -.
DR   PDBsum; 5TFA; -.
DR   PDBsum; 5TFB; -.
DR   PDBsum; 5TFC; -.
DR   PDBsum; 5TFD; -.
DR   PDBsum; 5TFF; -.
DR   PDBsum; 5TFG; -.
DR   PDBsum; 5TFI; -.
DR   PDBsum; 5TFJ; -.
DR   PDBsum; 5TGK; -.
DR   PDBsum; 5UAK; -.
DR   PDBsum; 6GJQ; -.
DR   PDBsum; 6GJS; -.
DR   PDBsum; 6GJU; -.
DR   PDBsum; 6GK4; -.
DR   PDBsum; 6GKD; -.
DR   PDBsum; 6HEP; -.
DR   PDBsum; 6MSM; -.
DR   PDBsum; 6O1V; -.
DR   PDBsum; 6O2P; -.
DR   PDBsum; 6UK1; -.
DR   PDBsum; 6WBS; -.
DR   PDBsum; 6ZE1; -.
DR   PDBsum; 7QI1; -.
DR   PDBsum; 7SV7; -.
DR   PDBsum; 7SVD; -.
DR   PDBsum; 7SVR; -.
DR   PDBsum; 8EIG; -.
DR   PDBsum; 8EIO; -.
DR   PDBsum; 8EIQ; -.
DR   PDBsum; 8EJ1; -.
DR   PDBsum; 8FZQ; -.
DR   PDBsum; 8GLS; -.
DR   PDBsum; 8UBR; -.
DR   PDBsum; 8V7Z; -.
DR   PDBsum; 8V81; -.
DR   PDBsum; 9DW4; -.
DR   PDBsum; 9DW5; -.
DR   PDBsum; 9DW7; -.
DR   PDBsum; 9DW8; -.
DR   PDBsum; 9DW9; -.
DR   AlphaFoldDB; P13569; -.
DR   BMRB; P13569; -.
DR   EMDB; EMD-0606; -.
DR   EMDB; EMD-0611; -.
DR   EMDB; EMD-25445; -.
DR   EMDB; EMD-25447; -.
DR   EMDB; EMD-25452; -.
DR   EMDB; EMD-28155; -.
DR   EMDB; EMD-28160; -.
DR   EMDB; EMD-28161; -.
DR   EMDB; EMD-28172; -.
DR   EMDB; EMD-29637; -.
DR   EMDB; EMD-40207; -.
DR   EMDB; EMD-41717; -.
DR   EMDB; EMD-41719; -.
DR   EMDB; EMD-41722; -.
DR   EMDB; EMD-41723; -.
DR   EMDB; EMD-41724; -.
DR   EMDB; EMD-41726; -.
DR   EMDB; EMD-41895; -.
DR   EMDB; EMD-41896; -.
DR   EMDB; EMD-41898; -.
DR   EMDB; EMD-41900; -.
DR   EMDB; EMD-41901; -.
DR   EMDB; EMD-41902; -.
DR   EMDB; EMD-41980; -.
DR   EMDB; EMD-41981; -.
DR   EMDB; EMD-42101; -.
DR   EMDB; EMD-42177; -.
DR   EMDB; EMD-42178; -.
DR   EMDB; EMD-42179; -.
DR   EMDB; EMD-42180; -.
DR   EMDB; EMD-43011; -.
DR   EMDB; EMD-43014; -.
DR   EMDB; EMD-47235; -.
DR   EMDB; EMD-47236; -.
DR   EMDB; EMD-47237; -.
DR   EMDB; EMD-47238; -.
DR   EMDB; EMD-47239; -.
DR   EMDB; EMD-8516; -.
DR   EMDB; EMD-9230; -.
DR   SMR; P13569; -.
DR   BioGRID; 107506; 1559.
DR   CORUM; P13569; -.
DR   DIP; DIP-32788N; -.
DR   FunCoup; P13569; 563.
DR   IntAct; P13569; 3494.
DR   MINT; P13569; -.
DR   STRING; 9606.ENSP00000003084; -.
DR   BindingDB; P13569; -.
DR   ChEMBL; CHEMBL4051; -.
DR   DrugBank; DB00171; ATP.
DR   DrugBank; DB00887; Bumetanide.
DR   DrugBank; DB02587; Colforsin.
DR   DrugBank; DB04941; Crofelemer.
DR   DrugBank; DB04522; Dexfosfoserine.
DR   DrugBank; DB09213; Dexibuprofen.
DR   DrugBank; DB15444; Elexacaftor.
DR   DrugBank; DB14894; Galicaftor.
DR   DrugBank; DB01645; Genistein.
DR   DrugBank; DB01016; Glyburide.
DR   DrugBank; DB01050; Ibuprofen.
DR   DrugBank; DB12959; IOWH-032.
DR   DrugBank; DB08820; Ivacaftor.
DR   DrugBank; DB06266; Lonidamine.
DR   DrugBank; DB09280; Lumacaftor.
DR   DrugBank; DB04395; Phosphoaminophosphonic Acid-Adenylate Ester.
DR   DrugBank; DB11712; Tezacaftor.
DR   DrugCentral; P13569; -.
DR   GuidetoPHARMACOLOGY; 707; -.
DR   MoonProt; P13569; -.
DR   TCDB; 3.A.1.202.1; the atp-binding cassette (abc) superfamily.
DR   GlyCosmos; P13569; 2 sites, No reported glycans.
DR   GlyGen; P13569; 13 sites.
DR   iPTMnet; P13569; -.
DR   PhosphoSitePlus; P13569; -.
DR   SwissPalm; P13569; -.
DR   BioMuta; CFTR; -.
DR   DMDM; 147744553; -.
DR   jPOST; P13569; -.
DR   MassIVE; P13569; -.
DR   PaxDb; 9606-ENSP00000003084; -.
DR   PeptideAtlas; P13569; -.
DR   ProteomicsDB; 52926; -. [P13569-1]
DR   ProteomicsDB; 52927; -. [P13569-2]
DR   ProteomicsDB; 52928; -. [P13569-3]
DR   ABCD; P13569; 10 sequenced antibodies.
DR   Antibodypedia; 4530; 1170 antibodies from 41 providers.
DR   DNASU; 1080; -.
DR   Ensembl; ENST00000003084.11; ENSP00000003084.6; ENSG00000001626.18. [P13569-1]
DR   Ensembl; ENST00000649781.2; ENSP00000497203.1; ENSG00000001626.18. [P13569-2]
DR   GeneID; 1080; -.
DR   KEGG; hsa:1080; -.
DR   MANE-Select; ENST00000003084.11; ENSP00000003084.6; NM_000492.4; NP_000483.3.
DR   UCSC; uc003vjd.4; human. [P13569-1]
DR   AGR; HGNC:1884; -.
DR   CTD; 1080; -.
DR   DisGeNET; 1080; -.
DR   GeneCards; CFTR; -.
DR   GeneReviews; CFTR; -.
DR   HGNC; HGNC:1884; CFTR.
DR   HPA; ENSG00000001626; Tissue enhanced (gallbladder, intestine, pancreas).
DR   MalaCards; CFTR; -.
DR   MIM; 219700; phenotype.
DR   MIM; 277180; phenotype.
DR   MIM; 602421; gene.
DR   neXtProt; NX_P13569; -.
DR   OpenTargets; ENSG00000001626; -.
DR   Orphanet; 498359; Aquagenic palmoplantar keratoderma.
DR   Orphanet; 48; Congenital bilateral absence of vas deferens.
DR   Orphanet; 586; Cystic fibrosis.
DR   Orphanet; 676; Hereditary chronic pancreatitis.
DR   Orphanet; 60033; Idiopathic bronchiectasis.
DR   Orphanet; 399805; Male infertility with azoospermia or oligozoospermia due to single gene mutation.
DR   PharmGKB; PA109; -.
DR   VEuPathDB; HostDB:ENSG00000001626; -.
DR   eggNOG; KOG0054; Eukaryota.
DR   GeneTree; ENSGT00940000158567; -.
DR   InParanoid; P13569; -.
DR   OMA; CQRYLVI; -.
DR   OrthoDB; 6500128at2759; -.
DR   PAN-GO; P13569; 6 GO annotations based on evolutionary models.
DR   PhylomeDB; P13569; -.
DR   TreeFam; TF105200; -.
DR   BioCyc; MetaCyc:HS00075-MONOMER; -.
DR   BRENDA; 2.7.4.3; 2681.
DR   BRENDA; 5.6.1.6; 2681.
DR   PathwayCommons; P13569; -.
DR   Reactome; R-HSA-382556; ABC-family proteins mediated transport.
DR   Reactome; R-HSA-5627083; RHO GTPases regulate CFTR trafficking.
DR   Reactome; R-HSA-5678895; Defective CFTR causes cystic fibrosis.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   Reactome; R-HSA-8856825; Cargo recognition for clathrin-mediated endocytosis.
DR   Reactome; R-HSA-8856828; Clathrin-mediated endocytosis.
DR   Reactome; R-HSA-9013406; RHOQ GTPase cycle.
DR   Reactome; R-HSA-9613829; Chaperone Mediated Autophagy.
DR   Reactome; R-HSA-9615710; Late endosomal microautophagy.
DR   Reactome; R-HSA-9646399; Aggrephagy.
DR   SignaLink; P13569; -.
DR   SIGNOR; P13569; -.
DR   BioGRID-ORCS; 1080; 8 hits in 1161 CRISPR screens.
DR   ChiTaRS; CFTR; human.
DR   EvolutionaryTrace; P13569; -.
DR   GenomeRNAi; 1080; -.
DR   Pharos; P13569; Tclin.
DR   PRO; PR:P13569; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; P13569; protein.
DR   Bgee; ENSG00000001626; Expressed in body of pancreas and 118 other cell types or tissues.
DR   ExpressionAtlas; P13569; baseline and differential.
DR   GO; GO:0016324; C:apical plasma membrane; IDA:UniProtKB.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0034707; C:chloride channel complex; IEA:UniProtKB-KW.
DR   GO; GO:0030669; C:clathrin-coated endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0005769; C:early endosome; IDA:UniProtKB.
DR   GO; GO:0031901; C:early endosome membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IDA:UniProtKB.
DR   GO; GO:0010008; C:endosome membrane; TAS:Reactome.
DR   GO; GO:0030660; C:Golgi-associated vesicle membrane; TAS:Reactome.
DR   GO; GO:0005765; C:lysosomal membrane; TAS:Reactome.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB.
DR   GO; GO:0055037; C:recycling endosome; IDA:UniProtKB.
DR   GO; GO:0055038; C:recycling endosome membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0071889; F:14-3-3 protein binding; IMP:DisProt.
DR   GO; GO:0140359; F:ABC-type transporter activity; IEA:InterPro.
DR   GO; GO:0005524; F:ATP binding; TAS:ProtInc.
DR   GO; GO:0016887; F:ATP hydrolysis activity; IDA:UniProtKB.
DR   GO; GO:0043225; F:ATPase-coupled inorganic anion transmembrane transporter activity; TAS:Reactome.
DR   GO; GO:0042626; F:ATPase-coupled transmembrane transporter activity; IBA:GO_Central.
DR   GO; GO:0015106; F:bicarbonate transmembrane transporter activity; IDA:UniProtKB.
DR   GO; GO:0005254; F:chloride channel activity; IDA:UniProtKB.
DR   GO; GO:0019869; F:chloride channel inhibitor activity; IDA:UniProtKB.
DR   GO; GO:0017081; F:chloride channel regulator activity; TAS:Reactome.
DR   GO; GO:0015108; F:chloride transmembrane transporter activity; ISS:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0005260; F:intracellularly ATP-gated chloride channel activity; IMP:UniProtKB.
DR   GO; GO:0030165; F:PDZ domain binding; IDA:UniProtKB.
DR   GO; GO:0051087; F:protein-folding chaperone binding; IPI:ARUK-UCL.
DR   GO; GO:0106138; F:Sec61 translocon complex binding; IDA:UniProtKB.
DR   GO; GO:0097186; P:amelogenesis; ISS:ARUK-UCL.
DR   GO; GO:0015701; P:bicarbonate transport; IDA:UniProtKB.
DR   GO; GO:0071320; P:cellular response to cAMP; ISS:UniProtKB.
DR   GO; GO:1904322; P:cellular response to forskolin; IDA:UniProtKB.
DR   GO; GO:1902476; P:chloride transmembrane transport; IDA:UniProtKB.
DR   GO; GO:0006695; P:cholesterol biosynthetic process; IEA:Ensembl.
DR   GO; GO:0030301; P:cholesterol transport; IEA:Ensembl.
DR   GO; GO:0051649; P:establishment of localization in cell; IEA:Ensembl.
DR   GO; GO:0051454; P:intracellular pH elevation; ISS:UniProtKB.
DR   GO; GO:0060081; P:membrane hyperpolarization; ISS:UniProtKB.
DR   GO; GO:0050891; P:multicellular organismal-level water homeostasis; IMP:UniProtKB.
DR   GO; GO:1902161; P:positive regulation of cyclic nucleotide-gated ion channel activity; IMP:UniProtKB.
DR   GO; GO:0070175; P:positive regulation of enamel mineralization; ISS:ARUK-UCL.
DR   GO; GO:0045921; P:positive regulation of exocytosis; IMP:UniProtKB.
DR   GO; GO:0035774; P:positive regulation of insulin secretion involved in cellular response to glucose stimulus; IMP:UniProtKB.
DR   GO; GO:1902943; P:positive regulation of voltage-gated chloride channel activity; IDA:UniProtKB.
DR   GO; GO:0034976; P:response to endoplasmic reticulum stress; IDA:UniProtKB.
DR   GO; GO:0048240; P:sperm capacitation; ISS:UniProtKB.
DR   GO; GO:0035377; P:transepithelial water transport; IMP:UniProtKB.
DR   GO; GO:0055085; P:transmembrane transport; TAS:Reactome.
DR   GO; GO:0006904; P:vesicle docking involved in exocytosis; IEA:Ensembl.
DR   CDD; cd18594; ABC_6TM_CFTR_D1; 1.
DR   CDD; cd18600; ABC_6TM_CFTR_D2; 1.
DR   CDD; cd03291; ABCC_CFTR1; 1.
DR   CDD; cd03289; ABCC_CFTR2; 1.
DR   DisProt; DP00012; -.
DR   FunFam; 1.20.1560.10:FF:000017; Cystic fibrosis transmembrane conductance regulator; 1.
DR   FunFam; 1.20.1560.10:FF:000019; Cystic fibrosis transmembrane conductance regulator; 1.
DR   FunFam; 3.40.50.300:FF:000581; Cystic fibrosis transmembrane conductance regulator; 1.
DR   FunFam; 3.40.50.300:FF:000591; Cystic fibrosis transmembrane conductance regulator; 1.
DR   Gene3D; 1.20.1560.10; ABC transporter type 1, transmembrane domain; 2.
DR   Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 2.
DR   IDEAL; IID00540; -.
DR   InterPro; IPR003593; AAA+_ATPase.
DR   InterPro; IPR011527; ABC1_TM_dom.
DR   InterPro; IPR036640; ABC1_TM_sf.
DR   InterPro; IPR003439; ABC_transporter-like_ATP-bd.
DR   InterPro; IPR017871; ABC_transporter-like_CS.
DR   InterPro; IPR050173; ABC_transporter_C-like.
DR   InterPro; IPR009147; CFTR/ABCC7.
DR   InterPro; IPR047082; CFTR1_ATP-bd_dom1.
DR   InterPro; IPR025837; CFTR_reg_dom.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   NCBIfam; TIGR01271; CFTR_protein; 1.
DR   PANTHER; PTHR24223; ATP-BINDING CASSETTE SUB-FAMILY C; 1.
DR   PANTHER; PTHR24223:SF19; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; 1.
DR   Pfam; PF00664; ABC_membrane; 2.
DR   Pfam; PF00005; ABC_tran; 2.
DR   Pfam; PF14396; CFTR_R; 1.
DR   PRINTS; PR01851; CYSFIBREGLTR.
DR   SMART; SM00382; AAA; 2.
DR   SUPFAM; SSF90123; ABC transporter transmembrane region; 2.
DR   SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 2.
DR   PROSITE; PS50929; ABC_TM1F; 2.
DR   PROSITE; PS00211; ABC_TRANSPORTER_1; 1.
DR   PROSITE; PS50893; ABC_TRANSPORTER_2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane; Chloride;
KW   Chloride channel; Disease variant; Endoplasmic reticulum; Endosome;
KW   Glycoprotein; Ion channel; Ion transport; Isomerase; Isopeptide bond;
KW   Lipoprotein; Membrane; Nucleotide-binding; Nucleus; Palmitate;
KW   Phosphoprotein; Proteomics identification; Reference proteome; Repeat;
KW   Transmembrane; Transmembrane helix; Transport; Ubl conjugation.
FT   CHAIN           1..1480
FT                   /note="Cystic fibrosis transmembrane conductance regulator"
FT                   /id="PRO_0000093419"
FT   TOPO_DOM        1..77
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        78..98
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000269|Ref.57"
FT   TOPO_DOM        99..122
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|Ref.57"
FT   TRANSMEM        123..146
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000269|Ref.57"
FT   TOPO_DOM        147..195
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|Ref.57"
FT   TRANSMEM        196..216
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000269|Ref.57"
FT   TOPO_DOM        217..222
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|Ref.57"
FT   TRANSMEM        223..243
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000269|Ref.57"
FT   TOPO_DOM        244..298
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|Ref.57"
FT   TRANSMEM        299..319
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000269|Ref.57"
FT   TOPO_DOM        320..339
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|Ref.57"
FT   TRANSMEM        340..358
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000269|Ref.57"
FT   TOPO_DOM        359..858
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|Ref.57"
FT   TRANSMEM        859..879
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000269|Ref.57"
FT   TOPO_DOM        880..918
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|Ref.57"
FT   TRANSMEM        919..939
FT                   /note="Discontinuously helical; Name=8"
FT                   /evidence="ECO:0000269|Ref.57"
FT   TOPO_DOM        940..990
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|Ref.57"
FT   TRANSMEM        991..1011
FT                   /note="Helical; Name=9"
FT                   /evidence="ECO:0000269|Ref.57"
FT   TOPO_DOM        1012..1013
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|Ref.57"
FT   TRANSMEM        1014..1034
FT                   /note="Helical; Name=10"
FT                   /evidence="ECO:0000269|Ref.57"
FT   TOPO_DOM        1035..1095
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|Ref.57"
FT   TRANSMEM        1096..1116
FT                   /note="Helical; Name=11"
FT                   /evidence="ECO:0000269|Ref.57"
FT   TOPO_DOM        1117..1130
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|Ref.57"
FT   TRANSMEM        1131..1151
FT                   /note="Helical; Name=12"
FT                   /evidence="ECO:0000269|Ref.57"
FT   TOPO_DOM        1152..1480
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|Ref.57"
FT   DOMAIN          81..365
FT                   /note="ABC transmembrane type-1 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00441"
FT   DOMAIN          423..646
FT                   /note="ABC transporter 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00434"
FT   DOMAIN          859..1155
FT                   /note="ABC transmembrane type-1 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00441"
FT   DOMAIN          1210..1443
FT                   /note="ABC transporter 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00434"
FT   REGION          654..831
FT                   /note="Disordered R region"
FT                   /evidence="ECO:0000269|PubMed:10792060"
FT   REGION          1386..1480
FT                   /note="Interaction with GORASP2"
FT                   /evidence="ECO:0000269|PubMed:21884936"
FT   REGION          1452..1480
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           1478..1480
FT                   /note="PDZ-binding"
FT                   /evidence="ECO:0000269|PubMed:11707463,
FT                   ECO:0000269|PubMed:16331976"
FT   COMPBIAS        1470..1480
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         401
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000269|PubMed:15528182,
FT                   ECO:0000269|PubMed:20150177, ECO:0007744|PDB:1XMI,
FT                   ECO:0007744|PDB:1XMJ, ECO:0007744|PDB:2BBO,
FT                   ECO:0007744|PDB:2BBS, ECO:0007744|PDB:2BBT,
FT                   ECO:0007744|PDB:2PZE, ECO:0007744|PDB:2PZF,
FT                   ECO:0007744|PDB:2PZG"
FT   BINDING         434
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000269|PubMed:20150177,
FT                   ECO:0007744|PDB:2PZE, ECO:0007744|PDB:2PZF,
FT                   ECO:0007744|PDB:2PZG"
FT   BINDING         458..465
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00434,
FT                   ECO:0000269|PubMed:15528182, ECO:0007744|PDB:1XMI,
FT                   ECO:0007744|PDB:1XMJ, ECO:0007744|PDB:2BBO,
FT                   ECO:0007744|PDB:2BBS, ECO:0007744|PDB:2BBT"
FT   BINDING         493
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000269|PubMed:15528182,
FT                   ECO:0007744|PDB:1XMI, ECO:0007744|PDB:2BBO,
FT                   ECO:0007744|PDB:2BBS"
FT   BINDING         1219
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0007744|PDB:3GD7"
FT   BINDING         1244..1251
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00434,
FT                   ECO:0007744|PDB:3GD7"
FT   MOD_RES         549
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         660
FT                   /note="Phosphoserine; by PKA"
FT                   /evidence="ECO:0000269|PubMed:1377674,
FT                   ECO:0000269|PubMed:22119790, ECO:0000269|PubMed:25330774,
FT                   ECO:0000269|PubMed:9385646"
FT   MOD_RES         670
FT                   /note="Phosphoserine; by PKA"
FT                   /evidence="ECO:0000269|PubMed:25330774"
FT   MOD_RES         686
FT                   /note="Phosphoserine; by PKC"
FT                   /evidence="ECO:0000269|PubMed:1377674,
FT                   ECO:0000269|PubMed:22119790"
FT   MOD_RES         700
FT                   /note="Phosphoserine; by PKA"
FT                   /evidence="ECO:0000269|PubMed:1377674,
FT                   ECO:0000269|PubMed:22119790, ECO:0000269|PubMed:25330774,
FT                   ECO:0000269|PubMed:9385646"
FT   MOD_RES         712
FT                   /note="Phosphoserine; by PKA"
FT                   /evidence="ECO:0000269|PubMed:22119790,
FT                   ECO:0000269|PubMed:25330774, ECO:0000269|PubMed:9385646"
FT   MOD_RES         717
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:22119790"
FT   MOD_RES         737
FT                   /note="Phosphoserine; by PKA"
FT                   /evidence="ECO:0000269|PubMed:1377674,
FT                   ECO:0000269|PubMed:22119790, ECO:0000269|PubMed:25330774,
FT                   ECO:0000269|PubMed:9385646"
FT   MOD_RES         753
FT                   /note="Phosphoserine; by PKA"
FT                   /evidence="ECO:0000269|PubMed:25330774,
FT                   ECO:0000269|PubMed:9385646"
FT   MOD_RES         768
FT                   /note="Phosphoserine; by PKA"
FT                   /evidence="ECO:0000269|PubMed:1377674,
FT                   ECO:0000269|PubMed:25330774, ECO:0000269|PubMed:9385646"
FT   MOD_RES         790
FT                   /note="Phosphoserine; by PKC"
FT                   /evidence="ECO:0000269|PubMed:1377674"
FT   MOD_RES         795
FT                   /note="Phosphoserine; by PKA"
FT                   /evidence="ECO:0000269|PubMed:1377674,
FT                   ECO:0000269|PubMed:22119790, ECO:0000269|PubMed:25330774,
FT                   ECO:0000269|PubMed:9385646"
FT   MOD_RES         813
FT                   /note="Phosphoserine; by PKA"
FT                   /evidence="ECO:0000269|PubMed:1377674,
FT                   ECO:0000269|PubMed:25330774, ECO:0000269|PubMed:9385646"
FT   MOD_RES         1444
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:22119790"
FT   MOD_RES         1456
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:22119790"
FT   LIPID           524
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:22119790"
FT   LIPID           1395
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:22119790"
FT   CARBOHYD        894
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:7518437,
FT                   ECO:0000305|PubMed:20008117"
FT   CARBOHYD        900
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:7518437,
FT                   ECO:0000305|PubMed:20008117"
FT   CROSSLNK        688
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:22119790"
FT   VAR_SEQ         404..464
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_022123"
FT   VAR_SEQ         589..605
FT                   /note="SCVCKLMANKTRILVTS -> RRRCSCLLDRNKKTIF (in isoform
FT                   3)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_022124"
FT   VAR_SEQ         606..1480
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_022125"
FT   VARIANT         13
FT                   /note="S -> F (in CF; dbSNP:rs397508635)"
FT                   /evidence="ECO:0000269|PubMed:9554753"
FT                   /id="VAR_000101"
FT   VARIANT         31
FT                   /note="R -> C (in dbSNP:rs1800073)"
FT                   /evidence="ECO:0000269|PubMed:7522211,
FT                   ECO:0000269|PubMed:9921909"
FT                   /id="VAR_000102"
FT   VARIANT         31
FT                   /note="R -> L (in CF; uncertain significance;
FT                   dbSNP:rs149353983)"
FT                   /evidence="ECO:0000269|PubMed:7537150"
FT                   /id="VAR_000103"
FT   VARIANT         42
FT                   /note="S -> F (in CF; dbSNP:rs143456784)"
FT                   /evidence="ECO:0000269|PubMed:7541510"
FT                   /id="VAR_000104"
FT   VARIANT         44
FT                   /note="D -> G (in CF; uncertain significance;
FT                   dbSNP:rs1800074)"
FT                   /evidence="ECO:0000269|PubMed:1379210"
FT                   /id="VAR_000105"
FT   VARIANT         44
FT                   /note="D -> V (in dbSNP:rs1800074)"
FT                   /evidence="ECO:0000269|PubMed:1379210"
FT                   /id="VAR_000106"
FT   VARIANT         50
FT                   /note="S -> Y (in CBAVD; dbSNP:rs397508220)"
FT                   /evidence="ECO:0000269|PubMed:9067761"
FT                   /id="VAR_000107"
FT   VARIANT         57
FT                   /note="W -> G (in CF; dbSNP:rs397508272)"
FT                   /evidence="ECO:0000269|PubMed:7544319"
FT                   /id="VAR_000108"
FT   VARIANT         67
FT                   /note="P -> L (in CF; dbSNP:rs368505753)"
FT                   /evidence="ECO:0000269|PubMed:9507391"
FT                   /id="VAR_000109"
FT   VARIANT         74
FT                   /note="R -> W (in CF and CBAVD; uncertain significance;
FT                   dbSNP:rs115545701)"
FT                   /evidence="ECO:0000269|PubMed:17329263"
FT                   /id="VAR_000110"
FT   VARIANT         75
FT                   /note="R -> Q (in CF; dbSNP:rs1800076)"
FT                   /evidence="ECO:0000269|PubMed:17329263,
FT                   ECO:0000269|PubMed:9521595, ECO:0000269|PubMed:9921909"
FT                   /id="VAR_000111"
FT   VARIANT         85
FT                   /note="G -> E (in CF; dbSNP:rs75961395)"
FT                   /evidence="ECO:0000269|PubMed:9401006"
FT                   /id="VAR_000112"
FT   VARIANT         87
FT                   /note="F -> L (in CF; dbSNP:rs397508403)"
FT                   /evidence="ECO:0000269|PubMed:8081395"
FT                   /id="VAR_000113"
FT   VARIANT         91
FT                   /note="G -> R (in CF; dbSNP:rs121908750)"
FT                   /evidence="ECO:0000269|PubMed:1284534"
FT                   /id="VAR_000114"
FT   VARIANT         92
FT                   /note="E -> K (in CF; dbSNP:rs121908751)"
FT                   /evidence="ECO:0000269|PubMed:1284529,
FT                   ECO:0000269|PubMed:7683954"
FT                   /id="VAR_000115"
FT   VARIANT         98
FT                   /note="Q -> R (in CF; dbSNP:rs397508464)"
FT                   /evidence="ECO:0000269|PubMed:7581407"
FT                   /id="VAR_000116"
FT   VARIANT         109
FT                   /note="Y -> C (in CF; dbSNP:rs121909031)"
FT                   /evidence="ECO:0000269|PubMed:7524909"
FT                   /id="VAR_000118"
FT   VARIANT         110
FT                   /note="D -> H (in CF and CBAVD; dbSNP:rs113993958)"
FT                   /evidence="ECO:0000269|PubMed:17329263,
FT                   ECO:0000269|PubMed:9521595"
FT                   /id="VAR_000119"
FT   VARIANT         111
FT                   /note="P -> L (in CBAVD; dbSNP:rs140502196)"
FT                   /evidence="ECO:0000269|Ref.118"
FT                   /id="VAR_000120"
FT   VARIANT         117
FT                   /note="R -> C (in CF; dbSNP:rs77834169)"
FT                   /evidence="ECO:0000269|PubMed:1284529"
FT                   /id="VAR_000121"
FT   VARIANT         117
FT                   /note="R -> H (in CF and CBAVD; strong decrease in single
FT                   channel conductance; promotes rapid return to the closed
FT                   state of the channel; decrease in bicarbonate transport;
FT                   dbSNP:rs78655421)"
FT                   /evidence="ECO:0000269|PubMed:11242048,
FT                   ECO:0000269|PubMed:17329263, ECO:0000269|PubMed:26846474,
FT                   ECO:0000269|PubMed:7508414, ECO:0000269|PubMed:9401006"
FT                   /id="VAR_000122"
FT   VARIANT         117
FT                   /note="R -> L (in CF; dbSNP:rs78655421)"
FT                   /evidence="ECO:0000269|PubMed:7541510"
FT                   /id="VAR_000123"
FT   VARIANT         117
FT                   /note="R -> P (in CF; dbSNP:rs78655421)"
FT                   /evidence="ECO:0000269|PubMed:9452048"
FT                   /id="VAR_000124"
FT   VARIANT         120
FT                   /note="A -> T (in CF; dbSNP:rs201958172)"
FT                   /evidence="ECO:0000269|PubMed:7517264"
FT                   /id="VAR_000125"
FT   VARIANT         138
FT                   /note="L -> P (in dbSNP:rs1800078)"
FT                   /id="VAR_009895"
FT   VARIANT         139
FT                   /note="H -> R (in CF; dbSNP:rs76371115)"
FT                   /evidence="ECO:0000269|PubMed:7541510"
FT                   /id="VAR_000126"
FT   VARIANT         141
FT                   /note="A -> D (in CF; dbSNP:rs397508700)"
FT                   /evidence="ECO:0000269|PubMed:9222768"
FT                   /id="VAR_000127"
FT   VARIANT         148
FT                   /note="I -> T (in CF; uncertain significance; loss of
FT                   bicarbonate transport; decreased inhibition of epithelial
FT                   sodium channel (ENaC), when tested in a heterologous
FT                   system; no effect on protein maturation, subcellular
FT                   location at the plasma membrane, nor on chloride channel
FT                   activity; dbSNP:rs35516286)"
FT                   /evidence="ECO:0000269|PubMed:11242048,
FT                   ECO:0000269|PubMed:12394343, ECO:0000269|PubMed:16822950"
FT                   /id="VAR_000128"
FT   VARIANT         149
FT                   /note="G -> R (in CBAVD; dbSNP:rs397508718)"
FT                   /evidence="ECO:0000269|PubMed:7529962"
FT                   /id="VAR_000129"
FT   VARIANT         170
FT                   /note="R -> H (in CBAVD; uncertain significance;
FT                   dbSNP:rs1800079)"
FT                   /evidence="ECO:0000269|PubMed:17329263"
FT                   /id="VAR_009896"
FT   VARIANT         178
FT                   /note="G -> R (in CF; loss of bicarbonate transport; no
FT                   effect on protein maturation, subcellular location at the
FT                   plasma membrane, nor on chloride channel activity;
FT                   dbSNP:rs80282562)"
FT                   /evidence="ECO:0000269|PubMed:11242048,
FT                   ECO:0000269|PubMed:1379210"
FT                   /id="VAR_000130"
FT   VARIANT         182
FT                   /note="S -> G (in dbSNP:rs1800080)"
FT                   /id="VAR_009897"
FT   VARIANT         192
FT                   /note="Missing (in CF)"
FT                   /evidence="ECO:0000269|PubMed:9452048"
FT                   /id="VAR_000131"
FT   VARIANT         193
FT                   /note="E -> K (in CBAVD and CF; decrease in bicarbonate
FT                   transport; no effect on chloride channel activity;
FT                   dbSNP:rs397508759)"
FT                   /evidence="ECO:0000269|PubMed:11242048,
FT                   ECO:0000269|PubMed:7529962, ECO:0000269|PubMed:7544319"
FT                   /id="VAR_000132"
FT   VARIANT         199
FT                   /note="H -> Q (in CF; dbSNP:rs397508765)"
FT                   /evidence="ECO:0000269|PubMed:1284534"
FT                   /id="VAR_000133"
FT   VARIANT         199
FT                   /note="H -> Y (in CF; dbSNP:rs121908802)"
FT                   /evidence="ECO:0000269|PubMed:7525450"
FT                   /id="VAR_000134"
FT   VARIANT         205
FT                   /note="P -> S (in CF; dbSNP:rs121908803)"
FT                   /evidence="ECO:0000269|PubMed:7505694"
FT                   /id="VAR_000135"
FT   VARIANT         206
FT                   /note="L -> W (in CF and CBAVD; dbSNP:rs121908752)"
FT                   /evidence="ECO:0000269|PubMed:17329263,
FT                   ECO:0000269|PubMed:8522333"
FT                   /id="VAR_000136"
FT   VARIANT         220..1480
FT                   /note="Missing (in CF)"
FT                   /evidence="ECO:0000269|PubMed:20691141"
FT                   /id="VAR_080302"
FT   VARIANT         225
FT                   /note="C -> R (in CF; uncertain significance;
FT                   dbSNP:rs397508780)"
FT                   /evidence="ECO:0000269|PubMed:1379210"
FT                   /id="VAR_000137"
FT   VARIANT         232
FT                   /note="V -> D (in CBAVD; dbSNP:rs397508783)"
FT                   /evidence="ECO:0000269|PubMed:17329263"
FT                   /id="VAR_080303"
FT   VARIANT         244
FT                   /note="M -> K (in CBAVD; dbSNP:rs397508790)"
FT                   /evidence="ECO:0000269|Ref.118"
FT                   /id="VAR_000138"
FT   VARIANT         258
FT                   /note="R -> G (in CBAVD; dbSNP:rs191456345)"
FT                   /evidence="ECO:0000269|PubMed:7529962"
FT                   /id="VAR_000139"
FT   VARIANT         287
FT                   /note="N -> Y (in CF; decreased presence at the cell
FT                   membrane due to increased internalization from the apical
FT                   cell membrane; no effect on single channel gating and
FT                   conductance; dbSNP:rs397508804)"
FT                   /evidence="ECO:0000269|PubMed:12529365,
FT                   ECO:0000269|PubMed:9401006"
FT                   /id="VAR_000140"
FT   VARIANT         297
FT                   /note="R -> Q (in CF; dbSNP:rs143486492)"
FT                   /evidence="ECO:0000269|PubMed:1284534"
FT                   /id="VAR_000141"
FT   VARIANT         301
FT                   /note="Y -> C (in CF; uncertain significance;
FT                   dbSNP:rs150691494)"
FT                   /evidence="ECO:0000269|PubMed:9921909"
FT                   /id="VAR_000142"
FT   VARIANT         307
FT                   /note="S -> N (in CBAVD and CF; dbSNP:rs397508817)"
FT                   /evidence="ECO:0000269|PubMed:10066035,
FT                   ECO:0000269|PubMed:32026723, ECO:0000269|PubMed:33572515"
FT                   /id="VAR_000143"
FT   VARIANT         311
FT                   /note="F -> L (in CF; dbSNP:rs121909016)"
FT                   /evidence="ECO:0000269|PubMed:1284534"
FT                   /id="VAR_000144"
FT   VARIANT         311
FT                   /note="Missing (in CF)"
FT                   /evidence="ECO:0000269|PubMed:9443874"
FT                   /id="VAR_000145"
FT   VARIANT         314
FT                   /note="G -> E (in CF; dbSNP:rs75763344)"
FT                   /evidence="ECO:0000269|PubMed:1284534"
FT                   /id="VAR_000146"
FT   VARIANT         314
FT                   /note="G -> R (in CF; dbSNP:rs397508819)"
FT                   /evidence="ECO:0000269|PubMed:8829633"
FT                   /id="VAR_000147"
FT   VARIANT         322
FT                   /note="V -> M (in dbSNP:rs1800085)"
FT                   /id="VAR_009898"
FT   VARIANT         334
FT                   /note="R -> W (in CF and CBAVD; mild; does not prevent
FT                   maturation of glycans; dbSNP:rs121909011)"
FT                   /evidence="ECO:0000269|PubMed:1379210,
FT                   ECO:0000269|PubMed:1699669, ECO:0000269|PubMed:17329263"
FT                   /id="VAR_000148"
FT   VARIANT         336
FT                   /note="I -> K (in CF; dbSNP:rs397508139)"
FT                   /evidence="ECO:0000269|PubMed:7508414"
FT                   /id="VAR_000150"
FT   VARIANT         338
FT                   /note="T -> I (in CF; mild; isolated hypotonic dehydration;
FT                   dbSNP:rs77409459)"
FT                   /evidence="ECO:0000269|PubMed:7543567,
FT                   ECO:0000269|PubMed:9554753"
FT                   /id="VAR_000151"
FT   VARIANT         346
FT                   /note="L -> P (in CF; dominant mutation but mild phenotype;
FT                   dbSNP:rs397508146)"
FT                   /evidence="ECO:0000269|PubMed:7513296"
FT                   /id="VAR_000152"
FT   VARIANT         347
FT                   /note="R -> H (in CF; dbSNP:rs77932196)"
FT                   /evidence="ECO:0000269|PubMed:7504969"
FT                   /id="VAR_000153"
FT   VARIANT         347
FT                   /note="R -> L (in CF; dbSNP:rs77932196)"
FT                   /evidence="ECO:0000269|PubMed:7504969"
FT                   /id="VAR_000154"
FT   VARIANT         347
FT                   /note="R -> P (in CF; mild; dbSNP:rs77932196)"
FT                   /evidence="ECO:0000269|PubMed:1284534"
FT                   /id="VAR_000155"
FT   VARIANT         351
FT                   /note="T -> S (in dbSNP:rs1800086)"
FT                   /id="VAR_009899"
FT   VARIANT         352
FT                   /note="R -> Q (in CF; dbSNP:rs121908753)"
FT                   /evidence="ECO:0000269|PubMed:7504969"
FT                   /id="VAR_000156"
FT   VARIANT         353
FT                   /note="Q -> H (in dbSNP:rs1800087)"
FT                   /id="VAR_009900"
FT   VARIANT         359..360
FT                   /note="QT -> KK (in CF; dbSNP:rs397508152)"
FT                   /evidence="ECO:0000269|PubMed:1284534"
FT                   /id="VAR_000158"
FT   VARIANT         359
FT                   /note="Q -> K (in CF; dbSNP:rs76879328)"
FT                   /evidence="ECO:0000269|PubMed:7504969"
FT                   /id="VAR_000157"
FT   VARIANT         370
FT                   /note="K -> KNK (in CF)"
FT                   /evidence="ECO:0000269|PubMed:9452073"
FT                   /id="VAR_000159"
FT   VARIANT         443
FT                   /note="D -> Y (in CBAVD; uncertain significance;
FT                   dbSNP:rs147422190)"
FT                   /evidence="ECO:0000269|PubMed:17329263"
FT                   /id="VAR_080304"
FT   VARIANT         455
FT                   /note="A -> E (in CF; dbSNP:rs74551128)"
FT                   /evidence="ECO:0000269|PubMed:2236053,
FT                   ECO:0000269|PubMed:7508414, ECO:0000269|PubMed:9401006"
FT                   /id="VAR_000160"
FT   VARIANT         456
FT                   /note="V -> F (in CF; dbSNP:rs397508195)"
FT                   /evidence="ECO:0000269|PubMed:7505767"
FT                   /id="VAR_000161"
FT   VARIANT         458
FT                   /note="G -> V (in CF; dbSNP:rs121909009)"
FT                   /evidence="ECO:0000269|PubMed:1284534,
FT                   ECO:0000269|PubMed:7508414"
FT                   /id="VAR_000162"
FT   VARIANT         467
FT                   /note="L -> F (in dbSNP:rs1800089)"
FT                   /id="VAR_000163"
FT   VARIANT         470
FT                   /note="V -> M (in dbSNP:rs213950)"
FT                   /evidence="ECO:0000269|PubMed:10651488,
FT                   ECO:0000269|PubMed:1379210, ECO:0000269|PubMed:1710598,
FT                   ECO:0000269|PubMed:17329263, ECO:0000269|PubMed:18987736,
FT                   ECO:0000269|PubMed:20691141, ECO:0000269|PubMed:2475911,
FT                   ECO:0000269|Ref.3"
FT                   /id="VAR_000164"
FT   VARIANT         480
FT                   /note="G -> C (in CF; dbSNP:rs79282516)"
FT                   /evidence="ECO:0000269|PubMed:1284534"
FT                   /id="VAR_000165"
FT   VARIANT         492
FT                   /note="S -> F (in CF; dbSNP:rs121909017)"
FT                   /evidence="ECO:0000269|PubMed:1284534"
FT                   /id="VAR_000166"
FT   VARIANT         504
FT                   /note="E -> Q (in CF; dbSNP:rs397508223)"
FT                   /evidence="ECO:0000269|PubMed:1284534"
FT                   /id="VAR_000167"
FT   VARIANT         506
FT                   /note="I -> M (in dbSNP:rs1800092)"
FT                   /id="VAR_009901"
FT   VARIANT         506
FT                   /note="I -> V (in dbSNP:rs1800091)"
FT                   /evidence="ECO:0000269|PubMed:1379210,
FT                   ECO:0000269|PubMed:9921909"
FT                   /id="VAR_000168"
FT   VARIANT         507
FT                   /note="I -> V (in dbSNP:rs1801178)"
FT                   /id="VAR_000169"
FT   VARIANT         507
FT                   /note="Missing (in CF; impaired maturation of glycan
FT                   chains; dbSNP:rs121908745)"
FT                   /evidence="ECO:0000269|PubMed:1699669,
FT                   ECO:0000269|PubMed:1710600"
FT                   /id="VAR_000170"
FT   VARIANT         508
FT                   /note="F -> C (in dbSNP:rs74571530)"
FT                   /evidence="ECO:0000269|PubMed:1379210"
FT                   /id="VAR_000172"
FT   VARIANT         508
FT                   /note="Missing (in CF and CBAVD; most common mutation in
FT                   Caucasian CF chromosomes; impairs protein folding and
FT                   stability; causes local changes to the surface that
FT                   mediates interactions between domains; decreases frequency
FT                   of channel opening in vitro; binds to the cytokeratin-8 and
FT                   through this binding is primed for the degradation pathway
FT                   that ends in the proteasome, thus impairing trafficking;
FT                   impairs maturation and trafficking to the cell membrane;
FT                   impairs recycling to the cell membrane after endocytosis;
FT                   abolishes MARCHF2-mediated degradation; dbSNP:rs121909001
FT                   and dbSNP:rs113993960)"
FT                   /evidence="ECO:0000269|PubMed:12394343,
FT                   ECO:0000269|PubMed:12529365, ECO:0000269|PubMed:1284548,
FT                   ECO:0000269|PubMed:1379210, ECO:0000269|PubMed:15528182,
FT                   ECO:0000269|PubMed:15716351, ECO:0000269|PubMed:1699669,
FT                   ECO:0000269|PubMed:17098864, ECO:0000269|PubMed:1710600,
FT                   ECO:0000269|PubMed:17329263, ECO:0000269|PubMed:20008117,
FT                   ECO:0000269|PubMed:20150177, ECO:0000269|PubMed:20691141,
FT                   ECO:0000269|PubMed:21884936, ECO:0000269|PubMed:23818989,
FT                   ECO:0000269|PubMed:25330774, ECO:0000269|PubMed:27241308,
FT                   ECO:0000269|PubMed:28001373, ECO:0000269|PubMed:28067262,
FT                   ECO:0000269|PubMed:28087700"
FT                   /id="VAR_000171"
FT   VARIANT         513
FT                   /note="D -> G (in CBAVD; dbSNP:rs397508225)"
FT                   /evidence="ECO:0000269|PubMed:10651488"
FT                   /id="VAR_000173"
FT   VARIANT         520
FT                   /note="V -> F (in CF; dbSNP:rs77646904)"
FT                   /evidence="ECO:0000269|PubMed:1284466"
FT                   /id="VAR_000174"
FT   VARIANT         532
FT                   /note="K -> E (in dbSNP:rs35032490)"
FT                   /id="VAR_048150"
FT   VARIANT         542..1480
FT                   /note="Missing (in CF)"
FT                   /evidence="ECO:0000269|PubMed:1379210"
FT                   /id="VAR_080305"
FT   VARIANT         544
FT                   /note="G -> V (in CBAVD; dbSNP:rs397508241)"
FT                   /evidence="ECO:0000269|Ref.118"
FT                   /id="VAR_000175"
FT   VARIANT         549
FT                   /note="S -> I (in CF; impaired maturation of glycan chains;
FT                   dbSNP:rs121908755)"
FT                   /evidence="ECO:0000269|PubMed:1699669,
FT                   ECO:0000269|PubMed:1712898, ECO:0000269|PubMed:2236053"
FT                   /id="VAR_000177"
FT   VARIANT         549
FT                   /note="S -> N (in CF; dbSNP:rs121908755)"
FT                   /evidence="ECO:0000269|PubMed:1284534,
FT                   ECO:0000269|PubMed:1695717"
FT                   /id="VAR_000176"
FT   VARIANT         549
FT                   /note="S -> R (in CF; impaired maturation of glycan chains;
FT                   dbSNP:rs121909005)"
FT                   /evidence="ECO:0000269|PubMed:1712898,
FT                   ECO:0000269|PubMed:2236053"
FT                   /id="VAR_000178"
FT   VARIANT         551
FT                   /note="G -> D (in CF; decrease in the frequency of channel
FT                   opening in vitro; decrease in channel activity and ATPase
FT                   activity; complete loss of bicarbonate transport; no effect
FT                   on trafficking to the cell membrane, protein stability, nor
FT                   on the maturation of glycans; dbSNP:rs75527207)"
FT                   /evidence="ECO:0000269|PubMed:11242048,
FT                   ECO:0000269|PubMed:1284548, ECO:0000269|PubMed:1379210,
FT                   ECO:0000269|PubMed:1695717, ECO:0000269|PubMed:1699669,
FT                   ECO:0000269|PubMed:1712898, ECO:0000269|PubMed:2236053,
FT                   ECO:0000269|PubMed:28087700, ECO:0000269|PubMed:8910473,
FT                   ECO:0000269|PubMed:9401006"
FT                   /id="VAR_000179"
FT   VARIANT         551
FT                   /note="G -> S (in CF; decrease in bicarbonate transport; no
FT                   effect on chloride channel activity; dbSNP:rs121909013)"
FT                   /evidence="ECO:0000269|PubMed:7606851"
FT                   /id="VAR_000180"
FT   VARIANT         553
FT                   /note="R -> Q (in CF; dbSNP:rs121909044)"
FT                   /evidence="ECO:0000269|PubMed:1284534"
FT                   /id="VAR_000181"
FT   VARIANT         556
FT                   /note="I -> V (in CBAVD; uncertain significance;
FT                   dbSNP:rs75789129)"
FT                   /evidence="ECO:0000269|PubMed:17329263"
FT                   /id="VAR_080306"
FT   VARIANT         558
FT                   /note="L -> S (in CF; dbSNP:rs193922504)"
FT                   /evidence="ECO:0000269|PubMed:1284534"
FT                   /id="VAR_000182"
FT   VARIANT         559
FT                   /note="A -> T (in CF; impaired maturation of glycan chains;
FT                   dbSNP:rs75549581)"
FT                   /evidence="ECO:0000269|PubMed:1695717,
FT                   ECO:0000269|PubMed:1712898"
FT                   /id="VAR_000183"
FT   VARIANT         560
FT                   /note="R -> K (in CF; dbSNP:rs80055610)"
FT                   /evidence="ECO:0000269|PubMed:1284534"
FT                   /id="VAR_000184"
FT   VARIANT         560
FT                   /note="R -> S (in CF; dbSNP:rs397508267)"
FT                   /evidence="ECO:0000269|PubMed:9482579"
FT                   /id="VAR_000185"
FT   VARIANT         560
FT                   /note="R -> T (in CF; impairs maturation and trafficking to
FT                   the cell membrane; decrease in channel activity;
FT                   dbSNP:rs80055610)"
FT                   /evidence="ECO:0000269|PubMed:17098864,
FT                   ECO:0000269|PubMed:2236053"
FT                   /id="VAR_000186"
FT   VARIANT         561
FT                   /note="A -> E (in CF; impairs maturation and trafficking to
FT                   the cell membrane; decrease in channel activity;
FT                   dbSNP:rs121909047)"
FT                   /evidence="ECO:0000269|PubMed:17098864"
FT                   /id="VAR_080307"
FT   VARIANT         562
FT                   /note="V -> I (in CBAVD and CF; uncertain significance;
FT                   found in cis of the IVS8 TG11-T5 allele, which affects exon
FT                   9 splicing; no effect on protein maturation, trafficking to
FT                   the cell membrane, nor on channel activity;
FT                   dbSNP:rs1800097)"
FT                   /evidence="ECO:0000269|PubMed:1379210,
FT                   ECO:0000269|PubMed:17098864, ECO:0000269|PubMed:17329263,
FT                   ECO:0000269|PubMed:20691141"
FT                   /id="VAR_000187"
FT   VARIANT         562
FT                   /note="V -> L (in CF; dbSNP:rs1800097)"
FT                   /evidence="ECO:0000269|PubMed:8956039"
FT                   /id="VAR_000188"
FT   VARIANT         563
FT                   /note="Y -> N (in CF; dbSNP:rs121909006)"
FT                   /evidence="ECO:0000269|PubMed:1284534,
FT                   ECO:0000269|PubMed:2236053"
FT                   /id="VAR_000189"
FT   VARIANT         569
FT                   /note="Y -> C (in CF; dbSNP:rs397508277)"
FT                   /evidence="ECO:0000269|PubMed:8723693"
FT                   /id="VAR_000190"
FT   VARIANT         569
FT                   /note="Y -> D (in CF; dbSNP:rs397508276)"
FT                   /evidence="ECO:0000269|PubMed:9482579"
FT                   /id="VAR_000191"
FT   VARIANT         569
FT                   /note="Y -> H (in CF; dbSNP:rs397508276)"
FT                   /evidence="ECO:0000269|PubMed:10869121,
FT                   ECO:0000269|PubMed:10923036"
FT                   /id="VAR_000192"
FT   VARIANT         571
FT                   /note="L -> S (in CF; dbSNP:rs397508280)"
FT                   /evidence="ECO:0000269|PubMed:9521595"
FT                   /id="VAR_000193"
FT   VARIANT         572
FT                   /note="D -> N (in CF; impaired maturation of glycan chains;
FT                   dbSNP:rs397508282)"
FT                   /evidence="ECO:0000269|PubMed:1712898,
FT                   ECO:0000269|PubMed:7541273"
FT                   /id="VAR_000194"
FT   VARIANT         574
FT                   /note="P -> H (in CF; dbSNP:rs121908758)"
FT                   /evidence="ECO:0000269|PubMed:1284534,
FT                   ECO:0000269|PubMed:2236053"
FT                   /id="VAR_000195"
FT   VARIANT         576
FT                   /note="G -> A (in CBAVD; uncertain significance;
FT                   dbSNP:rs1800098)"
FT                   /evidence="ECO:0000269|PubMed:1379210,
FT                   ECO:0000269|PubMed:17329263"
FT                   /id="VAR_000196"
FT   VARIANT         579
FT                   /note="D -> G (in CF; dbSNP:rs397508288)"
FT                   /evidence="ECO:0000269|PubMed:10094564,
FT                   ECO:0000269|PubMed:7544319"
FT                   /id="VAR_000197"
FT   VARIANT         601
FT                   /note="I -> F (in CF; impaired maturation of glycan chains;
FT                   dbSNP:rs397508306)"
FT                   /evidence="ECO:0000269|PubMed:9736778"
FT                   /id="VAR_000198"
FT   VARIANT         605
FT                   /note="S -> F (in dbSNP:rs766874)"
FT                   /id="VAR_048151"
FT   VARIANT         610
FT                   /note="L -> S (in CF; impaired maturation of glycan chains;
FT                   dbSNP:rs397508311)"
FT                   /evidence="ECO:0000269|PubMed:9736778"
FT                   /id="VAR_000199"
FT   VARIANT         613
FT                   /note="A -> T (in CF; impaired maturation of glycan chains;
FT                   dbSNP:rs201978662)"
FT                   /evidence="ECO:0000269|PubMed:9736778"
FT                   /id="VAR_000200"
FT   VARIANT         614
FT                   /note="D -> G (in CF; impaired maturation of glycan chains;
FT                   dbSNP:rs201124247)"
FT                   /evidence="ECO:0000269|PubMed:9736778"
FT                   /id="VAR_000201"
FT   VARIANT         618
FT                   /note="I -> T (in CF; impaired maturation of glycan chains;
FT                   dbSNP:rs139468767)"
FT                   /evidence="ECO:0000269|PubMed:9736778"
FT                   /id="VAR_000202"
FT   VARIANT         619
FT                   /note="L -> S (in CF; impaired maturation of glycan chains;
FT                   dbSNP:rs397508313)"
FT                   /evidence="ECO:0000269|PubMed:7525450,
FT                   ECO:0000269|PubMed:9736778"
FT                   /id="VAR_000203"
FT   VARIANT         620
FT                   /note="H -> P (in CF; impaired maturation of glycan chains;
FT                   dbSNP:rs397508314)"
FT                   /evidence="ECO:0000269|PubMed:9736778"
FT                   /id="VAR_000204"
FT   VARIANT         620
FT                   /note="H -> Q (in CF; strong decrease in bicarbonate
FT                   transport; increase in chloride channel activity in vitro;
FT                   no effect on glycan maturation; dbSNP:rs397508315)"
FT                   /evidence="ECO:0000269|PubMed:9736778"
FT                   /id="VAR_000205"
FT   VARIANT         622
FT                   /note="G -> D (in CBAVD; decreased channel activity; has no
FT                   effect on glycan maturation; dbSNP:rs121908759)"
FT                   /evidence="ECO:0000269|PubMed:17329263,
FT                   ECO:0000269|PubMed:9736778"
FT                   /id="VAR_000206"
FT   VARIANT         628
FT                   /note="G -> R (in CF; impaired maturation of glycan chains;
FT                   dbSNP:rs397508316)"
FT                   /evidence="ECO:0000269|PubMed:1379210,
FT                   ECO:0000269|PubMed:7508414, ECO:0000269|PubMed:9736778"
FT                   /id="VAR_000207"
FT   VARIANT         633
FT                   /note="L -> P (in CF; impaired maturation of glycan chains;
FT                   dbSNP:rs397508318)"
FT                   /evidence="ECO:0000269|PubMed:9736778"
FT                   /id="VAR_000208"
FT   VARIANT         648
FT                   /note="D -> V (in CF; decrease in bicarbonate transport; no
FT                   effect chloride channel activity; dbSNP:rs121909033)"
FT                   /evidence="ECO:0000269|PubMed:11242048"
FT                   /id="VAR_000209"
FT   VARIANT         651
FT                   /note="D -> N (in CF; dbSNP:rs780526529)"
FT                   /evidence="ECO:0000269|PubMed:9921909"
FT                   /id="VAR_000210"
FT   VARIANT         654
FT                   /note="S -> G (in dbSNP:rs1800099)"
FT                   /id="VAR_009902"
FT   VARIANT         665
FT                   /note="T -> S (in CF; uncertain significance; no effect on
FT                   glycan maturation and channel activity;
FT                   dbSNP:rs1177201180)"
FT                   /evidence="ECO:0000269|PubMed:8800923,
FT                   ECO:0000269|PubMed:9736778"
FT                   /id="VAR_000211"
FT   VARIANT         668
FT                   /note="R -> C (in CBAVD; uncertain significance;
FT                   dbSNP:rs1800100)"
FT                   /evidence="ECO:0000269|PubMed:1379210,
FT                   ECO:0000269|PubMed:17329263, ECO:0000269|PubMed:9921909"
FT                   /id="VAR_000212"
FT   VARIANT         693
FT                   /note="F -> L (in CF; uncertain significance; no effect on
FT                   glycan maturation; no effect on channel activity;
FT                   dbSNP:rs145540754 and dbSNP:rs397508338)"
FT                   /evidence="ECO:0000269|PubMed:12167682,
FT                   ECO:0000269|PubMed:8406518, ECO:0000269|PubMed:9736778"
FT                   /id="VAR_000213"
FT   VARIANT         710..1480
FT                   /note="Missing (in CF)"
FT                   /evidence="ECO:0000269|PubMed:1379210"
FT                   /id="VAR_080308"
FT   VARIANT         754
FT                   /note="V -> M (in CF; uncertain significance;
FT                   dbSNP:rs150157202)"
FT                   /evidence="ECO:0000269|PubMed:9921909"
FT                   /id="VAR_000214"
FT   VARIANT         766
FT                   /note="R -> M (in CBAVD; uncertain significance; no effect
FT                   on glycan maturation; no effect on channel activity;
FT                   dbSNP:rs397508363)"
FT                   /evidence="ECO:0000269|PubMed:9736778"
FT                   /id="VAR_000215"
FT   VARIANT         792
FT                   /note="R -> G (in CBAVD; no effect on glycan maturation but
FT                   decreased channel activity; dbSNP:rs145449046)"
FT                   /evidence="ECO:0000269|PubMed:9736778"
FT                   /id="VAR_000216"
FT   VARIANT         800
FT                   /note="A -> G (in CBAVD; small decrease in bicarbonate
FT                   transport; increase in chloride channel activity in vitro;
FT                   no effect on glycan maturation; dbSNP:rs397508373)"
FT                   /evidence="ECO:0000269|PubMed:11242048,
FT                   ECO:0000269|PubMed:7529962, ECO:0000269|PubMed:9736778"
FT                   /id="VAR_000217"
FT   VARIANT         807
FT                   /note="I -> M (in CBAVD; uncertain significance; no effect
FT                   on glycan maturation; no effect on channel activity;
FT                   dbSNP:rs1800103)"
FT                   /evidence="ECO:0000269|PubMed:9736778"
FT                   /id="VAR_000218"
FT   VARIANT         822
FT                   /note="E -> K (in CF; no effect on glycan maturation but
FT                   decreased channel activity; dbSNP:rs397508378)"
FT                   /evidence="ECO:0000269|PubMed:9736778"
FT                   /id="VAR_000219"
FT   VARIANT         826
FT                   /note="E -> K (in thoracic sarcoidosis; uncertain
FT                   significance; no effect on glycan maturation and channel
FT                   activity; dbSNP:rs397508381)"
FT                   /evidence="ECO:0000269|PubMed:9736778"
FT                   /id="VAR_000220"
FT   VARIANT         846..1480
FT                   /note="Missing (in CF)"
FT                   /evidence="ECO:0000269|PubMed:1379210"
FT                   /id="VAR_080309"
FT   VARIANT         866
FT                   /note="C -> Y (in CF; dbSNP:rs193922506)"
FT                   /evidence="ECO:0000269|PubMed:1284534"
FT                   /id="VAR_000221"
FT   VARIANT         890..1480
FT                   /note="Missing (in CF)"
FT                   /evidence="ECO:0000269|PubMed:12394343,
FT                   ECO:0000269|PubMed:7522211"
FT                   /id="VAR_080310"
FT   VARIANT         903
FT                   /note="Y -> H (in dbSNP:rs1800106)"
FT                   /id="VAR_009903"
FT   VARIANT         909
FT                   /note="S -> I (in dbSNP:rs1800107)"
FT                   /id="VAR_009904"
FT   VARIANT         912
FT                   /note="S -> L (in CF; uncertain significance;
FT                   dbSNP:rs121909034)"
FT                   /evidence="ECO:0000269|PubMed:7522211"
FT                   /id="VAR_000222"
FT   VARIANT         913
FT                   /note="Y -> C (in CF; dbSNP:rs121909008)"
FT                   /evidence="ECO:0000269|PubMed:1379210"
FT                   /id="VAR_000223"
FT   VARIANT         917
FT                   /note="Y -> C (in CF; dbSNP:rs397508428)"
FT                   /id="VAR_000224"
FT   VARIANT         938
FT                   /note="V -> G (in CBAVD; uncertain significance;
FT                   dbSNP:rs193922511)"
FT                   /evidence="ECO:0000269|PubMed:17329263"
FT                   /id="VAR_080311"
FT   VARIANT         949
FT                   /note="H -> Y (in CF; decrease in bicarbonate transport; no
FT                   effect on chloride channel activity; dbSNP:rs121909035)"
FT                   /evidence="ECO:0000269|PubMed:11242048,
FT                   ECO:0000269|PubMed:7522211"
FT                   /id="VAR_000225"
FT   VARIANT         952
FT                   /note="M -> I (in CF and CBAVD; uncertain significance;
FT                   dbSNP:rs151048781)"
FT                   /evidence="ECO:0000269|PubMed:17329263,
FT                   ECO:0000269|PubMed:9521595"
FT                   /id="VAR_000226"
FT   VARIANT         959
FT                   /note="A -> V (in CBAVD; uncertain significance;
FT                   dbSNP:rs397508448)"
FT                   /evidence="ECO:0000269|PubMed:17329263"
FT                   /id="VAR_080312"
FT   VARIANT         967
FT                   /note="L -> S (in dbSNP:rs1800110)"
FT                   /id="VAR_009905"
FT   VARIANT         977
FT                   /note="S -> F (in CBAVD; dbSNP:rs141033578)"
FT                   /evidence="ECO:0000269|PubMed:17329263"
FT                   /id="VAR_080313"
FT   VARIANT         997
FT                   /note="L -> F (in CF and CBAVD; uncertain significance;
FT                   dbSNP:rs1800111)"
FT                   /evidence="ECO:0000269|PubMed:17329263"
FT                   /id="VAR_000227"
FT   VARIANT         1005
FT                   /note="I -> R (in CF; dbSNP:rs397508479)"
FT                   /evidence="ECO:0000269|PubMed:7525450"
FT                   /id="VAR_000228"
FT   VARIANT         1006
FT                   /note="A -> E (in CF; dbSNP:rs397508480)"
FT                   /evidence="ECO:0000269|PubMed:20691141,
FT                   ECO:0000269|PubMed:7541510"
FT                   /id="VAR_000229"
FT   VARIANT         1013
FT                   /note="P -> L (in CF; dbSNP:rs193922516)"
FT                   /evidence="ECO:0000269|PubMed:9521595"
FT                   /id="VAR_000230"
FT   VARIANT         1023..1024
FT                   /note="Missing (in CF; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:12394343"
FT                   /id="VAR_080314"
FT   VARIANT         1027
FT                   /note="I -> T (in dbSNP:rs1800112)"
FT                   /evidence="ECO:0000269|PubMed:1379210"
FT                   /id="VAR_080315"
FT   VARIANT         1028
FT                   /note="M -> I (in CF; dbSNP:rs200553511)"
FT                   /evidence="ECO:0000269|PubMed:9521595"
FT                   /id="VAR_000231"
FT   VARIANT         1032
FT                   /note="Y -> C (in CBAVD; uncertain significance;
FT                   dbSNP:rs144055758)"
FT                   /evidence="ECO:0000269|PubMed:17329263"
FT                   /id="VAR_080316"
FT   VARIANT         1052
FT                   /note="F -> V (in CF; dbSNP:rs150212784)"
FT                   /evidence="ECO:0000269|PubMed:7683628"
FT                   /id="VAR_000232"
FT   VARIANT         1061
FT                   /note="G -> R (in CF; dbSNP:rs142394380)"
FT                   /evidence="ECO:0000269|PubMed:7683628,
FT                   ECO:0000269|PubMed:8723695"
FT                   /id="VAR_000233"
FT   VARIANT         1063..1480
FT                   /note="Missing (in CF)"
FT                   /evidence="ECO:0000269|PubMed:1379210"
FT                   /id="VAR_080317"
FT   VARIANT         1065
FT                   /note="L -> P (in CF; dbSNP:rs121909036)"
FT                   /evidence="ECO:0000269|PubMed:7522211"
FT                   /id="VAR_000234"
FT   VARIANT         1065
FT                   /note="L -> R (in CF; dbSNP:rs121909036)"
FT                   /evidence="ECO:0000269|PubMed:9452054"
FT                   /id="VAR_000235"
FT   VARIANT         1066
FT                   /note="R -> C (in CF; dbSNP:rs78194216)"
FT                   /evidence="ECO:0000269|PubMed:1379210,
FT                   ECO:0000269|PubMed:9375855"
FT                   /id="VAR_000236"
FT   VARIANT         1066
FT                   /note="R -> H (in CF; dbSNP:rs121909019)"
FT                   /evidence="ECO:0000269|PubMed:1284534"
FT                   /id="VAR_000237"
FT   VARIANT         1066
FT                   /note="R -> L (in CF; dbSNP:rs121909019)"
FT                   /evidence="ECO:0000269|PubMed:7683628"
FT                   /id="VAR_000238"
FT   VARIANT         1067
FT                   /note="A -> T (in CF; loss of bicarbonate transport; no
FT                   effect on protein maturation, subcellular location at the
FT                   plasma membrane, nor on chloride channel activity;
FT                   dbSNP:rs121909020)"
FT                   /evidence="ECO:0000269|PubMed:11242048"
FT                   /id="VAR_000239"
FT   VARIANT         1067
FT                   /note="A -> V (in dbSNP:rs1800114)"
FT                   /evidence="ECO:0000269|PubMed:7539342"
FT                   /id="VAR_000240"
FT   VARIANT         1069
FT                   /note="G -> R (in CBAVD; uncertain significance;
FT                   dbSNP:rs200321110)"
FT                   /evidence="ECO:0000269|PubMed:17329263"
FT                   /id="VAR_080318"
FT   VARIANT         1070
FT                   /note="R -> P (in CF; dbSNP:rs78769542)"
FT                   /evidence="ECO:0000269|PubMed:9401006"
FT                   /id="VAR_000242"
FT   VARIANT         1070
FT                   /note="R -> Q (in CF; decrease in bicarbonate transport; no
FT                   effect on chloride channel activity; dbSNP:rs78769542)"
FT                   /evidence="ECO:0000269|PubMed:11242048,
FT                   ECO:0000269|PubMed:7683628"
FT                   /id="VAR_000241"
FT   VARIANT         1070
FT                   /note="R -> W (in CBAVD; dbSNP:rs202179988)"
FT                   /evidence="ECO:0000269|PubMed:7539342"
FT                   /id="VAR_011564"
FT   VARIANT         1071
FT                   /note="Q -> P (in CF; dbSNP:rs121909037)"
FT                   /evidence="ECO:0000269|PubMed:7522211"
FT                   /id="VAR_000243"
FT   VARIANT         1072
FT                   /note="P -> L (in CF; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:9921909"
FT                   /id="VAR_000244"
FT   VARIANT         1077
FT                   /note="L -> P (in CF; dbSNP:rs139304906)"
FT                   /evidence="ECO:0000269|PubMed:1284534"
FT                   /id="VAR_000245"
FT   VARIANT         1085
FT                   /note="H -> R (in CF; dbSNP:rs79635528)"
FT                   /evidence="ECO:0000269|PubMed:7683628"
FT                   /id="VAR_000246"
FT   VARIANT         1092..1480
FT                   /note="Missing (in CF)"
FT                   /evidence="ECO:0000269|PubMed:1379210"
FT                   /id="VAR_080319"
FT   VARIANT         1098
FT                   /note="W -> R (in CF; dbSNP:rs397508531)"
FT                   /evidence="ECO:0000269|PubMed:7537150"
FT                   /id="VAR_000247"
FT   VARIANT         1101
FT                   /note="M -> K (in CF; dbSNP:rs36210737)"
FT                   /evidence="ECO:0000269|PubMed:7680525"
FT                   /id="VAR_000248"
FT   VARIANT         1101
FT                   /note="M -> R (in CF; dbSNP:rs36210737)"
FT                   /evidence="ECO:0000269|PubMed:7683628"
FT                   /id="VAR_011565"
FT   VARIANT         1137
FT                   /note="M -> V (in CF; decreases channel activity; no
FT                   visible effect on protein maturation; dbSNP:rs397508553)"
FT                   /evidence="ECO:0000269|PubMed:9804160"
FT                   /id="VAR_000249"
FT   VARIANT         1140
FT                   /note="Missing (in CF; abolishes channel activity; no
FT                   visible effect on protein maturation; dbSNP:rs397508557)"
FT                   /evidence="ECO:0000269|PubMed:9101301,
FT                   ECO:0000269|PubMed:9804160"
FT                   /id="VAR_000250"
FT   VARIANT         1152
FT                   /note="D -> H (in CF and CBAVD; decreases channel activity;
FT                   no visible effect on protein maturation; dbSNP:rs75541969)"
FT                   /evidence="ECO:0000269|PubMed:17329263,
FT                   ECO:0000269|PubMed:9804160"
FT                   /id="VAR_000251"
FT   VARIANT         1153
FT                   /note="V -> E (in CBAVD; uncertain significance;
FT                   dbSNP:rs397508567)"
FT                   /evidence="ECO:0000269|PubMed:17329263"
FT                   /id="VAR_080320"
FT   VARIANT         1162..1480
FT                   /note="Missing (in CF)"
FT                   /evidence="ECO:0000269|PubMed:1379210"
FT                   /id="VAR_080321"
FT   VARIANT         1162
FT                   /note="R -> L (in dbSNP:rs1800120)"
FT                   /evidence="ECO:0000269|PubMed:1379210"
FT                   /id="VAR_000252"
FT   VARIANT         1200
FT                   /note="K -> E (in CF; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:1379210"
FT                   /id="VAR_080322"
FT   VARIANT         1204..1480
FT                   /note="Missing (in CF)"
FT                   /evidence="ECO:0000269|PubMed:7522211"
FT                   /id="VAR_080323"
FT   VARIANT         1220
FT                   /note="T -> I (in dbSNP:rs1800123)"
FT                   /evidence="ECO:0000269|PubMed:7522211"
FT                   /id="VAR_000253"
FT   VARIANT         1234
FT                   /note="I -> V (in CF; dbSNP:rs75389940)"
FT                   /evidence="ECO:0000269|PubMed:1284534"
FT                   /id="VAR_000254"
FT   VARIANT         1235
FT                   /note="S -> R (in CF; dbSNP:rs34911792)"
FT                   /evidence="ECO:0000269|PubMed:7508414"
FT                   /id="VAR_000255"
FT   VARIANT         1244
FT                   /note="G -> E (in CF; loss of bicarbonate transport; no
FT                   effect on protein maturation, subcellular location at the
FT                   plasma membrane, nor on chloride channel activity;
FT                   dbSNP:rs267606723)"
FT                   /evidence="ECO:0000269|PubMed:11242048"
FT                   /id="VAR_000256"
FT   VARIANT         1249
FT                   /note="G -> E (in CF; dbSNP:rs121909040)"
FT                   /evidence="ECO:0000269|PubMed:7520022"
FT                   /id="VAR_000257"
FT   VARIANT         1251
FT                   /note="S -> N (in CF; dbSNP:rs74503330)"
FT                   /evidence="ECO:0000269|PubMed:1284534,
FT                   ECO:0000269|PubMed:7508414"
FT                   /id="VAR_000258"
FT   VARIANT         1255
FT                   /note="S -> P (in CF; loss of bicarbonate transport; no
FT                   effect on protein maturation, subcellular location at the
FT                   plasma membrane, nor on chloride channel activity;
FT                   dbSNP:rs121909041)"
FT                   /evidence="ECO:0000269|PubMed:11242048,
FT                   ECO:0000269|PubMed:1284530"
FT                   /id="VAR_000259"
FT   VARIANT         1270
FT                   /note="D -> N (in CF and CBAVD; dbSNP:rs11971167)"
FT                   /evidence="ECO:0000269|PubMed:17329263"
FT                   /id="VAR_000260"
FT   VARIANT         1282..1480
FT                   /note="Missing (in CF and CBAVD)"
FT                   /evidence="ECO:0000269|PubMed:1379210,
FT                   ECO:0000269|PubMed:17329263"
FT                   /id="VAR_080324"
FT   VARIANT         1282
FT                   /note="W -> R (in CF; dbSNP:rs397508616)"
FT                   /evidence="ECO:0000269|PubMed:1284534"
FT                   /id="VAR_000261"
FT   VARIANT         1283
FT                   /note="R -> M (in CF; dbSNP:rs77902683)"
FT                   /evidence="ECO:0000269|PubMed:1284468"
FT                   /id="VAR_000262"
FT   VARIANT         1286
FT                   /note="F -> S (in CF; dbSNP:rs121909028)"
FT                   /evidence="ECO:0000269|PubMed:1284534"
FT                   /id="VAR_000263"
FT   VARIANT         1291
FT                   /note="Q -> H (in CF; dbSNP:rs121909015)"
FT                   /evidence="ECO:0000269|PubMed:1284466"
FT                   /id="VAR_000264"
FT   VARIANT         1291
FT                   /note="Q -> R (in CF; dbSNP:rs397508621)"
FT                   /evidence="ECO:0000269|PubMed:7525450"
FT                   /id="VAR_000265"
FT   VARIANT         1303
FT                   /note="N -> H (in CF; dbSNP:rs121909042)"
FT                   /evidence="ECO:0000269|PubMed:1284534"
FT                   /id="VAR_000266"
FT   VARIANT         1303
FT                   /note="N -> K (in CF; impaired maturation of glycan chains;
FT                   has low in vitro channel activity at low temperature;
FT                   dbSNP:rs80034486)"
FT                   /evidence="ECO:0000269|PubMed:12394343,
FT                   ECO:0000269|PubMed:1379210, ECO:0000269|PubMed:1712898,
FT                   ECO:0000269|PubMed:17182731, ECO:0000269|PubMed:7508414,
FT                   ECO:0000269|PubMed:9401006, ECO:0000269|PubMed:9521595"
FT                   /id="VAR_000267"
FT   VARIANT         1349
FT                   /note="G -> D (in CF; loss of bicarbonate transport; no
FT                   effect on protein maturation, subcellular location at the
FT                   plasma membrane, nor on chloride channel activity;
FT                   dbSNP:rs193922525)"
FT                   /evidence="ECO:0000269|PubMed:11242048,
FT                   ECO:0000269|PubMed:1712898"
FT                   /id="VAR_000268"
FT   VARIANT         1352
FT                   /note="Q -> H (in CBAVD; uncertain significance;
FT                   dbSNP:rs113857788)"
FT                   /evidence="ECO:0000269|PubMed:17329263"
FT                   /id="VAR_080325"
FT   VARIANT         1364
FT                   /note="A -> V (in CBAVD; dbSNP:rs397508670)"
FT                   /evidence="ECO:0000269|Ref.118"
FT                   /id="VAR_000269"
FT   VARIANT         1397
FT                   /note="V -> E (in CF; dbSNP:rs397508691)"
FT                   /evidence="ECO:0000269|PubMed:7524913"
FT                   /id="VAR_000270"
FT   VARIANT         1453
FT                   /note="R -> W (in dbSNP:rs4148725)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_048152"
FT   VARIANT         1473..1480
FT                   /note="Missing (in CBAVD; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:17329263"
FT                   /id="VAR_080326"
FT   MUTAGEN         347
FT                   /note="R->D: Decreases glutathione uptake. Increases
FT                   affinity for glutathione."
FT                   /evidence="ECO:0000269|PubMed:12727866"
FT   MUTAGEN         464
FT                   /note="K->A: Decreases glutathione uptake."
FT                   /evidence="ECO:0000269|PubMed:12727866"
FT   MUTAGEN         464
FT                   /note="K->M: Impaired maturation of glycan chains
FT                   indicating impaired trafficking from the endoplasmic
FT                   reticulum to the cell membrane."
FT                   /evidence="ECO:0000269|PubMed:1699669"
FT   MUTAGEN         508
FT                   /note="F->R: Impaired maturation of glycan chains
FT                   indicating impaired trafficking from the endoplasmic
FT                   reticulum to the cell membrane."
FT                   /evidence="ECO:0000269|PubMed:1699669,
FT                   ECO:0000269|PubMed:1712898"
FT   MUTAGEN         539
FT                   /note="I->T: Enhances trafficking from the endoplasmic
FT                   reticulum to the cell membrane."
FT                   /evidence="ECO:0000269|PubMed:28001373"
FT   MUTAGEN         894
FT                   /note="N->D: Abolishes N-glycosylation, enhances
FT                   endocytosis and impairs subsequent recycling to the cell
FT                   surface; when associated with D-900."
FT                   /evidence="ECO:0000269|PubMed:20008117"
FT   MUTAGEN         900
FT                   /note="N->D: Abolishes N-glycosylation, enhances
FT                   endocytosis and impairs subsequent recycling to the cell
FT                   surface; when associated with D-894."
FT                   /evidence="ECO:0000269|PubMed:20008117"
FT   MUTAGEN         1137
FT                   /note="M->R: Abolishes channel activity. Impairs protein
FT                   maturation, suggesting the protein is retained in the
FT                   endoplasmic reticulum."
FT                   /evidence="ECO:0000269|PubMed:9804160"
FT   MUTAGEN         1139
FT                   /note="I->V: Decreases channel activity, no visible effect
FT                   on protein maturation."
FT                   /evidence="ECO:0000269|PubMed:9804160"
FT   MUTAGEN         1154
FT                   /note="D->G: Decreases channel activity, no visible effect
FT                   on protein maturation."
FT                   /evidence="ECO:0000269|PubMed:9804160"
FT   MUTAGEN         1250
FT                   /note="K->A: Decreases glutathione uptake."
FT                   /evidence="ECO:0000269|PubMed:12727866"
FT   MUTAGEN         1250
FT                   /note="K->M: No effect on maturation of glycans, suggesting
FT                   that trafficking to the plasma membrane is not altered."
FT                   /evidence="ECO:0000269|PubMed:1699669"
FT   MUTAGEN         1478..1480
FT                   /note="Missing: Reduces interaction with MARCHF2 and
FT                   abolishes subsequent MARCHF2-mediated degradation. No
FT                   effect on localization to the Golgi."
FT                   /evidence="ECO:0000269|PubMed:23818989"
FT   CONFLICT        620
FT                   /note="H -> N (in Ref. 1; AAA35680)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        833
FT                   /note="F -> L (in Ref. 1; AAA35680)"
FT                   /evidence="ECO:0000305"
FT   HELIX           5..8
FT                   /evidence="ECO:0007829|PDB:8UBR"
FT   HELIX           11..16
FT                   /evidence="ECO:0007829|PDB:7SVD"
FT   HELIX           18..20
FT                   /evidence="ECO:0007829|PDB:7SVD"
FT   HELIX           21..27
FT                   /evidence="ECO:0007829|PDB:7SVD"
FT   HELIX           34..36
FT                   /evidence="ECO:0007829|PDB:7SVD"
FT   HELIX           42..44
FT                   /evidence="ECO:0007829|PDB:7SVD"
FT   HELIX           46..63
FT                   /evidence="ECO:0007829|PDB:7SVD"
FT   HELIX           70..97
FT                   /evidence="ECO:0007829|PDB:7SVD"
FT   HELIX           99..107
FT                   /evidence="ECO:0007829|PDB:7SVD"
FT   HELIX           114..118
FT                   /evidence="ECO:0007829|PDB:8EIO"
FT   HELIX           120..164
FT                   /evidence="ECO:0007829|PDB:7SVD"
FT   TURN            169..173
FT                   /evidence="ECO:0007829|PDB:7SVD"
FT   HELIX           177..185
FT                   /evidence="ECO:0007829|PDB:7SVD"
FT   TURN            186..189
FT                   /evidence="ECO:0007829|PDB:9DW8"
FT   HELIX           190..193
FT                   /evidence="ECO:0007829|PDB:7SVD"
FT   HELIX           194..196
FT                   /evidence="ECO:0007829|PDB:7SVD"
FT   HELIX           200..216
FT                   /evidence="ECO:0007829|PDB:7SVD"
FT   TURN            220..222
FT                   /evidence="ECO:0007829|PDB:7SVD"
FT   HELIX           223..249
FT                   /evidence="ECO:0007829|PDB:7SVD"
FT   HELIX           252..266
FT                   /evidence="ECO:0007829|PDB:7SVD"
FT   HELIX           269..275
FT                   /evidence="ECO:0007829|PDB:7SVD"
FT   HELIX           278..312
FT                   /evidence="ECO:0007829|PDB:7SVD"
FT   HELIX           314..328
FT                   /evidence="ECO:0007829|PDB:7SVD"
FT   HELIX           333..351
FT                   /evidence="ECO:0007829|PDB:7SVD"
FT   HELIX           354..375
FT                   /evidence="ECO:0007829|PDB:7SVD"
FT   STRAND          386..388
FT                   /evidence="ECO:0007829|PDB:8UBR"
FT   STRAND          390..399
FT                   /evidence="ECO:0007829|PDB:2PZE"
FT   HELIX           403..411
FT                   /evidence="ECO:0007829|PDB:2BBS"
FT   HELIX           414..417
FT                   /evidence="ECO:0007829|PDB:2BBT"
FT   HELIX           433..436
FT                   /evidence="ECO:0007829|PDB:1XMI"
FT   STRAND          440..449
FT                   /evidence="ECO:0007829|PDB:2PZE"
FT   STRAND          450..452
FT                   /evidence="ECO:0007829|PDB:6MSM"
FT   STRAND          453..457
FT                   /evidence="ECO:0007829|PDB:2PZE"
FT   HELIX           460..462
FT                   /evidence="ECO:0007829|PDB:6ZE1"
FT   HELIX           464..471
FT                   /evidence="ECO:0007829|PDB:2PZE"
FT   STRAND          478..484
FT                   /evidence="ECO:0007829|PDB:2PZE"
FT   STRAND          488..491
FT                   /evidence="ECO:0007829|PDB:2PZE"
FT   STRAND          499..501
FT                   /evidence="ECO:0007829|PDB:2PZG"
FT   HELIX           502..507
FT                   /evidence="ECO:0007829|PDB:2PZE"
FT   HELIX           514..523
FT                   /evidence="ECO:0007829|PDB:2PZE"
FT   HELIX           527..530
FT                   /evidence="ECO:0007829|PDB:2PZE"
FT   STRAND          533..535
FT                   /evidence="ECO:0007829|PDB:2PZF"
FT   HELIX           536..538
FT                   /evidence="ECO:0007829|PDB:2PZE"
FT   STRAND          540..545
FT                   /evidence="ECO:0007829|PDB:5TFJ"
FT   HELIX           550..563
FT                   /evidence="ECO:0007829|PDB:2PZE"
FT   STRAND          567..573
FT                   /evidence="ECO:0007829|PDB:2PZE"
FT   TURN            574..577
FT                   /evidence="ECO:0007829|PDB:2PZE"
FT   HELIX           580..589
FT                   /evidence="ECO:0007829|PDB:2PZE"
FT   HELIX           590..594
FT                   /evidence="ECO:0007829|PDB:2PZE"
FT   TURN            595..597
FT                   /evidence="ECO:0007829|PDB:2PZE"
FT   STRAND          598..603
FT                   /evidence="ECO:0007829|PDB:2PZE"
FT   HELIX           607..612
FT                   /evidence="ECO:0007829|PDB:2PZE"
FT   STRAND          614..620
FT                   /evidence="ECO:0007829|PDB:2PZE"
FT   STRAND          623..628
FT                   /evidence="ECO:0007829|PDB:2PZE"
FT   HELIX           630..634
FT                   /evidence="ECO:0007829|PDB:2PZE"
FT   HELIX           640..644
FT                   /evidence="ECO:0007829|PDB:2PZE"
FT   HELIX           650..652
FT                   /evidence="ECO:0007829|PDB:2BBS"
FT   HELIX           655..669
FT                   /evidence="ECO:0007829|PDB:2BBS"
FT   HELIX           826..829
FT                   /evidence="ECO:0007829|PDB:9DW9"
FT   TURN            830..832
FT                   /evidence="ECO:0007829|PDB:9DW9"
FT   HELIX           849..853
FT                   /evidence="ECO:0007829|PDB:7SVD"
FT   HELIX           857..882
FT                   /evidence="ECO:0007829|PDB:7SVD"
FT   TURN            883..886
FT                   /evidence="ECO:0007829|PDB:7SVD"
FT   STRAND          904..906
FT                   /evidence="ECO:0007829|PDB:7SVD"
FT   TURN            910..913
FT                   /evidence="ECO:0007829|PDB:7SVD"
FT   HELIX           914..926
FT                   /evidence="ECO:0007829|PDB:7SVD"
FT   HELIX           931..956
FT                   /evidence="ECO:0007829|PDB:7SVD"
FT   HELIX           961..965
FT                   /evidence="ECO:0007829|PDB:7SVD"
FT   HELIX           969..1011
FT                   /evidence="ECO:0007829|PDB:7SVD"
FT   HELIX           1015..1046
FT                   /evidence="ECO:0007829|PDB:7SVD"
FT   HELIX           1049..1060
FT                   /evidence="ECO:0007829|PDB:7SVD"
FT   HELIX           1062..1068
FT                   /evidence="ECO:0007829|PDB:7SVD"
FT   HELIX           1071..1121
FT                   /evidence="ECO:0007829|PDB:7SVD"
FT   STRAND          1123..1125
FT                   /evidence="ECO:0007829|PDB:9DW8"
FT   HELIX           1128..1136
FT                   /evidence="ECO:0007829|PDB:7SVD"
FT   TURN            1137..1139
FT                   /evidence="ECO:0007829|PDB:7SVD"
FT   HELIX           1140..1167
FT                   /evidence="ECO:0007829|PDB:7SVD"
FT   STRAND          1204..1207
FT                   /evidence="ECO:0007829|PDB:3GD7"
FT   STRAND          1210..1220
FT                   /evidence="ECO:0007829|PDB:6UK1"
FT   STRAND          1226..1234
FT                   /evidence="ECO:0007829|PDB:6UK1"
FT   STRAND          1239..1243
FT                   /evidence="ECO:0007829|PDB:6UK1"
FT   HELIX           1250..1257
FT                   /evidence="ECO:0007829|PDB:6UK1"
FT   STRAND          1261..1269
FT                   /evidence="ECO:0007829|PDB:6UK1"
FT   HELIX           1274..1276
FT                   /evidence="ECO:0007829|PDB:7SVD"
FT   HELIX           1279..1283
FT                   /evidence="ECO:0007829|PDB:6UK1"
FT   STRAND          1286..1290
FT                   /evidence="ECO:0007829|PDB:6UK1"
FT   STRAND          1297..1299
FT                   /evidence="ECO:0007829|PDB:6UK1"
FT   HELIX           1300..1304
FT                   /evidence="ECO:0007829|PDB:6UK1"
FT   HELIX           1312..1321
FT                   /evidence="ECO:0007829|PDB:6UK1"
FT   HELIX           1325..1329
FT                   /evidence="ECO:0007829|PDB:6UK1"
FT   STRAND          1331..1333
FT                   /evidence="ECO:0007829|PDB:7SVD"
FT   HELIX           1334..1336
FT                   /evidence="ECO:0007829|PDB:6UK1"
FT   TURN            1341..1345
FT                   /evidence="ECO:0007829|PDB:6UK1"
FT   HELIX           1348..1361
FT                   /evidence="ECO:0007829|PDB:6UK1"
FT   STRAND          1365..1371
FT                   /evidence="ECO:0007829|PDB:6UK1"
FT   HELIX           1372..1375
FT                   /evidence="ECO:0007829|PDB:6UK1"
FT   HELIX           1378..1387
FT                   /evidence="ECO:0007829|PDB:6UK1"
FT   TURN            1388..1394
FT                   /evidence="ECO:0007829|PDB:6UK1"
FT   STRAND          1395..1403
FT                   /evidence="ECO:0007829|PDB:6UK1"
FT   HELIX           1404..1406
FT                   /evidence="ECO:0007829|PDB:6UK1"
FT   STRAND          1411..1415
FT                   /evidence="ECO:0007829|PDB:6UK1"
FT   STRAND          1422..1427
FT                   /evidence="ECO:0007829|PDB:6UK1"
FT   HELIX           1435..1439
FT                   /evidence="ECO:0007829|PDB:7SVD"
FT   HELIX           1443..1449
FT                   /evidence="ECO:0007829|PDB:7SVD"
FT   STRAND          1478..1480
FT                   /evidence="ECO:0007829|PDB:2LOB"
SQ   SEQUENCE   1480 AA;  168142 MW;  8D082AA2E768C065 CRC64;
     MQRSPLEKAS VVSKLFFSWT RPILRKGYRQ RLELSDIYQI PSVDSADNLS EKLEREWDRE
     LASKKNPKLI NALRRCFFWR FMFYGIFLYL GEVTKAVQPL LLGRIIASYD PDNKEERSIA
     IYLGIGLCLL FIVRTLLLHP AIFGLHHIGM QMRIAMFSLI YKKTLKLSSR VLDKISIGQL
     VSLLSNNLNK FDEGLALAHF VWIAPLQVAL LMGLIWELLQ ASAFCGLGFL IVLALFQAGL
     GRMMMKYRDQ RAGKISERLV ITSEMIENIQ SVKAYCWEEA MEKMIENLRQ TELKLTRKAA
     YVRYFNSSAF FFSGFFVVFL SVLPYALIKG IILRKIFTTI SFCIVLRMAV TRQFPWAVQT
     WYDSLGAINK IQDFLQKQEY KTLEYNLTTT EVVMENVTAF WEEGFGELFE KAKQNNNNRK
     TSNGDDSLFF SNFSLLGTPV LKDINFKIER GQLLAVAGST GAGKTSLLMV IMGELEPSEG
     KIKHSGRISF CSQFSWIMPG TIKENIIFGV SYDEYRYRSV IKACQLEEDI SKFAEKDNIV
     LGEGGITLSG GQRARISLAR AVYKDADLYL LDSPFGYLDV LTEKEIFESC VCKLMANKTR
     ILVTSKMEHL KKADKILILH EGSSYFYGTF SELQNLQPDF SSKLMGCDSF DQFSAERRNS
     ILTETLHRFS LEGDAPVSWT ETKKQSFKQT GEFGEKRKNS ILNPINSIRK FSIVQKTPLQ
     MNGIEEDSDE PLERRLSLVP DSEQGEAILP RISVISTGPT LQARRRQSVL NLMTHSVNQG
     QNIHRKTTAS TRKVSLAPQA NLTELDIYSR RLSQETGLEI SEEINEEDLK ECFFDDMESI
     PAVTTWNTYL RYITVHKSLI FVLIWCLVIF LAEVAASLVV LWLLGNTPLQ DKGNSTHSRN
     NSYAVIITST SSYYVFYIYV GVADTLLAMG FFRGLPLVHT LITVSKILHH KMLHSVLQAP
     MSTLNTLKAG GILNRFSKDI AILDDLLPLT IFDFIQLLLI VIGAIAVVAV LQPYIFVATV
     PVIVAFIMLR AYFLQTSQQL KQLESEGRSP IFTHLVTSLK GLWTLRAFGR QPYFETLFHK
     ALNLHTANWF LYLSTLRWFQ MRIEMIFVIF FIAVTFISIL TTGEGEGRVG IILTLAMNIM
     STLQWAVNSS IDVDSLMRSV SRVFKFIDMP TEGKPTKSTK PYKNGQLSKV MIIENSHVKK
     DDIWPSGGQM TVKDLTAKYT EGGNAILENI SFSISPGQRV GLLGRTGSGK STLLSAFLRL
     LNTEGEIQID GVSWDSITLQ QWRKAFGVIP QKVFIFSGTF RKNLDPYEQW SDQEIWKVAD
     EVGLRSVIEQ FPGKLDFVLV DGGCVLSHGH KQLMCLARSV LSKAKILLLD EPSAHLDPVT
     YQIIRRTLKQ AFADCTVILC EHRIEAMLEC QQFLVIEENK VRQYDSIQKL LNERSLFRQA
     ISPSDRVKLF PHRNSSKCKS KPQIAALKEE TEEEVQDTRL
//
